<SEC-DOCUMENT>0001493152-25-001485.txt : 20250110
<SEC-HEADER>0001493152-25-001485.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110061817
ACCESSION NUMBER:		0001493152-25-001485
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278874
		FILM NUMBER:		25520199

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(5)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-278874</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
Prospectus dated April 23, 2024)</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Up
to $1,700,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an At-the-Market Sales Agreement, or the Sales Agreement, with WallachBeth Capital, LLC, or the Sales Agent or WallachBeth,
acting as our sales agent, dated as of January 6, 2025, relating to the sale of our common stock offered by this prospectus supplement
and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock,
$0.0001 par value per share, from time to time through WallachBeth acting as agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;. On January 7, 2025, the last reported
sale price of our common stock on the Nasdaq Capital Market was $2.40 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be &ldquo;at-the-market
offerings&rdquo; as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. The Sales Agent is not required
to sell any specific number or dollar amount of shares of common stock but will act as our distribution agent using commercially reasonable
efforts consistent with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust
or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sales Agent is entitled to compensation at a commission rate of 3.5% of the gross proceeds of any shares of common stock sold under the
Sales Agreement. See &ldquo;Plan of Distribution&rdquo; on page S-18 for additional information regarding the compensation to be paid
to the Sales Agent. In connection with the sale of the common stock on our behalf, the Sales Agent will be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act and the Sales Agent&rsquo;s compensation will be deemed to be underwriting commissions or discounts.
We have agreed to provide indemnification and contribution to the Sales Agent with respect to certain liabilities, including liabilities
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 7, 2025, the aggregate market value of our outstanding common stock held by non-affiliates was $5,279,801, which
was based on a total of 2,249,290 shares of common stock outstanding, of which 2,199,917 shares were held by non-affiliates on such date,
and a price of $2.40 per share, which was the closing price of our common stock on the Nasdaq Capital Market on January 7,
2025. As of the date of this prospectus supplement, we have not offered or sold any securities pursuant to General Instruction I.B.6
of Form S-3 during the prior 12 calendar month period that ends on, and includes, the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. Before investing in our common stock, please read the &ldquo;Risk Factors&rdquo;
section on page S-15 of this prospectus supplement under the caption &ldquo;Risk Factors&rdquo; and in the documents incorporated by
reference into this prospectus supplement and the accompanying prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal
offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>WALLACHBETH
CAPITAL, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is January 8, 2025.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TABLE
OF CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>PROSPECTUS
SUPPLEMENT</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_001">about this prospectus supplement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_002">special note regarding forward-looking statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_003">prospectus supplement summary</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_004">risk factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_005">use of proceeds</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Ha_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">dividend policy</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_006">dilution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_007">plan of distribution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_008">legal matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_009">experts</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_010">where you can find more information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#me_011">incorporation of certain information by reference</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-20</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>PROSPECTUS</U></B></FONT></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">Page</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_002">NOTE ABOUT FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_003">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_004">RISK FACTORS</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_005">THE SECURITIES WE MAY OFFER</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_006">USE OF PROCEEDS</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_007">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_008">DESCRIPTION OF DEBT SECURITIES</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_009">DESCRIPTION OF WARRANTS</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_010">DESCRIPTION OF RIGHTS</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_011">DESCRIPTION OF UNITS</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_012">LEGAL OWNERSHIP OF SECURITIES</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_013">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_014">LEGAL MATTERS</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_015">EXPERTS</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_016">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_017">INFORMATION INCORPORATED BY REFERENCE</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_001"></A>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus relate to the offering of our common stock. Before purchasing any of the common
stock that we are offering, you should carefully read this prospectus supplement and the accompanying prospectus, together with the information
incorporated by reference into this prospectus supplement and the accompanying prospectus as described under the headings &ldquo;Where
You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo; on page S-20. These documents
contain important information that you should consider when making your investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus form part of a registration statement on Form S-3, File No. 333-278874, that we
filed with the SEC on April 23, 2024 using a &ldquo;shelf&rdquo; registration process. This document contains two parts. The first part
consists of this prospectus supplement, which provides you with specific information about this offering. The second part, the accompanying
prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer only to the &ldquo;prospectus&rdquo;,
we are referring to both parts combined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement may add, update, or change information contained in the accompanying prospectus. To the extent that any statement
we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any documents incorporated
by reference into this prospectus supplement or the accompanying prospectus, the statements made in this prospectus supplement will be
deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference herein and therein.
If any statement in this prospectus supplement or the accompanying prospectus is inconsistent with a statement in another document having
a later date, for example, a document incorporated by reference into this prospectus supplement, the statement in the document having
the later date will be deemed to modify or supersede the earlier statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, the terms &ldquo;the Company&rdquo;, &ldquo;our company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, and
&ldquo;our&rdquo; refer to Lixte Biotechnology Holdings, Inc., a Delaware corporation. When we refer to &ldquo;you&rdquo;, we mean the
purchaser or potential purchaser of the shares of common stock offered by this prospectus supplement and the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus
and any free writing prospectus that we may authorize for use in connection with this offering. We have not, and the Sales Agent has
not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information,
you should not rely on it. Neither we nor the Sales Agent is offering to sell, or seeking offers to buy, our common stock in any jurisdiction
where the offer or sale is not permitted. The distribution of this prospectus supplement and the offering of our common stock in certain
jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must
inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus
supplement outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer
to sell, or a solicitation of an offer to buy, any common stock offered by this prospectus supplement by any person in any jurisdiction
in which it is unlawful for such person to make such an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by
reference into this prospectus supplement and the accompanying prospectus and any free writing prospectus that we may authorize for use
in connection with this offering is accurate only as of the date of those respective documents. Our business, financial condition, results
of operations and prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement, the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the
accompanying prospectus contain summaries of certain provisions contained in some of the documents described herein and therein, but
reference is made to the actual documents for complete information. All the summaries are qualified in their entirety by the actual documents.
Copies of some of such documents have been or will be filed as exhibits to the registration statement of which this prospectus supplement
and the accompanying prospectus are a part or as exhibits to documents incorporated by reference herein or therein, and you may obtain
copies of those documents as described below under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
of Certain Information by Reference&rdquo; on page S-20. We further note that the representations, warranties and covenants made by
us in any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus supplement or
the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose
of allocating risk among the parties to the agreement, and should not be deemed to be a representation, warranty or covenant to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information contained in this prospectus supplement, the accompanying prospectus, the documents incorporated by
reference into this prospectus supplement and the accompanying prospectus and any free writing prospectus that we may authorize for use
in connection with this offering concerning our industry and the markets in which we operate, including our general expectations and
market opportunity, is based on information from our own management estimates and research, as well as from industry and general publications
and research, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our
knowledge of our industry and assumptions based on such information and knowledge. We believe such estimates to be reasonable, but we
have not independently verified the accuracy of information obtained from third parties. In addition, assumptions and estimates of our
and our industry&rsquo;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors,
including those described in &ldquo;Risk Factors&rdquo; in this prospectus supplement on page S-15, in the accompanying prospectus
and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is incorporated by reference into this prospectus
supplement and the accompanying prospectus. These and other important factors could cause our future performance to differ materially
from our assumptions and estimates. See &ldquo;Special Note Regarding Forward-Looking Statements&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_002"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying
prospectus and any free writing prospectus that we may authorize for use in connection with this offering contain forward-looking statements
within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements, other than statements of
historical fact, that do not relate to matters of historical fact should be considered forward-looking statements, including, but not
limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization
of our current and future products and product candidates, and statements regarding our anticipated revenues, expenses, margins, profits
and use of cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have identified some of these forward-looking statements with words such as &ldquo;believe&rdquo;, &ldquo;may&rdquo;, &ldquo;will&rdquo;,
&ldquo;should&rdquo;, &ldquo;could&rdquo;, &ldquo;expect&rdquo;, &ldquo;intend&rdquo;, &ldquo;plan&rdquo;, &ldquo;predict&rdquo;, &ldquo;anticipate&rdquo;,
&ldquo;estimate&rdquo;, &ldquo;continue&rdquo; or other words and terms of similar meaning and the use of future dates. These forward-looking
statements are based on current expectations about future events affecting us and are subject to uncertainties and factors relating to
our operations and business environment, all of which are difficult to predict and many of which are beyond our control and could cause
our actual results to differ materially from those matters expressed or implied by our forward-looking statements. Forward-looking statements
are only predictions or statements of current plans and can be affected by inaccurate assumptions we might make or by known or unknown
risks and uncertainties, including the risks described under the &ldquo;Risk Factors&rdquo; sections that are contained in this prospectus
supplement on page S-15, in the accompanying prospectus and in our filings with the SEC that are incorporated by reference into this
prospectus supplement and the accompanying prospectus, including, without limitation, the &ldquo;Risk Factors&rdquo; sections of our
most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Such risks and uncertainties are not exclusive and
further information concerning us and our business, including factors that potentially could materially affect our financial results
or condition, may emerge from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks of which you should be aware of before making an investment decision. Some of these risks include
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are engaged in early-stage research and as such might not be successful in our efforts to develop a portfolio of commercially viable
    products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses
    for the foreseeable future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    need significant additional financing to fund our operations and complete the development and, if approved, the commercialization
    of our lead product candidate, LB-100. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate
    our product development programs or commercialization efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently have no source of revenues. We might never generate revenues or achieve profitability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to use net operating losses to offset future taxable income might be subject to limitations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical-stage
    biopharmaceutical companies with product candidates in clinical development face a wide range of challenging activities which might
    entail substantial risk;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might find it difficult to enroll patients in our clinical trials which could delay or prevent the start of clinical trials for our
    product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our lead product candidate
    in clinical trials, and any other product candidates that might advance into clinical trials, might not have favorable results in
    later clinical trials or receive regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    drug development involves a lengthy and expensive process with an uncertain outcome;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with operating in foreign countries could materially adversely affect our product development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects
    or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label
    or result in significant negative consequences following any regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product development program might not uncover all possible adverse events that patients who take our lead product candidate may experience.
    The number of subjects exposed to our lead product candidate and the average exposure time in the clinical development program might
    be inadequate to detect rare adverse events or chance findings that might only be detected once the product is administered to more
    patients and for greater periods of time;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    future success is dependent on the regulatory approval of our lead product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    lead product candidate and future product candidates could fail to receive regulatory approval from the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to obtain regulatory approval in international jurisdictions would prevent our lead product candidate from being marketed abroad;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if our current primary product candidate received regulatory approval, it might still face future development and regulatory difficulties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on certain key scientific personnel for our success who do not work full time for us. The loss of any such personnel could
    adversely affect our business, financial condition and results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to rely heavily on third parties for the conduct of clinical trials of our product candidates. If these clinical trials are
    not successful, or if we or our collaborators are not able to obtain the necessary regulatory approvals, we will not be able to commercialize
    our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    interruptions could adversely affect future operations, revenues, and financial conditions, and might increase our costs and expenses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to find third party collaborators to assist or share in the costs of product development could materially harm our business,
    financial condition or results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims by third parties asserting that our employees, consultants, collaborators contractors or we have misappropriated
    their intellectual property, or claiming ownership of what we regard as our own intellectual property;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    cannot be certain we will be able to obtain patent protection to protect our product candidates and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not obtain patent term extension in the United States under the Hatch-Waxman Act or in foreign countries under similar legislation,
    our business might be materially harmed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with our obligations in agreements under which we have licensed or, might license, intellectual property rights
    from third parties, or if we otherwise experience disruptions to our business relationships with our licensors, we could lose rights
    that are important to our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us
    from commercializing or increase the costs of commercializing our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade
    secrets of one or more third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    intellectual property might not be sufficient to protect our intended products from competition, which might negatively affect our
    business as well as limit our partnership or acquisition appeal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are not able to protect and control our unpatented trade secrets, know-how and other technological innovation, we might suffer
    competitive harm;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might incur substantial costs prosecuting our patent applications, maintaining our patents and patent applications, enforcing our
    patents, defending against third party patent infringement suits, seeking invalidation of third party patents or in-licensing third
    party intellectual property, as a result of litigation or other proceedings relating to patent and other intellectual property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to protect our intellectual property rights, our competitors might develop and market products with similar or identical
    features that might reduce demand for our potential products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    commercial success depends upon attaining significant market acceptance of our current product candidate and future product candidates,
    if approved, among physicians, patients, healthcare payors and cancer treatment centers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are able to commercialize our lead product candidate or any future product candidates, the products might not receive coverage
    or adequate reimbursement from third party payors in the United States and in other countries in which we seek to commercialize our
    intended products, which could harm our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
    legislative measures aimed at reducing healthcare costs might have a material adverse effect on our business and results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
    controls might be imposed in foreign markets, which might adversely affect our future profitability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    relationships with customers and third party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare
    laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished
    profits and future earnings. If we or they are unable to comply with these provisions, we might become subject to civil and criminal
    investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    employees might engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
    which could cause significant liability for us and harm our reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that
    we might develop;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face substantial competition, which might result in others discovering, developing or commercializing products before or more successfully
    than we do;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    disruptions of information technology systems, computer system failures or breaches of information and cyber security could adversely
    affect our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might need to grow the size of our organization in the future, and we might experience difficulties in managing this growth;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inadequate
    funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other
    personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those
    agencies from performing normal business functions on which the operation of our business might rely, which could negatively impact
    our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unstable
    market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may
    have serious adverse consequences on our business, financial condition and stock price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a &ldquo;smaller reporting company&rdquo; and we have elected to comply with certain reduced reporting and disclosure requirements
    which could make its common stock less attractive to investors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    price of our common stock might fluctuate substantially;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    sale or perceived sale of a substantial number of shares of our common stock might cause the price of our common stock to decline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    and economic conditions might negatively impact our business, financial condition and share price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business,
    our stock price and trading volume might decline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    sales and issuances of our common stock could result in additional dilution of the percentage ownership of our stockholders and could
    cause our share price to fall;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be at risk of securities class action litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Certificate of Incorporation and our Amended and Restated Bylaws, and Delaware law might have anti-takeover effects that could discourage,
    delay or prevent a change in control, which might cause our stock price to decline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be
    required to devote substantial time to compliance matters; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with the rules under Sarbanes-Oxley related to accounting controls and procedures in the future, or, if we discover
    material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
    and raising capital could be more difficult.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
forward-looking statement is based on information available to us as of the date of the document in which the forward-looking statement
is contained. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise, except as otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
forward-looking statements that are made by us in this prospectus supplement, in the accompanying prospectus, in the documents incorporated
by reference into this prospectus supplement and the accompanying prospectus and in any free writing prospectus that we may authorize
for use in connection with this offering are qualified by these cautionary statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are not guarantees of future performance, and actual results may differ materially due to risks and uncertainties, including
those discussed under &ldquo;Risk Factors&rdquo; and in our filings with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_003"></A>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary highlights selected information about us, this offering and information contained elsewhere in or incorporated by reference
into this prospectus supplement or the accompanying prospectus. This summary does not contain all the information that may be important
to you. Before purchasing any of the common stock that we are offering, you should carefully read in their entirety this prospectus supplement
and the accompanying prospectus, including the documents incorporated by reference into this prospectus supplement and the accompanying
prospectus, and any free writing prospectus that we may authorize for use in this offering. In particular, you should carefully review
the &ldquo;Risk Factors&rdquo; sections that are contained in this prospectus supplement on page S-15, in the accompanying prospectus
and in our filings with the SEC that are incorporated by reference into this prospectus supplement and the accompanying prospectus, including,
without limitation, the &ldquo;Risk Factors&rdquo; sections of our most recently filed Annual Report on Form 10-K and Quarterly Report
on Form 10-Q.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing
cancer therapies. Our corporate office is located in Pasadena, California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation,
immune checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant therapeutic
potential for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor, referred
to as LB-100, which has been shown to have clinical anti-cancer activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
activities are subject to significant risks and uncertainties, including the need for additional capital. We have not yet commenced any
revenue-generating operations, do not have positive cash flows from operations, rely on stock-based compensation for a substantial portion
of employee and consultant compensation, and are dependent on periodic infusions of equity capital to fund our operating requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focusing our development activities on our lead clinical compound LB-100. We believe that the mechanism by which LB-100 affects cancer
cell growth is different from cancer agents currently approved for clinical use. LB-100 is currently being tested in clinical trials
in Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable (MSS) Colon Cancer and Advanced Soft Tissue Sarcoma. LB-100 has shown
anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. LB-100
has also been shown to enhance the effectiveness of commonly used anti-cancer drugs in animal models of melanoma, breast cancer and sarcoma.
The enhancement of anti-cancer activity of these anti-cancer drugs occurs at doses of LB-100 that do not significantly increase toxicity
in animals. It is therefore hoped that, when combined with standard anti-cancer regimens against many tumor types, LB-100 will improve
therapeutic benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment
at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, we have allocated resources
to expand the breadth and depth of our patent portfolio. Our approach has been to operate with a minimum of overhead, moving compounds
forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain milestones are reached.
Our longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical companies with
major programs in cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
cancer patients are treated with either chemotherapy or immunotherapy or both. These therapies often have limited benefit and there is
a high unmet medical need to enhance their effects. In many preclinical models we have shown that LB-100 enhances the effect of both
chemotherapy and Immunotherapy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form424b5_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-100,
a small molecule potent inhibitor of PP2A, was designed and developed by us. Numerous preclinical studies have documented that LB-100
potentiates most if not all anti-cancer drugs that damage DNA. LB-100 is not associated with any increase in cytotoxicity when given
with cytotoxic drugs. This synergy involves transient interruption of several DNA damage repair pathways by LB-100 and an increase in
cell division rate. LB-100 has FDA Investigational New Drug status in the US and Investigational Medicinal Product Dossier approval in
the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its initial Phase 1 clinical trial, LB-100 given alone daily for 3 days was non-toxic, except for a transient increase in serum creatinine
believed to be caused by inhibition of PP2A in the renal tubules. In the Phase 1 clinical trial, the Maximum Tolerated Dose (&ldquo;MTD&rdquo;)
was 2.33mg/m2 daily for 3 days every 3 weeks. Of the 25 patients with heavily-treated advanced solid tumors with measurable disease,
3 patients had stable disease for 2 cycles, 3 patients had stable disease for 4 cycles, and 3 patients had stable disease for 6 cycles.
One patient with pancreatic cancer had a partial response after 12 cycles lasting 534 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the DNA damage enhancing effect of PP2A inhibition with LB-100, we initiated a study in Advanced Soft Tissue Sarcoma (&ldquo;ASTS&rdquo;)
with the Spanish Sarcoma Group (Grupo Espa&ntilde;ol de Investigaci&oacute;n en Sarcomas or &ldquo;GEIS&rdquo;) for a collaborative clinical
trial in Madrid, Spain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
doses of LB-100 have now been shown to enhance immune checkpoint inhibition (&ldquo;ICI&rdquo;) by several different mechanisms affecting
the tumor compartment and immune T-cell compartment. LB-100 increases CD8+T-cell infiltration and CD8-Treg ratio, CD8+T-cell proliferation,
and cytokine production induces microsatellite instability, neoantigen production and immune responsiveness, converting immunologically
&ldquo;cold&rdquo; to &ldquo;hot&rdquo; cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><IMG SRC="form424b5_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ovarian
clear cell carcinoma patients with inactivating mutations in PPP2R1A, a gene coding for a scaffold component of PP2A, and treated with
immune checkpoint inhibitors, were recently found to have markedly longer survival than patients without the mutation in their cancers.
Retrospective reviews of patients with a variety of cancers treated with ICI or chemotherapy show much longer survival of ICI-treated
patients with a PPP2R1A mutation in their tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the observations in ovarian clear cell carcinoma, we have initiated a clinical trial in this disease combining LB-100 with a monoclonal
antibody blocking PD-1, a protein found on T-cells (NCT06065462).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
these preclinical and clinical observations, it is likely that LB-100 may be a general way to enhance immunotherapy responses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_004.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research on the LB-100 series was initiated in 2006 under a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) with
the National Institute of Neurologic Disorders and Stroke or NINDS of the National Institutes of Health or NIH dated March 22, 2006 that
was subsequently extended through a series of amendments until it terminated on April 1, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also designed and developed the LB-200 series, which consists of histone deacetylase inhibitors (HDACi). LB-200 has not advanced
to the clinical stage and would require additional capital to fund further development. Accordingly, because of our focus on the clinical
development of LB-100 and analogs for cancer therapy as described below in more detail, we have decided not to actively pursue the preclinical
development of our LB-200 series of compounds at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Trial Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spanish
Sarcoma Group Collaboration Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 31, 2019, we entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group
(Grupo Espa&ntilde;ol de Investigaci&oacute;n en Sarcomas or &ldquo;GEIS&rdquo;), Madrid, Spain, to carry out a study entitled &ldquo;Randomized
phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma&rdquo;. The purpose of
this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined with doxorubicin in soft tissue
sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&ldquo;ASTS&rdquo;). Doxorubicin
alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. We agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as well as to
provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over a period of
two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended Phase 2 dose
of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase 2 portion of
the study assumes a median progression-free survival (&ldquo;PFS&rdquo;), no evidence of disease progression or death from any cause)
of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a
statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, we announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&ntilde;ola de Medicamentos y Productos
Sanitarios or &ldquo;AEMPS&rdquo;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, our lead clinical compound, plus doxorubicin,
versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS). Consequently, this clinical
trial commenced during the quarter ended June 30, 2023 and to be completed and a report prepared by December 31, 2026. In April 2023,
GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&oacute;n Jim&eacute;nez D&iacute;az University
Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment phase of the Phase 1b portion of the protocol
was completed during the quarter ended September 30, 2024. We expect to have data on toxicity and preliminary efficacy from this portion
of the clinical trial during the quarter ending June 30, 2025, and subject to clinical results and the availability of capital resources,
anticipate that we will be in a position to decide about further development of LB-100 in ASTS at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
Research Support Agreement Relating to Small Cell Lung Cancer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have executed a Clinical Research Support Agreement with the City of Hope National Medical Center to carry out a Phase 1b clinical trial
of LB-100 combined with an FDA-approved standard regiment for treatment of untreated extensive-stage disease small cell lung cancer.
The clinical trial was initiated on March 9, 2021. However, due to the lack of patient accrual, the Company provided notice to the City
of Hope National Medical Center of the Company&rsquo;s intent to terminate the Clinical Research Support Agreement effective as of July
8, 2024. We are exploring alternative sites, including international locations, for the conduct of a small cell lung cancer clinical
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MD
Anderson Cancer Center Clinical Trial</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2023, we announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to
a human programmed death receptor-1 (&ldquo;PD-1&rdquo;) blocking antibody of GSK plc (&ldquo;GSK&rdquo;), dostarlimab-gxly, may enhance
the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (&ldquo;OCCC&rdquo;). The clinical trial is being
sponsored by The University of Texas MD Anderson Cancer Center (&ldquo;MD Anderson&rdquo;) and is being conducted at The University of
Texas - MD Anderson Cancer Center. We are providing LB-100 and GSK is providing dostarlimab-gxly and financial support for the clinical
trial. On January 29, 2024, we announced the entry of the first patient into this clinical trial. We currently expect that this clinical
trial will be completed by December 31, 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands
Cancer Institute Clinical Trial</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 10, 2024, we entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (&ldquo;NKI&rdquo;) to conduct a Phase
1b clinical trial of the Company&rsquo;s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary
molecule of F. Hoffman-La Roche Ltd. (&ldquo;Roche&rdquo;), for patients with microsatellite stable metastatic colon cancer. Under the
agreement, we will provide our lead clinical compound, LB-100, and under a separate agreement between NKI and Roche, Roche will provide
atezolizumab and financial support for the clinical trial. We have no obligation to and will not provide any reimbursement of clinical
trial costs. Pursuant to the agreement and the protocol set forth in the agreement, the clinical trial will be conducted by NKI at NKI&rsquo;s
site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and NKI will be responsible for the recruitment of patients. The
agreement provides for the protection of the respective intellectual property rights of each of Lixte, NKI and Roche.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&rsquo;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. Patient accrual is expected to take up to 24 months, with a maximum
of 37 patients with advanced colorectal cancer to be enrolled in this study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&ldquo;SAEs&rdquo;) observed in the clinical trial that was launched in August 2024. Evaluation is underway to determine
next steps. For additional information about SAEs, see &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations &ndash; Specific Risks Associated with the Company&rsquo;s Business Activities &ndash; Serious Adverse Events&rdquo;
in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, which is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Cancer Institute Pharmacologic Clinical Trial</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic clinical trial. This study was being conducted
and funded by the NCI under a Cooperative Research and Development Agreement, with the Company being required to provide the LB-100 clinical
compound.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&rsquo;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
and License Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Institute of Health</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 23, 2024, we entered into a Patent License Agreement (the &ldquo;License Agreement&rdquo;) with the National Institute of Neurological
Disorders and Stroke (&ldquo;NINDS&rdquo;) and the National Cancer Institute (&ldquo;NCI&rdquo;), each an institute or center of the
National Institute of Health (&ldquo;NIH&rdquo;). Pursuant to the License Agreement, we have licensed exclusively NIH&rsquo;s intellectual
property rights claimed for a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) subject invention co-developed with
the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer
drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis, until the expiration
of the last-to-expire valid claim of the jointly owned licensed patent rights in each such country in the licensed territory, unless
sooner terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that we will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, we would be expected to commercialize the licensed products in markets where regulatory approval has been
obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
Property</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property includes proprietary know-how, proprietary methodologies and extensive clinical validation data and publications.
To provide legal protection of our intellectual property, we rely on a combination of patents, licenses, trade secrets, trademarks, confidentiality
and non-disclosure clauses and agreements, and other forms of intellectual property protection to define and protect our rights to our
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are expected to be covered by our patents. These patents now cover sole rights to the composition and synthesis of our LB-100
series of drugs, which is our lead clinical compound in development. We have filed patent applications covering the treatment of cancer
with LB-100. We have also filed joint patent applications with the NIH and the Netherlands Cancer Institute for the treatment of cancer
using LB-100 in combination with other drugs such as an immune checkpoint inhibitor and a WEE1 inhibitor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
applications for the LB-100 series (oxabicycloheptanes and oxabicycloheptenes) have been filed in the United States and internationally
under the Patent Cooperation Treaty. Patents for composition of matter and for several uses of the LB-100 series have been issued in
the United States, Mexico, Australia, Japan, China, Hong Kong, Canada, and by the European Patent Office</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development
of our business, including seeking, maintaining, and defending our patent rights, which are owned solely by our wholly-owned Delaware
subsidiary, Lixte Biotechnology, Inc., except in several instances jointly with one of our many collaborators. We also rely on trade
secrets relating to our proprietary pipeline of product candidates and on know-how and continuing technological innovation to develop
and strengthen our pipeline. We intend to rely on regulatory protection afforded by regulatory agencies through data exclusivity, market
exclusivity, and patent term extensions, where available.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in large part on our ability to obtain and maintain patent and other proprietary protection for commercially important
technology, inventions and know-how related to its business; defend and enforce our patents; preserve the confidentiality of our trade
secrets; and operate without infringing valid and enforceable patents or proprietary rights of third parties. Our ability to stop third
parties from making, using, selling, offering to sell, or importing our technology may depend on the extent to which we have rights under
valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, enforcement of these rights may
depend on cooperation of the joint owners of our jointly owned patents and patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to both our solely and jointly owned intellectual property, we cannot be sure that patents will be granted on any of our pending
patent applications or on any patent applications filed solely or jointly by us in the future; we cannot be sure that any of our existing
patents or any patents that may be granted to us in the future will be commercially useful in protecting our intended commercial products
or therapeutic methods; and we cannot be sure that an agency or court would determine that our solely or jointly owned patents are valid
and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Going
Concern</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a history of operating losses since inception. Because we are currently engaged in various early-stage clinical trials, it is expected
that it will take a significant amount of time and resources to develop any product or intellectual property capable of generating sustainable
revenues. Accordingly, our business is unlikely to generate any sustainable operating revenues in the next several years and may never
do so. Even if we are able to generate revenues through licensing our technology, product sales or other commercial activities, there
can be no assurance that we will be able to achieve and maintain positive earnings and operating cash flows. As discussed further in
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources&rdquo;
included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is incorporated herein by reference, our
auditor has included a &ldquo;going concern&rdquo; explanatory paragraph in its report on our consolidated financial statements for the
fiscal year ended December 31, 2023, expressing substantial doubt about our ability to continue as a going concern for the next twelve
months. Our consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty. If
we cannot secure the financing needed to continue as a viable business, our shareholders may lose some or all of their investment in
us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nasdaq
Compliance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2024, we received a deficiency letter from the Listing Qualifications Department of Nasdaq indicating that we are not in compliance
with Nasdaq Listing Rule 5550(b)(1) (the &ldquo;Stockholders&rsquo; Equity Rule&rdquo;), which requires us to maintain a minimum stockholders&rsquo;
equity of $2,500,000. This notice of non-compliance has no immediate impact on the continued listing or trading of our securities on
Nasdaq, which will continue to be listed and traded on Nasdaq, subject to our compliance with the other Nasdaq continued listing requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, we submitted a letter to Nasdaq with our plan to regain compliance with the Stockholders&rsquo; Equity Rule, which outlined
our proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2024, Nasdaq provided us notice that it had granted an extension through February 18, 2025 to regain compliance with the
Stockholders&rsquo; Equity Rule. We must complete our capital raising initiatives and evidence compliance with the Stockholders&rsquo;
Equity Rule through filing a Current Report on Form 8-K with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) providing
certain required information by February 18, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to evidence compliance with the Stockholders&rsquo; Equity Rule upon filing our periodic report for the quarter ending March
31, 2025 with the SEC, we may be subject to delisting. If Nasdaq determines to delist our common stock, we will have the right to appeal
to a Nasdaq hearings panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to take reasonable measures available to regain compliance under Nasdaq&rsquo;s listing rules and to remain listed on Nasdaq.
However, there can be no assurances that we will ultimately regain compliance with the Stockholders&rsquo; Equity Rule, or be able to
maintain compliance with all other applicable requirements for continued listing on Nasdaq. If we do not regain compliance with Nasdaq&rsquo;s
listing rules within the time period permitted by Nasdaq, then our securities will be delisted from Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated as a Delaware corporation on May 24, 2005 under the name SRKP7, Inc. On June 30, 2006, pursuant to a share exchange
agreement, we acquired all of the outstanding shares of Lixte Biotechnology, Inc. which then became a wholly owned subsidiary. On December
7, 2006, we changed our name to Lixte Biotechnology Holdings, Inc. Effective September 26, 2023, Bastiaan van der Baan, a director of
the Company since June 17, 2022, replaced our founder, John S. Kovach, as President and Chief Executive Officer. Dr. Kovach passed away
on October 5, 2023. Effective October 6, 2023, Mr. van der Baan was appointed as Chairman of our Board of Directors. Our common stock
and common stock warrants to purchase common stock are traded on Nasdaq under the symbols &ldquo;LIXT&rdquo; and &ldquo;LIXTW&rdquo;,
respectively. On June 2, 2023, we effected a one-for-ten reverse split of our outstanding shares of common stock in order to remain in
compliance with the $1.00 minimum closing bid price requirement of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal address is 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101. Our telephone number is (631) 830-7092. We maintain
a website at www.lixte.com. The information contained on our website is not, and should not be interpreted to be, incorporated into this
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer</FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
    Biotechnology Holdings, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock Offered by Us</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of our common stock having an aggregate offering price of up to $1,700,000.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock Outstanding Prior to Offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,249,290
    shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manner
    of Offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;At-the-market
    offering&rdquo; that may be made from time to time by our sales agent, WallachBeth Capital, LLC. See &ldquo;Plan of Distribution&rdquo;
    on page S-18 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of Proceeds</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds of this offering for working capital and general corporate expenses, including for the further development
    of our lead clinical compound LB-100. See &ldquo;Use of Proceeds&rdquo; on page S-17 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our common stock involves a high degree of risk. Before investing in our common stock, please read the &ldquo;Risk Factors&rdquo;
    section on page S-15 of this prospectus supplement and the corresponding sections in the accompanying prospectus and in our Annual
    Report on Form 10-K for the fiscal year ended December 31, 2023, as well as our subsequent filings with the SEC, which are incorporated
    herein by reference.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    Capital Market Symbol</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;LIXT&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on 2,249,290 shares of common stock outstanding as
of December 31, 2024 and excludes as of that date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,917
    shares of our common stock issuable upon the conversion of 350,000 shares of Series A Convertible Preferred Stock outstanding at
    a conversion rate of 0.2083 common shares per preferred share, reflecting a conversion price of $48.00 per common share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">623,232
    shares of common stock issuable upon the exercise of common stock options issued to members of management, consultants, and directors
    at a weighted average exercise price of $12.441 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">808,365
    shares of our common stock issuable upon the exercise of outstanding common stock warrants at a weighted average exercise price of
    $16.4074 per share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">126,768
    shares of common stock reserved for future grants pursuant to our 2020 Stock Incentive Plan, as amended.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our common stock involves a high degree of risk. Before purchasing any of the common stock that we are offering, you should
carefully read in their entirety this prospectus supplement and the accompanying prospectus, including the documents incorporated by
reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we may authorize for
use in this offering. In particular, you should carefully review the risks described below and in the &ldquo;Risk Factors&rdquo; sections
that are contained in the accompanying prospectus and in our filings with the SEC that are incorporated by reference into this prospectus
supplement and the accompanying prospectus, including, without limitation, the &ldquo;Risk Factors&rdquo; sections of our most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in any free writing prospectus that we have authorized for use
in connection with this offering. If any of these risks actually occurs, our business, financial condition, results of operations, or
cash flow could be materially and adversely affected. This could cause the market price of our common stock to decline, resulting in
a loss of all or part of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to This Offering</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
have broad discretion in the use of the net proceeds of this offering and may not use them effectively.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds from this offering will be immediately available to our management to use at their discretion. We currently intend to use
the net proceeds of this offering for the development of our lead candidate and for other general corporate and working capital purposes.
However, our management will have broad discretion in the application of the net proceeds from this offering and will have the right
to use the net proceeds for purposes that differ substantially from our current plans. Management may spend the net proceeds in ways
that do not enhance the value of our common stock or that does not result in a favorable, or any, return for us or our stockholders.
The failure by management to apply these funds effectively could result in financial losses that could have a material and adverse effect
on our business and cause the price of our common stock to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
you purchase shares of our common stock sold in this offering, you will experience immediate and substantial dilution in the net tangible
book value of your shares.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
price per share of our common stock being offered may be higher than the net tangible book value per share of our outstanding common
stock prior to this offering. Assuming that an aggregate of 708,333 shares of our common stock are sold at a price of $2.40
per share, the last reported sale price of our common stock on the Nasdaq Capital Market on January 7, 2025, for aggregate
gross proceeds of $1,700,000, and after deducting commissions and estimated offering expenses payable by us, new investors in this offering
will incur immediate dilution of $1.43 per share, representing the difference between the assumed offering price and our as adjusted
net tangible book value as of September 30, 2024. For a more detailed discussion of the foregoing, see the section entitled &ldquo;Dilution&rdquo;
on page S-17. To the extent outstanding stock options and warrants are exercised, there may be further dilution to new investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
actual number of shares we will issue under the sales agreement with WallachBeth, at any one time or in total, is uncertain.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations in the sales agreement with WallachBeth and compliance with applicable law, we have the discretion to deliver
placement notices to WallachBeth at any time throughout the term of the sales agreement. The number of shares that are sold by WallachBeth
after delivering a placement notice will fluctuate based on the market price of our common stock during the sales period and limits that
we set with WallachBeth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
may experience future dilution as a result of future equity offerings.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into
or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. The price per share
at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions
may be lower than the price per share paid by investors in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
substantial number of shares of common stock may be sold in the market following this offering, which may depress the market price for
our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our common stock in the public market following this offering could cause the market price of our
common stock to decline. A substantial majority of the outstanding shares of our common stock are, and the shares of common stock sold
in this offering upon issuance will be, freely tradable without restriction or further registration under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
common stock offered by this prospectus supplement will be sold in &ldquo;at-the-market offerings&rdquo;, and investors who buy shares
at different times will likely pay different prices.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes in
their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold,
and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share
sales made at prices lower than the prices they paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
may be diluted by conversions of outstanding shares of preferred stock and exercises of outstanding options and warrants.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had outstanding (i) 623,232 shares of common stock issuable upon exercise of options at a weighted average
exercise price of $12.441 per share, (ii) 808,365 shares of common stock issuable upon exercise of warrants outstanding with a weighted
average exercise price of $16.4074 per share, and (iii) 72,917 shares of common stock issuable upon conversion of our outstanding preferred
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
may need, but be unable, to obtain additional funding on satisfactory terms, which could dilute our stockholders or impose burdensome
financial restrictions on our business.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon cash from financing activities and in the future, we hope to rely on revenues generated from licensing to fund the cash
requirements of our activities. However, there can be no assurance that we will be able to generate any significant cash from our operating
activities in the future. Future financing may not be available on a timely basis, in sufficient amounts or on terms acceptable to us,
if at all. Any debt financing or other financing of securities senior to the common stock will likely include financial and other covenants
that will restrict our flexibility. Any failure to comply with these covenants would have a material adverse effect on our business,
prospects, financial condition and results of operations because we could lose our existing sources of funding and impair our ability
to secure new sources of funding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
ability to raise funds through the sale of our shares depends on the performance of WallachBeth.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will rely on WallachBeth to execute sales of our common stock under the &ldquo;at-the-market offering&rdquo; consistent with our instructions.
If WallachBeth fails to perform its obligations, including selling shares in accordance with the terms of the Sales Agreement, or if
there are delays or interruptions in sales, our ability to raise funds under this &ldquo;at-the-market offering&rdquo; could be adversely
impacted. Such events could harm our financial condition and ability to achieve our business objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_005"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue and sell shares of our common stock having aggregate gross proceeds of up to $1,700,000 from time to time. Because there is
no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions paid
to the Sales Agent and proceeds to us, if any, are not determinable at this time. We estimate that the net proceeds from the sale of
the shares of common stock that we are offering may be up to approximately $1,520,500, after deducting commissions payable to the Sales
Agent and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds of this offering for continuing operating expenses and working capital, including for the further development
of our lead clinical compound LB-100. We may also use a portion of the net proceeds of this offering to acquire other products or businesses,
although we are not currently a party to an agreement regarding any such acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not determined the amounts we plan to spend in any of the areas identified above or the timing of these expenditures. As a result,
our management will have broad discretion to allocate the net proceeds to us from this offering, and investors will be relying on the
judgment of our management regarding the application of the proceeds from this offering. We reserve the right to change the use of these
proceeds as a result of certain contingencies such as competitive developments, acquisition and investment opportunities and other factors.
Pending use of the proceeds as described above, we intend to invest the net proceeds of this offering in short-term, interest-bearing,
investment-grade securities or certificates of deposit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Ha_002"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s dividend policy is determined by its Board of Directors and will depend upon a number of factors, including the
Company&rsquo;s financial condition and performance, its cash needs and research and development plans <FONT>and activities</FONT>, income tax consequences,
and the restrictions that applicable laws and any credit or other contractual arrangements may then impose. The Company has not paid
any cash dividends on its common stock to date and at the current time the Company does not anticipate paying a cash dividend on its
common stock in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_006"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the public offering price per share and the as adjusted net tangible book value per share of our common stock after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, we had a net tangible book value of $1,360,008, or $0.60 per share of common stock. Our net tangible book value
per share represents total tangible assets less total liabilities, divided by the number of shares of common stock outstanding at September
30, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the issuance and sale by us of our common stock in the aggregate amount of $1,700,000 at an assumed public offering
price of $2.40 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on January 7, 2025,
and after deducting commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of September
30, 2024 would have been approximately $2,880,507, or approximately $0.97 per share. This amount represents an immediate increase
in net tangible book value of approximately $0.37 per share to our existing stockholders and an immediate dilution in as adjusted net
tangible book value of approximately $1.43 per share to new investors in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this calculation on a per share basis. The as adjusted information is illustrative only and will adjust based
on the actual public offering price, the actual number of shares sold and other terms of the offering determined at the time shares of
our common stock are sold pursuant to this prospectus supplement. The as adjusted information assumes that all of our common stock in
the aggregate amount of $1,700,000 is sold at the assumed public offering price of $2.40 per share. The shares sold in this offering,
if any, will be sold from time to time at various prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Assumed public offering price per share</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">2.40</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book value per share as of September 30, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Increase in net tangible book value per share attributable to this offering</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.37</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">As adjusted net tangible book value per share after this offering</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.97</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">Dilution per share to new investors participating in this offering</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.43</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares pursuant to the Sales Agreement are being sold from time to time at various prices. An increase of $0.25 per share in the price
at which the shares are sold from the assumed offering price of $2.40 per share, the last reported sale price of our common stock
on the Nasdaq Capital Market on January 7, 2025, assuming all of our common stock in the aggregate amount of $1,700,000 during
the term of the Sales Agreement is sold at that price, would increase our pro forma as adjusted net tangible book value per share after
the offering to $1.03 per share and would increase the dilution in net tangible book value per share to new investors in this offering
to $1.62 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $0.25 per
share in the price at which the shares are sold from the assumed offering price of $2.40 per share, the last reported sale price
of our common stock on the Nasdaq Capital Market on January 7, 2025, assuming all of our common stock in the aggregate amount
of $1.700,000 during the term of the Sales Agreement is sold at that price, would decrease our pro forma as adjusted net tangible book
value per share after the offering to $0.92 per share and would decrease the dilution in net tangible book value per share to new
investors in this offering to $1.23 per share, after deducting commissions and estimated aggregate offering expenses payable by
us. This information is supplied for illustrative purposes only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on 2,249,290 shares of common stock outstanding as
of December 31, 2024 and excludes as of that date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,917
    shares of our common stock issuable upon the conversion of 350,000 shares of Series A Convertible Preferred Stock outstanding at
    a conversion rate of 0.2083 common shares per preferred share, reflecting a conversion price of $48.00 per common share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">623,232
    shares of common stock issuable upon the exercise of common stock options issued to members of management, consultants, and directors
    at a weighted average exercise price of $12.441 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">808,365
    shares of our common stock issuable upon the exercise of outstanding common stock warrants at a weighted average exercise price of
    $16.4074 per share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">126,768
    shares of common stock reserved for future grants pursuant to our 2020 Stock Incentive Plan, as amended.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_007"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into the Sales Agreement with WallachBeth Capital, LLC, under which we may issue and sell from time to time, shares of our
common stock having an aggregate offering price of up to $1,700,000 through the Agent. The Sales Agent, WallachBeth Capital, LLC, acts
solely as an agent for the Company in connection with the offering and is not obligated to purchase any shares on a principal basis unless
expressly agreed in writing. The Sales Agent&rsquo;s liability is limited to the scope of its agency role as set forth in the Sales Agreement.
The Agent may sell the common stock by any method that is deemed to be an &ldquo;at-the-market offering&rdquo; as defined in Rule 415
under the Securities Act, including sales made directly on or through the Nasdaq Capital Market or any other existing trading market
for the common stock in the U.S. or to or through a market maker, subject to the limitations imposed by General Instruction I.B.6. to
Form S-3, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
time we wish to issue and sell shares of common stock under the Sales Agreement, we will notify the Agent of the number of shares to
be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day
and any minimum price below which sales may not be made. Once we have so instructed the Agent, subject to the terms and conditions of
the Sales Agreement, the Agent has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices
to sell such shares up to the amount specified on such terms. The obligations of the Agent under the Sales Agreement to sell our shares
of common stock are subject to a number of conditions that we must meet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>The Agent will provide written confirmation to us no later
than the opening of the trading day immediately following the trading day on which shares of our common stock are sold under the Sales
Agreement. Each confirmation will include the number of shares sold, the volume-weighted average price of the shares sold, the compensation
payable by us to the Agent with respect to such sales and the net proceeds payable to us. The settlement of sales of shares between us
and the Agent is generally anticipated to occur on the second trading day following the date on which the sale was made. Sales of our
shares of common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company
or by such other means as we and the Agent may agree. There is no arrangement for funds to be received in an escrow, trust or similar
arrangement. We will report at least quarterly the number of shares of common stock sold through the Agent under the Sales Agreement,
the net proceeds to us and the compensation paid by us to the Agent in connection with the sales of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay the Agent a commission equal to 3.5% of the aggregate gross proceeds we receive from each sale of our shares of common stock.
Because there is no minimum offering amount required as a condition of this offering, the actual total public offering amount, commissions
and proceeds to us, if any, are not determinable at this time. In addition, we have agreed to reimburse the Agent for certain of its
expenses incurred in connection with acting as Agent, including the fees and expenses of its legal counsel of up to $50,000, plus certain
ongoing disbursements of its legal counsel of up to $5,000 per bring down.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of common stock on our behalf, the Agent may be deemed to be an &ldquo;underwriter&rdquo; within the meaning
of the Securities Act, and the compensation paid to the Agent may be deemed to be underwriting commissions or discounts. We have agreed
in the Sales Agreement to provide indemnification and contribution to the Agent against certain civil liabilities, including liabilities
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of their business, the Agent and/or their affiliates may in the future perform investment banking, broker-dealer,
financial advisory or other services for us, for which they may receive separate fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of shares of our common stock pursuant to the Sales Agreement will terminate upon the earliest of (i) the sale of the maximum
dollar amount of shares of common stock subject to the Sales Agreement, (ii) the termination of the Sales Agreement by us or the Agent,
and (iii) the expiration of the shelf registration statement on Form S-3 (File No. 333-278874) on the third anniversary of the initial
effective date of such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required by Regulation M, the Agent will not engage in any market making activities involving our shares while the offering
is ongoing under this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and conditions. A
copy of the Sales Agreement was filed as an exhibit to our Current Report on Form 8-K filed with the SEC on January 6, 2025, and is incorporated
by reference into the registration statement of which this prospectus is a part. See &ldquo;Where You Can Find More Information&rdquo;
and &ldquo;Incorporation of Certain Information by Reference&rdquo; below.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_008"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock offered by this prospectus supplement has been passed upon for us by TroyGould PC, Los Angeles,
California. As of the date of this prospectus supplement, certain attorneys who are employed by TroyGould PC beneficially owned, in the
aggregate, less than one percent of the outstanding shares of our common stock. Sichenzia, Ross, Ference, Carmel LLP, New York, New York
is counsel for the Sales Agent in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_009"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Lixte Biotechnology Holdings, Inc. as of December 31, 2023 and 2022, and for the years then ended, that are incorporated
by reference into this prospectus supplement, have been so incorporated in reliance upon the report of Weinberg &amp; Company, P.A.,
an independent registered public accounting firm, incorporated by reference herein, given upon the authority of said firm as experts
in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_010"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information
statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is <U>www.lixte.com</U>. The information contained on, or accessible through, our website is not incorporated by reference
into this prospectus supplement or the accompanying prospectus, and you should not consider it to be a part of this prospectus supplement
or the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 that we filed with the SEC and
do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or
us, as provided below. Other documents establishing the terms of the common stock being offered are or may be filed as exhibits to the
registration statement. Statements in this prospectus supplement or in the accompanying prospectus about these documents are summaries,
and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents
for a more complete description of the relevant matters. You may inspect a copy of the registration statement at the SEC&rsquo;s Public
Reference Room in Washington, D.C. or through the SEC&rsquo;s website, as provided above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_011"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC&rsquo;s rules allow us to &ldquo;incorporate by reference&rdquo; information into this prospectus supplement and the accompanying
prospectus, which means that we can disclose important information to you by referring you to another document filed separately with
the SEC. The information incorporated by reference is deemed to be part of this prospectus supplement and the accompanying prospectus,
and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained
in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus
supplement and the accompanying prospectus to the extent that a statement contained in this prospectus supplement or the accompanying
prospectus modifies or replaces that statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference the following documents or information previously filed by us with the SEC:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224010427/form10-k.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the fiscal year ended December 31, 2023 filed with the SEC on March 19, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224004201/form8-k.htm" STYLE="-sec-extract: exhibit">January
    30, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224007784/form8-k.htm" STYLE="-sec-extract: exhibit">February
    26, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224007997/form8-k.htm" STYLE="-sec-extract: exhibit">February
    27, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224010934/form8-k.htm" STYLE="-sec-extract: exhibit">March
    22, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224011582/form8-k.htm" STYLE="-sec-extract: exhibit">March
    28, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224018355/form8-k.htm" STYLE="-sec-extract: exhibit">May
    9, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224020752/form8-k.htm" STYLE="-sec-extract: exhibit">May
    20, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224021837/form8-k.htm" STYLE="-sec-extract: exhibit">May
    29, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/form8-k.htm" STYLE="-sec-extract: exhibit">June
    5, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224023834/form8-k.htm" STYLE="-sec-extract: exhibit">June
    14, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224023798/form8-k.htm" STYLE="-sec-extract: exhibit">June
    14, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224026924/form8-k.htm" STYLE="-sec-extract: exhibit">July
    11, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224027085/form8-k.htm" STYLE="-sec-extract: exhibit">July
    12, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224033144/form8-k.htm" STYLE="-sec-extract: exhibit">August
    19, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224033705/form8-k.htm" STYLE="-sec-extract: exhibit">August
    23, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224033870/form8-k.htm" STYLE="-sec-extract: exhibit">August
    26, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224035144/form8-k.htm" STYLE="-sec-extract: exhibit">September
    5, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224042172/form8-k.htm" STYLE="-sec-extract: exhibit">October
    23, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224048292/form8-k.htm" STYLE="-sec-extract: exhibit">December
    2, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224051050/form8-k.htm" STYLE="-sec-extract: exhibit">December
    20, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224052249/form8-k.htm" STYLE="-sec-extract: exhibit">December 27, 2024</A>, and January 6, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Quarterly Reports on Form 10-Q filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224018337/form10-q.htm" STYLE="-sec-extract: exhibit">May 9, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224030757/form10-q.htm" STYLE="-sec-extract: exhibit">August 8, 2024</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224044810/form10-q.htm" STYLE="-sec-extract: exhibit">November 12, 2024</A>; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Definitive Proxy Statement on Form 14A filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224043583/formdef14a.htm" STYLE="-sec-extract: exhibit">November 5, 2024</A>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also incorporate by reference into this prospectus supplement and the accompanying prospectus all reports and other documents that we
subsequently file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus
supplement and the termination of the offering of the common stock described in this prospectus supplement. However, we are not incorporating
by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed &ldquo;filed&rdquo;
with the SEC, including any information furnished pursuant to Item 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to
Item 9.01 of Form 8-K. The reports and documents specifically listed above or filed in the future (excluding any information furnished
to, rather than filed with, the SEC) are deemed to be part of this prospectus supplement and the accompanying prospectus from the date
of the filing of each such report or document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may request a copy of any of the documents incorporated by reference into this prospectus supplement and the accompanying prospectus,
without charge, by writing or telephoning us as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680
East Colorado Boulevard, Suite 180</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pasadena,
California 91101</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(631)
830-7092</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Chief Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference into this prospectus
supplement and the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>$50,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Debt
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may offer and sell up to an aggregate amount of $50,000,000 of any combination of the securities described in this prospectus
in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise
of any securities registered hereunder, including any applicable antidilution provisions. We may sell the securities to or through underwriters
and also to other purchasers or through agents. The names of any underwriters or agents, and any fees, discounts or other compensation
payable to them will be set forth in the applicable prospectus supplement accompanying this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide the specific terms of these offerings in one or more supplements to this prospectus. We may also authorize one or more free
writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing
prospectus may also update or change information contained in this prospectus. You should carefully read this prospectus, the applicable
prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any
of the securities being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;. On April 19, 2024, the last reported sale price
of our common stock on The Nasdaq Capital Market was $3.47 per share. As of April 19, 2024, the aggregate market value of our outstanding
shares of Common Stock held by non-affiliates was $7,606,053 based on 2,249,290 shares of common stock outstanding, of which 2,191,946
shares were held by non-affiliates on such date, and based on a closing sale price of our common stock of $3.47 per share on that date.
Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding
1/3 of our public float in any 12-month period so long as our public float remains below $75,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters, dealers, or
through a combination of these methods on a continuous or delayed basis. See &ldquo;Plan of Distribution&rdquo; in this prospectus. We
may also describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters
or dealers are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their
names and the nature of our arrangements with them in a prospectus supplement. The price to the public of such securities and the net
proceeds we expect to receive from any such sale by us will also be included in a prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves significant risks. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk
Factors&rdquo; beginning on page 5 of this prospectus and in any applicable prospectus supplement and free writing prospectuses we have
authorized for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by
reference into this prospectus or any prospectus supplement or free writing prospectuses.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus is April &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>TABLE
OF CONTENTS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_002">NOTE ABOUT FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_003">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_004">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_005">THE SECURITIES WE MAY OFFER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_006">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_007">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_008">DESCRIPTION OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_009">DESCRIPTION OF WARRANTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_010">DESCRIPTION OF RIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_011">DESCRIPTION OF UNITS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_012">LEGAL OWNERSHIP OF SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_013">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_014">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_015">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_016">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_017">INFORMATION INCORPORATED BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_001"></A>ABOUT
THIS PROSPECTUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) using
a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may, from time to time, offer and sell, either
individually or in combination, in one or more offerings, up to a total dollar amount of $50,000,000 of shares of our common stock (&ldquo;Common
Stock&rdquo;), preferred stock (&ldquo;Preferred Stock&rdquo;), various series of debt securities, rights to purchase shares of our Common
Stock or Preferred Stock, and/or warrants to purchase any such securities, <FONT STYLE="background-color: white">either individually
or as units comprised of a combination of one or more of the other securities </FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus,
we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We may also authorize
one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus
supplement and any related free writing prospectus that we may authorize to be provided to you may also update or change any of the information
contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. We urge you to read carefully
this prospectus, any applicable prospectus supplement and any related free writing prospectuses we have authorized for use in connection
with a specific offering, together with the information incorporated herein by reference as described under the heading &ldquo;Information
Incorporated by Reference&rdquo;, before buying any of the securities being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement,
along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering.
We have not authorized anyone to provide you with information in addition to or different from that contained in this prospectus, any
applicable prospectus supplement and any related free writing prospectus. We take no responsibility for and can provide no assurances
as to the reliability of, any information not contained in this prospectus, any applicable prospectus supplement or any related free
writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities offered hereby,
but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus,
any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document
and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless
of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale
of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
in this prospectus to the terms &ldquo;Lixte&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo; or the &ldquo;Company&rdquo;
or other similar terms refer, collectively, to Lixte Biotechnology Holdings, Inc. and its consolidated subsidiary, unless we state otherwise
or the context indicates otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we refer to &ldquo;you&rdquo;, we mean the potential holders of the applicable series of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_002"></A>NOTE
ABOUT FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and the information incorporated herein by reference includes forward-looking statements within the meaning of Section 27A
of the Securities Act, as amended (the &ldquo;Securities Act&rdquo;), and Section 21E of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;). For this purpose, any statements contained herein, other than statements of historical fact, may be
forward-looking statements under the provisions of the Private Securities Litigation Reform Act of 1995, including any statements about
our future performance, business, financial condition, strategic transactions (including mergers, acquisitions and management services
agreements), sources of revenue, operating results, plans, objectives, expectations and intentions; any statements regarding future economic
conditions; and any statements of belief or assumptions including underlying any of the foregoing. In this prospectus and the information
incorporated herein by reference, words such as &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;estimate&rdquo;, and variations
of such words or similar expressions are used to identify these forward-looking statements. Actual results may differ materially from
those indicated by such forward-looking statements as a result of various important factors. These risks are described in greater detail
in the section entitled &ldquo;Risk Factors&rdquo; of this prospectus. Many of these factors that will determine actual results are beyond
our ability to control or predict. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, actual
results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by
these forward-looking statements. In addition, any forward-looking statements in this prospectus represent our views only as of the date
of this prospectus and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events
and developments will cause its views to change. However, while we may elect to update these forward-looking statements publicly at some
point in the future, we specifically disclaim any obligation to do so, except as may be required by law, whether as a result of new information,
future events or otherwise. Our forward-looking statements generally do not reflect the potential impact of any future acquisitions,
mergers, dispositions, joint ventures or investments we may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to the section entitled &ldquo;Risk Factors&rdquo; of this prospectus, and any other risk factors set forth in any accompanying prospectus
supplement and in any information incorporated by reference in this prospectus or any accompanying prospectus supplement to better understand
the risks and uncertainties inherent in our business and underlying any forward-looking statements, as well as any other risk factors
and cautionary statements described in the documents we file from time to time with the SEC, specifically our most recent Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q, Definitive Proxy Statements on Schedule 14A and Current Reports on Form 8-K, including
sections therein titled &ldquo;Risk Factors&rdquo; and &ldquo;Note About Forward-Looking Statements&rdquo;, respectively. See &ldquo;Information
Incorporated by Reference&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_003"></A>PROSPECTUS
SUMMARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights selected information contained elsewhere in this prospectus. This summary is not complete and does not contain all
the information that you should consider before making a decision to invest in our securities. We urge you to carefully read this entire
prospectus and all applicable prospectus supplements, including the more detailed information regarding our Company, the securities being
registered hereby, as well as our consolidated financial statements, the notes to the consolidated financial statements and other information
incorporated by reference from our other filings with the SEC. Investing in our securities involves a high degree of risks. Therefore,
carefully consider the risk factors set forth in Lixte&rsquo;s most recent annual and quarterly filings with the SEC, as well as other
information in this prospectus, all applicable prospectus supplements and the documents incorporated by reference herein or therein,
before purchasing our securities. Each of the risk factors could adversely affect our business, operating results and financial condition,
as well as adversely affect the value of an investment in our securities.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><A NAME="ar_018"></A>The
Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company dedicated to improving patients&rsquo; lives by developing a drug class called Protein
Phosphatase 2A inhibitors. Our corporate office is located in Pasadena, California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product pipeline is primarily focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-ray,
immune checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant therapeutic
potential for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor, referred
to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
activities are subject to significant risks and uncertainties, including the need for additional capital. We have not yet commenced any
revenue-generating operations, do not have positive cash flows from operations, rely on stock-based compensation for a substantial portion
of employee and consultant compensation, and are dependent on periodic infusions of equity capital to fund its operating requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Associated with Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks of which you should be aware of before making an investment decision. Some of these risks include
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are engaged in early-stage research and as such might not be successful in our efforts to develop a portfolio of commercially viable
    products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses
    for the foreseeable future.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    need significant additional financing to fund our operations and complete the development and, if approved, the commercialization
    of our lead product candidate, LB-100. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate
    our product development programs or commercialization efforts.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently have no source of revenues. We might never generate revenues or achieve profitability.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical-stage
    biopharmaceutical companies with product candidates in clinical development face a wide range of challenging activities which might
    entail substantial risk.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might find it difficult to enroll patients in our clinical trials which could delay or prevent the start of clinical trials for our
    product candidate.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    drug development involves a lengthy and expensive process with an uncertain outcome.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with operating in foreign countries could materially adversely affect our product development.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects
    or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label
    or result in significant negative consequences following any regulatory approval.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product development program might not uncover all possible adverse events that patients who take our lead product candidate may experience.
    The number of subjects exposed to our lead product candidate and the average exposure time in the clinical development program might
    be inadequate to detect rare adverse events or chance findings that might only be detected once the product is administered to more
    patients and for greater periods of time.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    future success is dependent on the regulatory approval of our lead product candidate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    lead product candidate and future product candidates could fail to receive regulatory approval from the FDA.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to obtain regulatory approval in international jurisdictions would prevent our lead product candidate from being marketed abroad.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if our current primary product candidate received regulatory approval, it might still face future development and regulatory difficulties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on certain key scientific personnel for our success who do not work full time for us. The loss of any such personnel could
    adversely affect our business, financial condition and results of operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to rely heavily on third parties for the conduct of clinical trials of our product candidates. If these clinical trials are
    not successful, or if we or our collaborators are not able to obtain the necessary regulatory approvals, we will not be able to commercialize
    our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to find third party collaborators to assist or share in the costs of product development could materially harm our business,
    financial condition or results of operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims by third parties asserting that our employees, consultants, collaborators contractors or we have misappropriated
    their intellectual property, or claiming ownership of what we regard as our own intellectual property.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    cannot be certain we will be able to obtain patent protection to protect our product candidates and technology.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not obtain patent term extension in the United States under the Hatch-Waxman Act or in foreign countries under similar legislation,
    our business might be materially harmed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with our obligations in agreements under which we have licensed or, might license, intellectual property rights
    from third parties, or if we otherwise experience disruptions to our business relationships with our licensors, we could lose rights
    that are important to our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us
    from commercializing or increase the costs of commercializing our product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade
    secrets of one or more third parties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    intellectual property might not be sufficient to protect our intended products from competition, which might negatively affect our
    business as well as limit our partnership or acquisition appeal.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are not able to protect and control our unpatented trade secrets, know-how and other technological innovation, we might suffer
    competitive harm.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might incur substantial costs prosecuting our patent applications, maintaining our patents and patent applications, enforcing our
    patents, defending against third party patent infringement suits, seeking invalidation of third party patents or in-licensing third
    party intellectual property, as a result of litigation or other proceedings relating to patent and other intellectual property rights.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    commercial success depends upon attaining significant market acceptance of our current product candidate and future product candidates,
    if approved, among physicians, patients, healthcare payors and cancer treatment centers.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are able to commercialize our lead product candidate or any future product candidates, the products might not receive coverage
    or adequate reimbursement from third party payors in the United States and in other countries in which we seek to commercialize our
    intended products, which could harm our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face substantial competition, which might result in others discovering, developing or commercializing products before or more successfully
    than we do.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business might be adversely affected by a recurrence of the Coronavirus pandemic or a pandemic due to the emergence of another virus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    disruptions of information technology systems, computer system failures or breaches of information and cyber security could adversely
    affect our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might need to grow the size of our organization in the future, and we might experience difficulties in managing this growth.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_004"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves significant risks. Before making an investment decision, with respect to any of our securities, you should
carefully consider the information set forth in this prospectus, including under the heading &ldquo;Risks Associated with our Business&rdquo;
and in any applicable prospectus supplement and in the documents incorporated by reference into this prospectus, including our most recent
Annual Report on Form 10-K, as revised or supplemented by our subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K
on file with the SEC, all of which are incorporated herein by reference, and which may be amended, supplemented or superseded from time
to time by other reports we file with the SEC in the future</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risks included in this prospectus, the applicable prospectus supplement and the documents we have incorporated by reference are not the
only ones we face. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could
have material adverse effects on our future results. The occurrence of any of these risks could materially adversely affect our business,
financial condition, results of operations and prospects. As a result, the value of our securities could decline and you could lose part
or all of your investment therein. Past financial performance may not be a reliable indicator of future performance and historical trends
should not be used to anticipate results or trends in future periods. Conditions that we currently deem to be immaterial may also materially
and adversely affect our business, financial condition, cash flows and results of operation. For more information, see &ldquo;Information
Incorporated by Reference&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_005"></A>THE
SECURITIES WE MAY OFFER</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer shares of Common Stock and Preferred Stock, various series of debt securities, rights to purchase shares of Common Stock and
Preferred Stock, and/or warrants to purchase any such securities, either individually or in combination, up to a total dollar amount
of $50,000,000 from time to time under this prospectus, together with any applicable prospectus supplement and any related free writing
prospectuses, at prices and on terms to be determined by market conditions at the time of any offering. This prospectus provides you
with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we
will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including,
to the extent applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designation
    or classification;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">aggregate
    principal amount or aggregate offering price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maturity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">original
    issue discount, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rates
    and times of payment of interest or dividends, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redemption,
    conversion, exchange or sinking fund terms, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conversion
    or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange
    prices or rates and in the securities or other property receivable upon conversion or exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ranking;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictive
    covenants, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting
    or other rights, if any; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">important
    U.S. federal income tax considerations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may add, update
or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus
supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the
effectiveness of the registration statement of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE BY US OF OUR SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities directly to investors or to or through agents, underwriters or dealers. We and our agents or underwriters, reserve
the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters,
we will include in the applicable prospectus supplement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    names of those agents or underwriters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable
    fees, discounts and commissions to be paid to them;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">details
    regarding over-allotment or other options, if any; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    net proceeds to us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_006"></A>USE
OF PROCEEDS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described in any applicable prospectus supplement or in any related free writing prospectuses we have authorized for use in connection
with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any,
for working capital, research and development costs, capital expenditures, and general corporate purposes, funding future acquisition
of other companies, purchasing other assets or lines of business, repurchasing Common Stock, or for any other purpose we describe in
the applicable prospectus supplement. We have not determined the amounts we plan to spend on any of these areas or the timing of these
expenditures. As a result, our management will have broad discretion regarding the application of the net proceeds from the sale of securities
described in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_007"></A>DESCRIPTION
OF CAPITAL STOCK</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following is a summary description of the Common Stock, which does not purport to be complete and is summarized from, and is qualified
in its entirety by reference to, our Certificate of Incorporation, as amended, and Amended and Restated Bylaws, and Certificate of Designation,
to which you should refer and copies of which are incorporated herein by reference as Exhibits 3.1 - 3.5 and 4.1, respectively, and to
the registration statement on Form S-3 of which this prospectus forms a part. The summary below is also qualified by provisions of applicable
law, including the Delaware General Corporation Law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue up to a total of 100,000,000 shares of common stock, par value $0.0001 per share. Holders of our common stock
are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have
no cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
holders of our common stock have no pre-emptive or conversion rights or other subscription rights. Upon our liquidation, dissolution
or winding-up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation
preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares
of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our
board of directors out of our assets which are legally available. Each outstanding share of our common stock is, and all shares of common
stock to be issued in this offering when they are paid for, will be fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of 33-1/3% of the shares of our common stock outstanding, represented in person or by proxy, are necessary to constitute a quorum
for the transaction of business at any meeting. Except in regards to proposals that require the approval of a majority of the issued
and outstanding shares, if a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes
cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of the election of directors,
which requires a plurality of the votes cast.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock
in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional, or special
rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights,
voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of the common stock.
Our board of directors, without stockholder approval, will be able to issue convertible preferred stock with voting, conversion, or other
rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued
quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the
issuance of preferred stock may have the effect of decreasing the market price of our common stock, and may adversely affect the voting
and other rights of the holders of common stock. At present, we have no plans to issue any shares of preferred stock following this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have designated a total of 350,000 shares as our Series A Convertible Preferred Stock, which are non-voting and not subject to increase
without the written consent of a majority of the holders of such series. The holders of each tranche of 175,000 shares are entitled to
receive a per share dividend equal to 1% of our annual net revenue divided by 175,000, until converted or redeemed. Each share of Series
A Convertible Preferred Stock may be converted, at the option of the holder, into 2.083 shares of common stock (subject to customary
anti-dilution provisions), and are subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction
resulting in gross proceeds to us of at least $21,875,000. Each share has a liquidation preference based on its assumed conversion into
shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will fix the designations, voting powers, rights, preferences and privileges of each series, as well as the qualifications,
limitations or restrictions thereof, of the Preferred Stock of each series that we offer under this prospectus and applicable prospectus
supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which
this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation
that describes the terms of the series of Preferred Stock we are offering before the issuance of that series of Preferred Stock. This
description will include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title and stated value;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares being offered;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    liquidation preference per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purchase price per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    dividend rate per share, dividend period and payment dates and method of calculation for dividends;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    right, if any, to defer payment of dividends and the maximum length of any such deferral period;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    procedures for any auction and remarketing, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions for a sinking fund, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase
    rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    listing of the Preferred Stock on any securities exchange or market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the Preferred Stock will be convertible into Common Stock, and the conversion rate or conversion price, or how they will be calculated,
    and the exchange period;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting
    rights, if any, of the Preferred Stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preemption
    rights, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on transfer, sale or other assignment, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion of any material or special United States federal income tax considerations applicable to the Preferred Stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative ranking and preferences of the Preferred Stock as to dividend rights and rights if we liquidate, dissolve or wind up our
    affairs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    limitations on issuances of any class or series of Preferred Stock ranking senior to or on a parity with the series of Preferred
    Stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other specific terms, rights, preferences, privileges, qualifications or restrictions of the Preferred Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
issuance, the shares of Preferred Stock will be fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Provisions of Delaware Law, our Certificate of Incorporation and our Amended and Restated Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delaware
Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are governed by the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly traded
Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date
of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed
manner. A business combination includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder.
An interested stockholder is a person who, together with affiliates and associates, owns (or within three years, did own) 15% or more
of the corporation&rsquo;s voting stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing
a change in control of our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
of Directors Vacancies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Amended and Restated Bylaws authorize only our board of directors to fill vacant directorships. In addition,
the number of directors constituting our board of directors may be set only by resolution of the majority of the incumbent directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stockholder
Action; Special Meeting of Stockholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Amended and Restated Bylaws provide that our stockholders may take action by written consent. Our Certificate
of Incorporation and Amended and Restated Bylaws further provide that special meetings of our stockholders may be called by a majority
of the board of directors, the Chief Executive Officer, or the Chairman of the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice Requirements for Stockholder Proposals and Director Nominations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate
candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To
be timely, a stockholder&rsquo;s notice must be delivered to the secretary at our principal executive offices not later than the close
of business on the 90<SUP>th</SUP> day nor earlier than the close of business on the 120<SUP>th</SUP> day prior to the first anniversary
of the preceding year&rsquo;s annual meeting; provided, however, that in the event the date of the annual meeting is more than 30 days
before or more than 60 days after such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder
to be timely must be so delivered not earlier than the close of business on the 120<SUP>th</SUP> day prior to such annual meeting and
not later than the close of business on the later of the 90<SUP>th</SUP> day prior to such annual meeting or the 10<SUP>th</SUP> day
following the day on which a public announcement of the date of such meeting is first made by us. These provisions may preclude our stockholders
from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions could discourage a potential acquirer from acquiring Lixte Biotechnology Holdings, Inc. or otherwise attempting to obtain
control and increase the likelihood that its incumbent directors and officers will retain their positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
Agent and Registrar</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Computershare Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nasdaq Capital Market</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_008"></A>DESCRIPTION
OF DEBT SECURITIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus,
summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell
a particular series of debt securities, we will describe the specific terms of the series in a prospectus supplement. We will also indicate
in the prospectus supplement to what extent the general terms and provisions described in this prospectus apply to a particular series
of debt securities. To the extent the information contained in the prospectus supplement differs from this summary description, you should
rely on the information in the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities
described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise
specified in the prospectus supplement, the debt securities will be our direct, unsecured obligations and may be issued in one or more
series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt securities will be issued under an indenture between us and a trustee named in the prospectus supplement. We have summarized select
portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration
statement of which this prospectus is a part, and you should read the indenture for provisions that may be important to you. Capitalized
terms used in the summary and not defined in this prospectus have the meanings specified in the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or
determined in the manner provided in a resolution of our board of directors, in an officer&rsquo;s certificate or by a supplemental indenture.
The particular terms of each series of debt securities will be described in a prospectus supplement relating to such series (including
any pricing supplement or term sheet).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture would not limit the amount of debt securities that we may issue under it. Debt securities issued under the indenture may be
in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will set forth in a prospectus
supplement (including any pricing supplement or term sheet) relating to any series of debt securities being offered, the aggregate principal
amount and the following terms of the debt securities, if applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title and ranking of the debt securities (including the terms of any subordination provisions);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices (expressed as a percentage of the principal amount) at which we will sell the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    limit on the aggregate principal amount of the debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date or dates on which the principal on a particular series of debt securities is payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any commodity,
    commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from
    which interest will accrue, the date or dates on which interest will commence and be payable and any regular record date for the
    interest payable on any interest payment date;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    place or places where principal of, and interest, if any, on the debt securities will be payable (and the method of such payment),
    where the debt securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands
    to us in respect of the debt securities may be delivered;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    period or periods within which, the price or prices at which and the terms and conditions upon which we may redeem the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous provisions or at the option
    of a holder of debt securities and the period or periods within which, the price or prices at which and the terms and conditions
    upon which the debt securities of a particular series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    dates on which and the price or prices at which we will repurchase debt securities at the option of the holders of debt securities
    and other detailed terms and provisions of these repurchase obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    denominations in which the debt securities will be issued, if other than denominations of 000 and any integral multiple thereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the debt securities will be issued in the form of certificated debt securities or global debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the
    principal amount;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    currency of denomination of the debt securities, which may be U.S. dollars or any foreign currency, and if such currency of denomination
    is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    designation of the currency, currencies or currency units in which payment of principal of, and premium and interest on, the debt
    securities will be made;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    payments of principal of, or premium or interest on, the debt securities will be made in one or more currencies or currency units
    other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these
    payments will be determined;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    manner in which the amounts of payment of principal of, and premium, if any, and interest on, the debt securities will be determined,
    if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity
    index, stock exchange index or financial index;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    provisions relating to any security provided for the debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    addition to, deletion of or change in the events of default described in this prospectus or in the indenture with respect to the
    debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the
    debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    addition to, deletion of or change in the covenants described in this prospectus or in the indenture with respect to the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions, if any, relating to conversion or exchange of any debt securities of such series, including if applicable, the conversion
    or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment
    of the conversion or exchange price and provisions affecting conversion or exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as it applies to that series,
    including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the
    securities; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including the terms of subordination,
    if any, of such guarantees.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of
acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the material U.S. federal
income tax considerations applicable to any of these debt securities in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we denominate the purchase price of any of the debt securities in a foreign currency or currencies or a foreign currency unit or units,
or if the principal of, and premium, if any, and interest on, any series of debt securities is payable in a foreign currency or currencies
or a foreign currency unit or units, we will provide you with information on the restrictions, elections, general tax considerations,
specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign
currency unit or units in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
and Exchange</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company (&ldquo;DTC&rdquo;
or the &ldquo;Depositary&rdquo;) or a nominee of the Depositary (we will refer to any debt security represented by a global debt security
as a &ldquo;book-entry debt security&rdquo;), or a certificate issued in definitive registered form (we will refer to any debt security
represented by a certificated security as a &ldquo;certificated debt security&rdquo;) as set forth in the applicable prospectus supplement.
Except as set forth under the heading &ldquo;Legal Ownership of Securities&rdquo; below, book-entry debt securities will not be issuable
in certificated form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certificated
Debt Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the terms of the
indenture. No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of
a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may effect the transfer of certificated debt securities and the right to receive the principal of, premium and interest on certificated
debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the
trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Global
Debt Securities and Book-Entry System</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
global debt security representing book-entry debt securities will be deposited with, or on behalf of, the Depositary, and registered
in the name of the Depositary or a nominee of the Depositary. See the section of this prospectus entitled &ldquo;Legal Ownership of Securities&rdquo;
for more information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenants</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Protection in the Event of a Change of Control</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford holders
of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether
or not such transaction results in a change in control) that could adversely affect holders of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidation,
Merger and Sale of Assets</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to,
any person (a &ldquo;successor person&rdquo;) unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are the surviving corporation or the successor person (if other than Lixte Biotechnology Holdings, Inc.) is a corporation organized
    and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities
    and under the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately
    after giving effect to the transaction, no default or event of default, shall have occurred and be continuing; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    other conditions are met.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its properties to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Events
of Default</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;event of default&rdquo; means with respect to any series of debt securities, any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">default
                                            in the payment of any interest upon any debt security of that series when it becomes due
                                            and payable, and continuance of such default for a period of 30 days (unless the entire amount
                                            of the payment is deposited by us with the trustee or with a paying agent prior to the expiration
                                            of the 30-day period);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">default
    in the payment of principal of any debt security of that series at its maturity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">default
    in the performance or breach of any other covenant or warranty by us in the indenture or any debt security (other than a covenant
    or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series),
    which default continues uncured for a period of 60 days after we receive written notice from the trustee or Lixte Biotechnology Holdings,
    Inc. and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities
    of that series as provided in the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    voluntary or involuntary events of bankruptcy, insolvency or reorganization of Lixte Biotechnology Holdings, Inc.; or</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other event of default provided with respect to debt securities of that series that is described in the applicable prospectus supplement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization)
necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of certain events of
default or an acceleration under the indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries
outstanding from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide the trustee written notice of any default or event of default within 30 days of becoming aware of the occurrence of such
default or event of default, which notice will describe in reasonable detail the status of such default or event of default and what
action we are taking or propose to take in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee
or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing
to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if the debt securities
of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued
and unpaid interest, if any, on all debt securities of that series. In the case of an event of default resulting from certain events
of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on
all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the
trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to debt securities
of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders
of a majority in principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all events
of default, other than the non-payment of accelerated principal and interest, if any, with respect to debt securities of that series,
have been cured or waived as provided in the indenture. We refer you to the prospectus supplement relating to any series of debt securities
that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount
securities upon the occurrence of an event of default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture unless
the trustee receives indemnity satisfactory to it against any cost, liability or expense that might be incurred by it in performing such
duty or exercising such right or power. Subject to certain rights of the trustee, the holders of a majority in principal amount of the
outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any
remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that
series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the
indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
    holder has previously given to the trustee written notice of a continuing event of default with respect to debt securities of that
    series; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holders of not less than 25% in principal amount of the outstanding debt securities of that series have made written request, and
    offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee
    has not received from the holders of not less than a majority in principal amount of the outstanding debt securities of that series
    a direction inconsistent with that request and has failed to institute the proceeding within 60 days.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment
of the principal of, and premium and any interest on, that debt security on or after the due dates expressed in that debt security and
to institute suit for the enforcement of payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with
the indenture. If a default or event of default occurs and is continuing with respect to the securities of any series and if it is known
to a responsible officer of the trustee, the trustee shall mail to each holder of the securities of that series notice of a default or
event of default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such default
or event of default. The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of any
default or event of default (except in payment on any debt securities of that series) with respect to debt securities of that series
if the trustee determines in good faith that withholding notice is in the interest of the holders of those debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modification
and Waiver</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder
of any debt security:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    cure any ambiguity, defect or inconsistency;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    comply with covenants in the indenture described above under the heading &ldquo;Consolidation, Merger and Sale of Assets&rdquo;;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide for uncertificated securities in addition to or in place of certificated securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add guarantees with respect to debt securities of any series or secure debt securities of any series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    surrender any of our rights or powers under the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add covenants or events of default for the benefit of the holders of debt securities of any series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    comply with the applicable procedures of the Depositary;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    make any change that does not adversely affect the rights of any holder of debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted by the
    indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    effect the appointment of a successor trustee with respect to the debt securities of any series and to add to or change any of the
    provisions of the indenture to provide for or facilitate administration by more than one trustee; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act
    of 1939.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding
debt securities of each series affected by the modification or amendment. We may not make any modification or amendment without the consent
of the holders of each affected debt security then outstanding if that amendment would:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the amount of debt securities whose holders must consent to an amendment, supplement or waiver;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the rate of or extend the time for payment of interest (including default interest) on any debt security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of, or postpone the date fixed
    for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the principal amount of discount securities payable upon acceleration of maturity;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">waive
    a default or event of default in the payment of the principal of, or premium or interest on, any debt security (except a rescission
    of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the outstanding
    debt securities of that series and a waiver of the payment default that resulted from such acceleration);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    the principal of, or premium or interest on, any debt security payable in a currency other than that stated in the debt security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any change to certain provisions of the indenture relating to, among other things, the right of the holders of debt securities to
    receive payment of the principal of, and premium and interest on, those debt securities and to institute suit for the enforcement
    of any such payment and to waivers or amendments; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">waive
    a redemption payment with respect to any debt security.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series
may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. The holders
of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all of the debt securities
of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment
of the principal of, or any interest on, any debt security of that series; provided, however, that the holders of a majority in principal
amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment
default that resulted from the acceleration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defeasance
of the Debt Securities and Certain Covenants in Certain Circumstances</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Defeasance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged from
any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon
the deposit with the trustee, in trust, of cash and/or U.S. government obligations or, in the case of debt securities denominated in
a single currency other than U.S. dollars, cash and/or government obligations of the government that issued or caused to be issued such
currency, that, through the payment of interest and principal in accordance with their terms, will provide cash in an amount sufficient
in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment
of principal of, premium and interest on, and any mandatory sinking fund payments in respect of, the debt securities of that series on
the stated maturity of those payments in accordance with the terms of the indenture and those debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received
from, or there has been published by, the U.S. Internal Revenue Service a ruling or, since the date of execution of the indenture, there
has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such opinion shall
confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes
as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amounts and in the same
manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Defeasance
of Certain Covenants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon compliance with certain
conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may omit to comply with the covenant described under the heading &ldquo;Consolidation, Merger and Sale of Assets&rdquo; and certain
    other covenants set forth in the indenture, as well as any additional covenants that may be set forth in the applicable prospectus
    supplement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    omission to comply with those covenants will not constitute a default or an event of default with respect to the debt securities
    of that series (a &ldquo;covenant defeasance&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
conditions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">depositing
    with the trustee cash and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other
    than U.S. dollars, cash and/or government obligations of the government that issued or caused to be issued such currency, that, through
    the payment of interest and principal in accordance with their terms, will provide cash in an amount sufficient in the opinion of
    a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal
    of, premium and interest on, and any mandatory sinking fund payments in respect of, the debt securities of that series on the stated
    maturity of those payments in accordance with the terms of the indenture and those debt securities; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delivering
    to the trustee an opinion of counsel to the effect that we have received from, or there has been published by, the U.S. Internal
    Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal
    income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the debt securities
    of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related
    covenant defeasance and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times
    as would have been the case if the deposit and related covenant defeasance had not occurred.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Personal Liability of Directors, Officers, Employees or Stockholders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our past, present or future directors, officers, employees or stockholders, as such, will have any liability for any of our obligations
under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation.
By accepting a debt security, each holder waives and releases all such liability. This waiver and release is part of the consideration
for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities under U.S. federal securities
laws, and it is the view of the SEC that such a waiver is against public policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
Law</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the debt securities,
will be governed by the laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably
waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or
relating to the indenture, the debt securities or the transactions contemplated thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated
thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the
State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt securities (by their acceptance
of the debt securities) irrevocably submit to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. The
indenture further provides that service of any process, summons, notice or document by mail (to the extent allowed under any applicable
statute or rule of court) to such party&rsquo;s address set forth in the indenture will be effective service of process for any suit,
action or other proceeding brought in any such court. The indenture further provides that we, the trustee and the holders of the debt
securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of
any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or
claim any such suit, action or other proceeding has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_009"></A>DESCRIPTION
OF WARRANTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue warrants for the purchase of shares of Common Stock or Preferred Stock or for the purchase of debt securities. We may issue
warrants independently or together with other securities, and the warrants may be attached to or separate from any offered securities.
If a series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant
agent, we will so specify in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of the material terms of the warrants and warrant agreements is subject to, and qualified in its entirety by reference
to, all of the provisions of the warrants and any warrant agreement applicable to a particular series of warrants. The terms of any warrants
offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement
and any related free writing prospectus, as well as the complete warrants and any warrant agreements that contain the terms of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms of any issue of warrants will be described in the prospectus supplement relating to the issue. Those terms may include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares of Common Stock or Preferred Stock purchasable upon the exercise of warrants to purchase such shares and the price
    at which such number of shares may be purchased upon exercise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    summary of the terms (including, without limitation, liquidation, dividend, conversion and voting rights) of the series of Preferred
    Stock purchasable upon exercise of warrants to purchase Preferred Stock as set forth in the certificate of designations for such
    series of Preferred Stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date, if any, on and after which the warrants and the related debt securities, Preferred Stock or Common Stock will be separately
    transferable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms of any rights to redeem or call the warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the right to exercise the warrants will commence and the date on which the right will expire;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    material U.S. federal income tax consequences applicable to the warrants; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    additional material terms of the warrants, including terms, procedures, and limitations relating to the exchange, exercise and settlement
    of the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of equity warrants will not be entitled:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    vote, consent or received dividends;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">receive
    notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">exercise
    any rights as stockholders of Lixte Biotechnology Holdings, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of Preferred Stock or Common
Stock at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify
in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the
expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised
warrants will become void. A holder of warrant certificates may exchange them for new warrant certificates of different denominations,
present them for registration of transfer and exercise them at the corporate trust office of the warrant agent or any other office indicated
in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised, the holder of the warrants will
not have any rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive payments of
principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants
to purchase Common Stock or Preferred Stock are exercised, the holders of the warrants will not have any rights of holders of the underlying
Common Stock or Preferred Stock, including any rights to receive dividends or payments upon any liquidation, dissolution or winding up
on the Common Stock or Preferred Stock, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_010"></A>DESCRIPTION
OF RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue rights to our stockholders to purchase shares of our common stock, preferred stock or the other securities described in this
prospectus. We may offer rights separately or together with one or more additional rights, debt securities, preferred stock, common stock
or warrants, or any combination of those securities in the form of units, as described in the applicable prospectus supplement. Each
series of rights will be issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights
agent. The rights agent will act solely as our agent in connection with the certificates relating to the rights of the series of certificates
and will not assume any obligation or relationship of agency or trust for or with any holders of rights certificates or beneficial owners
of rights. The following description sets forth certain general terms and provisions of the rights to which any prospectus supplement
may relate. The particular terms of the rights to which any prospectus supplement may relate and the extent, if any, to which the general
provisions may apply to the rights so offered will be described in the applicable prospectus supplement. To the extent that any particular
terms of the rights, rights agreement or rights certificates described in a prospectus supplement differ from any of the terms described
below, then the terms described below will be deemed to have been superseded by that prospectus supplement. We encourage you to read
the applicable rights agreement and rights certificate for additional information before you decide whether to purchase any of our rights.
We will provide in a prospectus supplement the following terms of the rights being issued:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date of determining the stockholders entitled to the rights distribution;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    aggregate number of shares of common stock, preferred stock or other securities purchasable upon exercise of the rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    aggregate number of rights issued;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the rights are transferrable and the date, if any, on and after which the rights may be separately transferred;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the right to exercise the rights will commence, and the date on which the right to exercise the rights will expire;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    method by which holders of rights will be entitled to exercise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    conditions to the completion of the offering, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    withdrawal, termination and cancellation rights, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    there are any backstop or standby purchaser or purchasers and the terms of their commitment, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    stockholders are entitled to oversubscription rights, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    applicable material U.S. federal income tax considerations; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the rights, including terms, procedures and limitations relating to the distribution, exchange and exercise of the
    rights, as applicable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
right will entitle the holder of rights to purchase for cash the principal amount of shares of common stock, preferred stock or other
securities at the exercise price provided in the applicable prospectus supplement. Rights may be exercised at any time up to the close
of business on the expiration date for the rights provided in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
may exercise rights as described in the applicable prospectus supplement. Upon receipt of payment and the rights certificate properly
completed and duly executed at the corporate trust office of the rights agent or any other office indicated in the prospectus supplement,
we will, as soon as practicable, forward the shares of common stock, preferred stock or other securities, as applicable, purchasable
upon exercise of the rights. If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed
securities directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such
methods, including pursuant to standby arrangements, as described in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Rights
Agent</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights agent for any rights we offer will be set forth in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_011"></A>DESCRIPTION
OF UNITS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We
may evidence each series of units by unit certificates that we will issue under a separate unit agreement. We may enter into unit agreements
with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit
agent in the applicable prospectus supplement relating to a particular series of units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description, together with the additional information included in any applicable prospectus supplement, summarizes the general
features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus
that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that
contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file each
unit agreement as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from
another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without
limitation, the following, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title of the series of units;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    and description of the separate constituent securities comprising the units;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices at which the units will be issued;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date, if any, on and after which the constituent securities comprising the units will be separately transferable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    material U.S. federal income tax considerations applicable to the units; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other material terms of the units and their constituent securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_012"></A>LEGAL
OWNERSHIP OF SECURITIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary
or warrant agent maintain for this purpose as the &ldquo;holders&rdquo; of those securities. These persons are the legal holders of the
securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered
in their own names, as &ldquo;indirect holders&rdquo; of those securities. As discussed below, indirect holders are not legal holders,
and investors in securities issued in book-entry form or in street name will be indirect holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Book-Entry
Holders </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be
represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf
of other financial institutions that participate in the depositary&rsquo;s book-entry system. These participating institutions, which
are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will
be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize
only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary
passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial
owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are
not obligated to do so under the terms of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, investors in book-entry securities will not own securities directly. Instead, they will own beneficial interests in a global
security, through a bank, broker or other financial institution that participates in the depositary&rsquo;s book-entry system or holds
an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not holders,
of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Street
Name Holders </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate a global security or issue securities in non-global form. In these cases, investors may choose to hold their securities
in their own names or in &ldquo;street name&rdquo;. Securities held by an investor in street name would be registered in the name of
a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those
securities through an account he or she maintains at that institution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names
the securities are registered as the holders of those securities, and we will make all payments on those securities to them. These institutions
pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their
customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders,
not holders, of those securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
Holders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the
legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street
name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has
no choice because we are issuing the securities only in global form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that
holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but
does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences
of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we
would seek approval only from the holders, and not the indirect holders, of the securities. Whether or how the holders contact the indirect
holders is the responsibility of the holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
Considerations for Indirect Holders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check
with your own institution to find out:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    performance of third-party service providers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
    it handles securities payments and notices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    it imposes fees or charges;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
    it would handle a request for the holders&rsquo; consent, if ever required;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the
    future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
    it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect
    their interests; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the securities are in book-entry form, how the depositary&rsquo;s rules and procedures will affect these matters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
Securities</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities
represented by the same global securities will have the same terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial
institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless
we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary,
unless special termination situations arise. We describe those situations below under the section entitled &ldquo;Special Situations
When a Global Security Will Be Terminated&rdquo; in this prospectus. As a result of these arrangements, the depositary, or its nominee,
will be the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to own
only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other
financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose
security is represented by a global security will not be a holder of the security, but only an indirect holder of a beneficial interest
in the global security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security
will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may
issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry
clearing system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
Considerations for Global Securities</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights of an indirect holder relating to a global security will be governed by the account rules of the investor&rsquo;s financial institution
and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of
securities and instead deal only with the depositary that holds the global security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are issued only in the form of a global security, an investor should be aware of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her
    interest in the securities, except in the special situations described below;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection
    of his or her legal rights relating to the securities, as described above;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required
    by law to own their securities in non-book-entry form;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the
    securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    depositary&rsquo;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating
    to an investor&rsquo;s interest in a global security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    and any applicable trustee have no responsibility for any aspect of the depositary&rsquo;s actions or for its records of ownership
    interests in a global security, nor do we or any applicable trustee supervise the depositary in any way;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its
    book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    institutions that participate in the depositary&rsquo;s book-entry system, and through which an investor holds its interest in a
    global security, may also have their own policies affecting payments, notices and other matters relating to the securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for
the actions of any intermediary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
Situations When a Global Security Will Be Terminated</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be the responsibility
of the investor. Investors must consult their own banks or brokers to learn how to have their interests in securities transferred to
their own names so that they will be direct holders. We have described the rights of holders and street name investors above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations
occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security
    and we do not appoint another institution to act as depositary within 90 days;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we notify any applicable trustee that we wish to terminate that global security; or</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular
series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or
any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_013"></A>PLAN
OF DISTRIBUTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities offered by this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions,
block trades or a combination of these methods or through underwriters or dealers, through agents and/or directly to one or more purchasers.
The securities may be distributed from time to time in one or more transactions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a fixed price or prices, which may be changed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    market prices prevailing at the time of sale;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    prices related to such prevailing market prices; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    negotiated prices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
time that we sell securities offered by this prospectus, we will provide a prospectus supplement or supplements that will describe the
method of distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the
securities and the proceeds to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offers
to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers
to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal.
The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed
with the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter
will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the purchasers of securities
for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter
may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions
from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus
supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal, and may then resell
the securities at varying prices to be determined by the dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions
or commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters,
dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities
Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to
be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities,
including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse
those persons for certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Common Stock issued by us under this prospectus will be listed on The Nasdaq Capital Market, but any other securities may or may not
be listed on a national securities exchange. To facilitate the offering of securities, certain persons participating in the offering
may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments
or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to
them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market
or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities
by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers
participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions.
The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might
otherwise prevail in the open market. These transactions may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
indicated in the applicable prospectus supplement, underwriters or other persons acting as agents may be authorized to solicit offers
by institutions or other suitable purchasers to purchase the securities at the public offering price set forth in the prospectus supplement
pursuant to delayed delivery contracts providing for payment and delivery on the date or dates stated in the prospectus supplement. These
purchasers may include, among others, commercial and savings banks, insurance companies, pension funds, investment companies and educational
and charitable institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In
addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties
in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the
third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.
If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related
open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings
of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in
the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial
institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement.
Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection
with a concurrent offering of other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for
which they receive compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_014"></A>LEGAL
MATTERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TroyGould
PC, Los Angeles, California, has issued an opinion regarding certain legal matters relating to the issuance of the securities offered
by this prospectus on behalf of Lixte Biotechnology Holdings, Inc. Additional legal matters may be passed upon for us, or any underwriters,
dealers or agents, by counsel that we will name in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_015"></A>EXPERTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Lixte Biotechnology Holdings, Inc. appearing in Lixte Biotechnology Holdings, Inc.&rsquo;s Annual
Report on Form 10-K for the fiscal year ended December 31, 2023 have been audited by Weinberg &amp; Company, P.A., an independent registered
public accounting firm, as stated in their report thereon, which includes an explanatory paragraph as to the Company&rsquo;s ability
to continue as a going concern. Such financial statements have been incorporated herein by reference in reliance on such report given
on the authority of such firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_016"></A>WHERE
YOU CAN FIND MORE INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website at www.sec.gov
that contains reports, proxy and information statements and other information regarding us and other issuers that file electronically
with the SEC. This prospectus is only part of a registration statement on Form S-3 that we have filed with the SEC under the Securities
Act, and therefore omits certain information contained in the registration statement. We have also filed exhibits and schedules with
the registration statement that are excluded from this prospectus, and you should refer to the applicable exhibit or schedule for a complete
description of any statement referring to any contract or other document. You may access the registration statement of which this prospectus
forms a part by visiting www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain a website at www.lixte.com, through which you can access our SEC filings free of charge. The information set forth on our
website is not part of this prospectus. The reference to our website address does not constitute incorporation by reference of the information
contained on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_017"></A>INFORMATION
INCORPORATED BY REFERENCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rules of the SEC allow us to &ldquo;incorporate by reference&rdquo; into this prospectus information that we have filed with the SEC
under the Commission File No. 001-39717. This means we can disclose important information to you without actually including the specific
information in this prospectus by referring you to SEC filings that contain that information. The information incorporated by reference
is considered to be a part of this prospectus, provided that it will be automatically updated and superseded by information that we file
later with the SEC. This prospectus incorporates by reference the documents listed below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224010427/form10-k.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the fiscal year ended December 31, 2023, as filed with the SEC on March 19, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form 8-K, as filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224010934/form8-k.htm" STYLE="-sec-extract: exhibit">March 22, 2024</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000149315224011582/form8-k.htm" STYLE="-sec-extract: exhibit">March 28, 2024</A>;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of the Common Stock incorporated by reference to our Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220021857/form8-a12b.htm" STYLE="-sec-extract: exhibit">Form 8-A</A> that was filed with the SEC on
    November 17, 2020, including any amendment or report filed for the purpose of updating such description; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the
    date of this prospectus and prior to the termination or completion of the offering of securities under this prospectus shall be deemed
    to be incorporated by reference in this prospectus and to be a part hereof from the date of filing such reports and other documents.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, we are not incorporating by reference any documents, portions of documents, exhibits or other information that is deemed
to have been furnished to, rather than filed with, the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus shall
be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or
any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the
statement. Any statements so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of
this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written
or oral request of any such person, a copy of any or all of the documents that has been or may be incorporated by reference into this
prospectus (excluding certain exhibits to the documents) at no cost. Any such request to us may be made by writing or telephoning our
Investor Relations department at the following address and telephone number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680
East Colorado Boulevard, Suite 180</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pasadena,
California 91101</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(631) 830-7092</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also access these documents on our website at www.lixte.com. The information contained on, or that can be accessed through, our
website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual
reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Up
to $1,700,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>___________________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>___________________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>WallachBeth
Capital, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>January
8, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 51; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "? D # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI#>V4\UO*T$\,JI(3'(K ,.C@ACMX8;>%0D,$<<,2#HD<2"-$7.3A44*,DG
MY)J6BIN[6N[)MI7=DVDFTKV3:23=KM)*]@LKWLKVM>VMM[7WM?6P4444AA11
M10 4444 %)SGVZ8QWZYS^E+1^/X?Y_S[4 ?&?[>!5?V>]8)'7Q5X0S@<G_B;
M1=< DXZ_3O7XSZGX<GTWP_H6OMJ6C30Z\VIHEG:ZMI]SJ%H--N8H"T]E;W4M
MSB3S09]T"&P<+!<%7E53^V/[:/ASQ#XM^!VJ:)X7T/5/$6KR>)/"US%I>CV<
ME[?206NJ1R7,T<$?S-'!&#)*P&$0$GCI^0A^!7QL(&?A)\0<#.U?^$>OBH+8
M+$+C";B!N*J,X!.237^-/T^N&,^SGQJCBLNX(XGXEI5?#+A[!X#,LERW/L5A
M,LS.GG.<5JM2M+*\GS##8R:PCG1G@JU>@X+$TZTK>YS?WY]&#/,KR[P^='%\
M59'D4J?&F:8K&8',L7E-'$9A@9Y7@:5.E36.S+!U\+'ZSR5HXNE2K*7U>=%)
MJ4[8EGX8TJ;QQX+\,RW%R+'Q%8^#KO4&-U#!<QGQ!IUO?7RP7#QM':P1R2N(
MI9(I1!$"TADV',FI^$K>ZTC1M3\,Q6]S=:A?:OI]Y8Z;XLTKQ7I]G]AM+*]M
MI)=9CATZ"SU"\AGO9/[*FEN7EM+-;VWE4.T"]Y'\.OVEH5TQ8OAY\15.CC3U
MTJ8>#;'[98)I04:8D&H-IAU!X[)45(8I[J6-HU\J59(LH<W4OA)^T#K%O!9Z
MI\+_ (@W5I:RR7%M:IX1CLK2.>5$CDN/LFF6-E;O<M'&D7VB6-YUC01(ZQD@
M_P JUN$Z\<ISG"TO"/Q%K8W,<2L5@:W^HF=8.IEJE@\FI+"4,9++L?*%*ABL
M%F=55/836(AF,E+#<U_8_LE//YRS/+,3/Q$X+H87!T'1Q5/_ %LR_&4\=*.)
MS27UFOA/K6"4ZE?#XO 0E26(I^QG@5;$N*3J\U=:'X9LM!MO%D]AJTM@GAS2
M;JYT2+78H99]8U/Q%KFB>>=5;3)'L])BBT5[GR5L9Y'O;B"T%SY!9CL3^!?#
MVGZSH>A7;Z[=S>,]<ETW1;V*ZMK-] M6L-#N[!]2T_[)<)K&HI<:]"FJVZ7&
MFP0Z?:M=08ENHQ!J6/PK_:(TYH6L?AK\2(1;:>VDPI)X8-U;+IKWC:B;%[.]
MM;BTGMUU!WO8UN8)C#=$30M&Z*18B^&_[2D(U%8/ 'Q07^U;FYO+]G\/2S3S
M7E[";:]O(KJXMY;JQN[RV8VUS<:;-:3SVP6W=VBCC1>ZED55TJ/UCP6XZC7Y
M,,JDJ?AYFM6$:U.&'6958\V"HJM#-Z=.>$HT94Z$,BJ<V:X)8C$UYX>GR5<R
ME[2O['Q0X6E2<\0Z*GQGA*4_95)UOJ-.35>LZ4LMG..*JU(SJRSB-LLQ;H8>
MA"O4_0/_ ()V@CX4>,4?!>/XE7L;;267*:!X>4E23RC$94^F.3V_0FOAC]A'
MP;XK\%?#+Q1IWBWPSK/A:^N/'MU?6MAK=E)87,UBVAZ' EU##+AFMVE@FB60
M#:7B=1]W)^YZ_P!M_HNX+%Y=]'WPHP6.P.+RS%X?A2C"OE^.P^(PN,P<WF6=
M3C0Q&'Q5'#XFE4ITJE*+C6H4ZC2C-Q_>)O\ SQ\7\10Q?BAQUB<+B:&-P];B
M'$U*6+PM6E7PV)B\/EZ=:C5H5*U&=.<XU)1=*K4@KN*D^1V****_>S\X"BBB
M@ HHHH **** "BBB@ HHHH *0G .,9'K^?\ *EI&Z'V!_D:&)]/5'YB_M9_M
M9^.?!?C#6/A3X AB\/S:;:V)U;Q=+MNM4E;5+-;O[/HL$@-M8"&*15:_G2>X
M:3)@CA"AV_.S4?!_C;5M"D^)=S'>^(]&O9I?[9\5+>R:K+8ZD)$6>T\1W-PQ
MO+/4!)-$R1S[X9([B)K>5MQ"^S?MG\?M'>/<8R;7PV1G'#?V);>I'4=![DYQ
MQ5+5?#^G:_\  ;1M>M[^\AO?!5M81DWUAXCM+6[;4+Z]AU70[:]NI(O#6H$S
MRV%WI+:1:R7,:6NHQW]S/)L\K^X>$<%E7"7"W 6+RG+\)A*_$JRF&=8^IA9X
MK$XB>/P4ZK<\1&I'$TU4Q7LJ="-.7U:A>\L-4IQFS_)KQ2S'/_$/C_Q1P>?Y
MQF68X3@RIQ#+AS*(8^&"P.#I93F$:$%1P4H/!3=/!QJU,35J4WC<4[1AC(5)
MP@?-K+L;;@#@' Z '/KSGKG/^-)3Y<;\_P"PG7@#KCN?\^M=5X)\!^,?B/K<
M7AWP/X?O_$.J2,GFI9Q8M;&-R +C4[^39::?;KG+274T>0"$5W 4_K]?%8?!
MX:IB\;B:&$PM"#J5L3B:M.A0HTU]JI5J3A"*2ZN5WM%2;47_ #KEN QV:8C"
MX#+<%B\PQV*G&CAL%@L/5Q6*Q%64K1IT:%"G5J3DVTK*-DDW.<4I27(LP49.
M>F<\8Z]SG@8YR:[S1OAIXWUWPCKWCZR\/WH\%^&K876I^(;L?8M/D+7$-JMM
MILDVUM5NC+.BF.R$L<0W--(FW#?IS\%/V#/#?AO['K_Q<N(/&.N((IH_#%H9
M$\*:?+PP6[9ECN->EC8#/G""QW+@6TH(:O=?VL;&ST[]FSXC65A:V]E96VAV
M4-M:6L4=O;6\,6J:<L<4$$2)%%&@ "HBA0!TK^._I"_25GPKX<^(F*\-91JY
M[DW!O%./P'$N)HJ>"P6/P&29EB<-B<!@<1#_ &^I0Q%"G5IU<7"G@Y.$7["O
M'27]]?1[^AGBN).+.#L3XN2EEV1YAQ%D-#$<(8&NEFN/PF+S/ 4J^'S;,*$Y
M0RJE5I59TZN'P4Z^8*,IQ>(PLVW'\&QNYV!43:=HP"YR?XGX+#\!USC@Y:J$
M-N)!X/\ #@\X^@ XZ 8_G4B]!]!_*EK_ (\N./$+C?Q.XBQ_&'B%Q3G?&'$V
M:R]IC<XS_'XC,,7/F]Y4:+K5'2P>%IN;C1P>"H8/"4(*$*6'BHIO_J/X'X"X
M+\-N'<#PIP%PQDO"7#F74XT\+E.1X##X'#1Y4H.M6]E!5<7BJBBI5\9C*^+Q
M5>;E.KB)-V6YH/\ Q]2_]<3_ .A+U_R*[/ &?Q)/?U_&N+T)E%U)D@9A(_'>
MH XR22>  "2>!S7V1\)?V6?B)\36MM2U&VE\&>%)2KOJ^KVTBZC>Q'#9T?1Y
M#'/<;D/R75TUO:#.4,VTJ?>\.?#OC3Q*S##Y!P1P[F.?YC4K2]K'!T)?5L%2
ME*">)S#'S4<%E^&BFY2K8K$4TXIN%.K)*#\;CGBOA[A&G5S/B+-<+EF%C2@H
M>VFG7Q,XQE+V.$PL'+$8JL]$H4:4[.2YYTU[R^<;2SO=3N[:PTZTNK_4;R18
MK/3[&&6ZN[J5FVJD%O"CR2LQ( VKM7JQ &:^Y?A'^Q9KNLFUUOXIW4OA_2V5
M)H_"MA*KZ]<J0I":G?KO@TI&_CAMOM-V>09+<]/N7X7? WX??":U*>&M'635
M9(PE[XCU,K=ZW>''S#[4R@6MN26(M;)8( "H*,1FO6;F:WL[:XN[EQ%;VL$M
MQ/(0S".&&-I99-JAF.Q$+$*I8@8 )XK_ %>\$/H#<+\+_5,_\6L10XOSN/LZ
M]/AC"SJPX8P%6/+-4\=5O2Q&?5:4U:47]4RV4HN]+$P=I?P_XA_23SO.O;Y9
MP33JY!ELE.E+-JJ@\YQ,;M<U"*YZ664Y1^%Q]OC$GK5I2NH_R)_\%'O^"(?[
M13>)/$?QN_9[\=>)/VCM$G:YO[KX9>--0M_^%J>%[+S))/[-\$78^QZ!XKT>
MTB"1VND06VAZ]MV1QPZS.&>3^:;5](U?0-8U/P_XATG5- \0:+>2V&M:#KFG
M7FDZSH]_"Y6:RU+3+^*"^LKF-\J\5S"C@'< 003_ *B'P]^(GA+XGZ--X@\'
MWT]_IMM>KI\TEQ9W5C*ES)ING:Q"#!=11.4GTK5]-OH9%!'E7:(_ESI+%'\@
M_MF?\$V_V7?VWM(F?XH>#1HGQ$@LFMM ^,'@I;?1?B!I#+&5MX[N_6"2T\3Z
M5$WEE](\26NHVGEH4M#92L)U_P!4.#>+L+PSEV!X?65X+!Y'@*-/"X"CD^"P
MN7TL!AX1C&G"G@,'1PV$E3A%*_LJ5*M)WE.5:;<I?QUGV1ULWQ.(S*6,Q%?,
M,34E6Q-3&XFOB9XJK)N4ISQ%>I6K<[;T]I.=-;)0BE%?YSZ[>PP1U]C['/3C
MV^E+G''))Z?CGGCL,<G'ZU^LG[97_!&W]KG]DW5)=2\/>&=2_:#^%-S>+;:3
MX^^&.B7U]KFGI-,([2W\;>!;9KS6-!N6WQ1R:G8-JOAQI&+'4;0Y@CR?@'_P
M3BU;5OL/B;X\W\FBZ>Q26+X?Z#>1OK5P V?*\2:U$7BTH-RDMAI;7%XI)2:[
MMF!53Q>^DIX.^"'"M/BOCWBW"8.AC(UHY/DV"B\=Q%GN)P\%*IA<KRBERXB<
MX.4(5Z^(GA,'A7.,J^(4+<YP+X0<?^(V</)>%\BK8FI1G#^T,?B)0PN59;2G
M)Q5?&XZHW"%.:C-TH4HUJ]?D<:5)O;\\_AI\)OB%\8==3P[\//#-_P"(;Y67
M[;<QJ+?1](C<#_2=9UB8)8Z="J_,!-*9Y!\L,,KD*?UD^%O_  39^'FF>&[W
M_A;FNZIXK\5:G8M$I\*WLNB:+X5FD&1/I4KPM<ZSJ-LRD?:-2B73I<%!I^QR
M]?H7X2\$^%/ 6A6GACP7X?TKPOH%A@0Z7HUJEK SJ IGNG7,]Y=N,F6[NY9[
MB1F+-)S@=0WW3]#7^&7T@_VFOC)XE8Z67>%5?$^$?!^#Q<<1A:F65J.(XQS9
M86JZN'JYOG,J-6A@Z%25.$ZN5930CAYPDZ&+Q>+ASQG_ *4>%?T.. .$,+'%
M\;TZ/'6?5Z$J=6GBJ=2ED& ]M#EJ0P6!52-3$U8J<XQQN-J^TC)1J4*%&2BU
M^+7[1'_!*?\ :7^#'P[T[XY^!M OOC3\#=6LKG4Y?$?@VPEN_&'@BVL[RZM;
MA/'O@ZV66^2VMVMG=_$'AY=2T@1%9+U=.)"'\R(IDF4/&P9#G#*0RY'4;AQN
M'(*\$$$$ @@?Z7G[' #?LX_#8,,@V.K*<\@@Z[JP((.00<<@@BOS]_;G_P""
M)G[-7[5S:SXZ^&T-O^SY\;[[S;N3Q3X0TJ%O!'BS42KLI\=>!H&M;*>:YE"+
M/X@T!]*UI=TD]TVJ-B$_[7^"7B]F/$'AOX?9IQI4^MYIG/!O#&99CG="A"G+
M$8W'9+E^)Q6)Q6#HQA2BZM>K4J3EA8QBG.7[A1LE_G-XA<"X3+.+.*L%P_%T
M,'EW$.=X+"X"K4E45+#87,\90P]*C7J-SDJ=*G&"6(E*3LFZK;9_"53)'$:L
MQSA03P">@R>!DDXR0!R<8'-?7?[67["_[3'[%'B5M%^.O@"ZL/#]U=26OA[X
MF>'6GUSX:>* "/*.G>)4AB33K^6,I(VA:_#I6LQ%RGV255\T_(4F3&S*H8[&
MVJ1D,2IVJ1T(9L>Q'0U_1N'Q.'Q=&&(PM>EB:%1<T*M"4:D9)K2SBW:71PDH
M33]V48O;\JJT:U"HZ->E.E5B[2IU(N,EKYJS3W33DFK--GNOC3]G?XB?#_X>
M>&?BMK=]X)?P_P"(Y-!N-&CT'QM8ZEXILY=:M7U'2;FYT6S6/4-+F@C@9I9_
M-22QN%1=QDYK]>/^"<7_  6B_:8^$OC;X:? CXQ37/[0'PM\5^+?"O@/2-0\
M2ZD\/Q-\#'Q%J]EH%A<6'BZX$[^*-&TV2\BDDTCQ,MQ?"TA,&GZU; )"_P \
M_M4W\,O[ W[)FFCQAXBA@LQ:3:+X;N?C%X>O](\>PS6]W_:_C.X^#BZ1%XIN
MK[PI?AO#&G_$5M53P[;6$2^'K:QEO8)KFO@']G3C]HS]GX=<_'3X3<^O_%?:
M#^GL?YC-?/5,/AL^RC&/-</2Q/LJF9*A+V?LYT?JRQ$:4J<HMRA47LXN3A4Y
M9M6J0<E)+U(5:V68VA]2JU*7M(X7VB;;C/VLJ;DI0D^64;2:3<;]8M*Q_IY*
M>HSG!QTQV!X]N?\ (IU(._N3G\\?R %+7\ZK;^O3]#]7V/*_CCQ\'OB<<@ >
M!/%!.3@8_LBZZ^PZD]!7\[-AXDU&TT:YT2VUF>#2-2^QRWVGQWCI;W#VBRF(
MM&DH0*3<3>>FTBZ!C$P8(M?TXWEE::A;3V5_;07EG=126]U:7423VUS;RHT<
ML%Q!*K130RHS+)%(K(ZDJRD<5P@^$/PI P/AIX# Z ?\(EH/ '8?Z!Q^%?QC
M]*'Z+G$?CYQ!PIGF0<=X+@Y\/9!G.18F&(R_-,56QM'.,?2Q591K9;C\%R8>
M=&F\/7H5?:1JJ6J<=#]^\&_&;+/"_+,]R[,>%ZO$<<WS3+<SI..-P>&IX2KE
MN&J4:4O9XO!XOFK1JSC6I58<CIN.GO69_.W#XAT5O#\6@:EH\>H_9+W5[^PO
MXM=N=->WFUBSTNUF6:UB@GANTA;2+:6,,\3,6DC8E6#5TFK?$Z348-5\BW:T
MO=;BTR"\FN/$NHZKI]F-+;3Y(;K2-#NA'I^FWOFZ9#]GN2MS)80SW<-IL$[M
M7] '_"HOA3_T37P'_P"$EH/_ ,@4?\*A^%/_ $33P%_X26@]O^W"OYUPW[/W
MQ1P>%G@\+XT<,8>C4P.'RZI*CP9F%/$5<)A,-B<'AJ=7$QQL:]25#"XS$X>E
M5J2J584:KBI7C"I2_4J_TH.#L376(Q'AKFE:I'%5\;&-7BBA.C'$XFO0Q6)G
M"A+!NE"-?$X:A7JTX*%.I5IJ4DHN=.I_/18>/;^Q\W[0UEJS7NKW>IZI)?RL
MKZK;ZCH$OAS4=,N?LQA$4%SIT\A6YMVCN8+@1RQ']V096\;:=-:#0;G0;"?P
MA%9V]M;:!_;>H1W-O<VU]>:B-577DVWDFHSW&HZA!=L;=8)-/N!9PV\!@AGC
M_H2_X5%\*?\ HFO@/_PDM!],?\^'ZT?\*A^%/_1-? ?_ (26@_\ R!10_9_>
M*F'HQP\/&SAR=&-.5%PQ'!^/Q7/AZDISKX2K+$XJM.M@\5.?M<9A*LYT,76A
M2K8B%2I1HSIJI])[@NI5=:7ACF$:CJ1K)T>)J.'C#$4W#V.)I0H8>G3I8G#Q
M@J>&Q%.$:N&I2J4J$J=.K4C/\Q?V!]:F\0?&_P"(.K7)MA<WG@/S7AM,K;VT
M,6MZ-;VEK;H6=EMK2UA@MH=\CR%8@TKO(S.WZ^COSGGGZX'],>OUKE]"\#>"
M_#%S->^&_"7AO0+RXA^SSW6BZ)INEW$UOO63[/+-8VT$DD'F*LGDNS1[U5]N
MY01U/]:_NWZ/_A9FO@[X<8/@K.L_P_$V9T<[XBSG%YQA<)7P-+%5<^S2692_
MV?$5:M2-2G*4U4ESJ$I->SA3A&,(_P W^)O&6#X\XMQ/$67Y54R3!U,OR?+\
M/EE3$T\7+#4LIR^& @E7I4Z<90E"$7!<O-%*TYSFY3D4445^V'P 4444 %%%
M% !1110 4444 %%%% !1110 4444 1F)2Q;G)]^/PXZ_X4NP>I_3_"O&_P!H
M;X]_#O\ 9?\ @SX[^//Q8N]7LOA[\.=.L]4\2W&@:'J'B364M]0UC3M"LTT[
M0M*BGU'4[F?4]5LH$MK2)Y3YA?&U&(\K\(?MN? K6O"6I>-_B%J'B3]FGP_8
M>()?#5K/^UCX>G_9PF\0ZC!H:^(KJ3PK#\4I] /B*RL]*\Z>\NM,,\=L;.^6
M7:+2<HN5??YO_-"<8MW:3?FE^J9]<;!ZG]/\*-@]3^G^%?'&O?M]?LL>%OC1
MX5^"OB;XM>"?#E[X[^#&A?'/P-\0]>\9>#-(^$_C;PIXG\<R_#_P]I/A#QU?
M^([?3_$OBO6M8B-YIFCZ/'>+?:.\=_:74^\15[@/CY\"V\=:_P#"]?C1\*&^
M)?A32;G7O%'P]'Q$\(GQOX;T.RL8-3O=9U[PH-8_MW2-+L]-NK74;N_U"QM[
M6VL+FVO)Y8[:XAE<LO/[W_F+DCV7W+_Y$]7V#U/Z?X4;%]S^7^%>*>%_VF?V
M</&^C^,/$/@O]H#X)^+O#_P\L+?5?'^N^&/BIX%U_1O ^EWED^I6FI^+]4TK
M7;NQ\-Z==:=')?6]]K,]E:S6D<EQ'*T2,PHG]JS]E]?#?@[QDW[1_P !QX0^
M(>L7/A[P#XI/Q<\ #P[XVU^RGCM+W0_">M?\)!_9OB'5[*[EBM;S3M)N;N\M
M;F6.WGACF=4)9>?WO_,?*NR^Y?\ R)[T$ Y[\<X&>#GT_/UZTZOE#XQ?MK?L
M\?!3XB?#3X0>)?'^@ZQ\6/BA\5_A[\(]*^&'A7Q!X7UGXA:#JWQ,34I/#?B;
MQ;X,_MVV\1Z%X'*Z9(;SQ'+ILT,7VJQ,4,XN5(]B\8?&OX-_#SQ1X2\#^/OB
MS\-/ _C3Q_<BR\">$?%_CKPOX;\3^-+QKA+-;;PIH&LZK9:KXBG:\DBM%BTF
MTNY&NI8K95,TL:,_Z_3\AI):+1>7](]-HKY(_9O_ &X?V;OVH_#=[K7PW^(_
MAJVUO1_^$UG\3?#CQ)XE\*:;\3_!^D> _&>N>!M8\1^+_!%MK]_K'AWPY<:K
MH-Q=Z;K.IQ065SI-WIUZ\L/VL1+W"?M7_LMR>"HOB2G[27P$;X=S^(+OPE!X
M\'Q@^'W_  ALWBK3],N=;OO#,/B8^(?[%D\06FBV=UK%SHR7K:C#I5M/J+VX
MLXI)U /?Z*\;\)?M%_L^^/M4U+1/ OQT^#OC36M&\*V?CK5](\)_$WP5XBU/
M2O!&H0175AXQU*PTC6[RZL?"UY:W$%S:Z_=11:5/;SPS17;1RQLWE/BW]O;]
MC+P9X6\$^-]6_:8^"]UX,^(?Q3TWX+>%/%OA_P"(7ACQ1X:O?B1JD;3Q^'[G
M7/#VI:EIFF&PM@EWK=_J-U:Z?H5E<6EYJ]U96UW;2R@'UU17R?\ !G]M?]G;
MXX^._B!\+/"OQ"\/:7\4?A[\4/B/\++WX9^*/$?A;2?B#XAO_A=/;P>)/%?A
M+P8FO77B+7/ D@N//TSQ-#I\=O=6L%S<216\<+&N\M/VH?V:+_1O%GB.Q_:&
M^!UWX=\!:U:>&_'.O6WQ8\!S:+X,\0W]T]C8Z'XJU6/7FL?#VKWM[')9V>G:
MM/:7=U=QO;0123HR  ]THKP_0/VF_P!F[Q5J^K^'_#'[07P2\1Z[X?\ "W_"
M<Z]HNA?%7P+JVK:)X*&G6NL-XOU;3K#7;B[TWPPFD7UCJLFO7D,.EQZ;>V=\
M]TMK=02R,\*_M/?LU^.F1/!'[0GP/\8M+XIT7P/$/"OQ7\!^(3+XU\2:?>ZM
MX=\(1C2->N_,\3Z_I>F:EJ.BZ"F=4U6RTZ^N;&UGAM+AXP#W.BN>\/>+?"OB
MY-7E\*>)?#_B:+P_K^J>%-=E\/ZSIVLQZ+XHT*5;?6_#>K/IUQ<IIVO:-.Z0
M:KI%VT6H:?.PAN[>&3Y:Z&@ HHHH *1NA^A_E2TC=#]#_*D_\OS0NWJC\%_V
MT/\ DX[QYZ_9O#1'&>FA6Q_I_G%$MG>P_L][[KQ/)K=@;/2+NUT&[A\+W<6B
M27.K7CQ+HEV=3C\4Z5'H;1DZK;/:7%K=3ZS$+6U5$EN$/VT/^3C_ !X.YM_#
M8'XZ%;#/X9&:L1W6BK^SU)J2Z.G]JG3CX2DU%?#WBOS&F:3[29?[2%L/#QA-
MD"IU!IQ;?:E^S,?M7%?W*G47 _A-R0<DZO"R;5.A-J;PB4&IUFITDFJEYX>2
MJ-)Q:E%\K_R5S2G2J>)_CLJE2--J/'+4I5<7!*'U^?M6J>&4J5>27LN6CC(^
MP;DI)QG!27RO=MB)Y$89$1(*D9!"G' Z'H<<X.>Y!K^BKX&^%/#?A?X7>";?
MPYHNG:+%?>&- U.^_L^VB@DOK^]TRVNKJ[O)D0375Q--*[/+/)(W( (  '\Z
M5TH$,NT$*8"P!.2/E;.>X(QC&.O;J:_I-^%7_)-/A_\ ]B5X6_\ 3)9U\;])
M"K4CE?"M&%6HJ57'YI*K3C4G&E5=+"85TO:TU-0J.G*4Y4_:1GR.3<>5MR?Z
MI]"##8:IG_'>)G0HU*^&R3)(X;$5*-.=>A'$9EC575&K.G*K0]M&$(U?93IN
MJH)3<HI1.^QCZ8Q_AS[5\U_M??\ )NWQ+_[!%K_Z==/KZ5KYJ_:^_P"3=OB7
M_P!@BU_].NGU_ /C-_R:3Q/_ .S>\8_^L[FQ_J%P'_R7'!G_ &5G#G_JZRX_
M!->@^@_E2TB]!]!_*EK_ )B8?!#_  0_])B?[.1^%?UU9]R?L#>%_#OB3XI>
M*9M>T>QUB70?"]KJ.D#4($N8K"^EU2.%KN&&57A^T>42J2,C-&?FC*N=P_9I
M5"#  [9P,=.. .@ Z <5^0O_  3J_P"2E_$+_L2['_T\PU^OE?[V?0#P.#H?
M1SR+%T<+AJ6*QW$?%D\9B:6'HT\1BI8?-X4*#Q->%.-;$>QI15.BJU6HJ5/W
M*:A&]_\ +OZ3]>O5\7LZHU*U:I2PV79%##TIU:DZ5"-3+(U*D:-.4Y0I*I4;
MJ35.$.>;YYN<K->=>./B+9^#[/619Z7>^)M=T?0;KQ%<:'IK1PFVTNVM=1ND
MO=5U&X'V32K.Y_LJ]@M99?.N+JXB,%I:7,H*#PBT_:ZT'6O@IX2^*_A#X=?$
M#Q[KOQ(\!Z3XY^%WPP\'6-CJ/B#XCVFO:'I.MZ;%X?UV^NM+\*V&GP1:YIT6
MOZYXIU7P_8>&=\\NM"U$*)-WOQ-MM4\._P#"T?%8TK4]8TCQ#\+$T-1H GFU
M?3]1T&W\97 :2RM8IM0>WOQK]O';WNEV]]/930R23V@B*RCYK^''BSXD>!O@
M=\!_BUJ_P.\5:G%X,^$VJ:K\2? /PVLS?>*M&U7QOI?AGQ)J^D?"[P%J4>DZ
MOXNT7PA?V=_HUKI,8TOQ#J-M#:CP[HNKW(%I)_:Z5UYWTUMT]>^G3>]S^?#T
M'X6_$S4_@_X$\+:#\;_ S_#GQ]XWUC7?$-CX2\.ZE:>-O#NDR^)O$T+1>'YO
M&>B:3I&E"7P]J'B;P]X;UG5;K2]/TQM2U.SFTVXU#3I?MB?9\;,R([H8W9%+
MQE@QC8@%D+*2C%3E2RDJV,J2"#7R'H7QZN?CSIGPY\<?L_\ @V#QS\/M76PU
MR7Q?XZT'5?"'V6"^U#2H FF:;XHMM)\0:3JFF::/%)UN*ZTA=9TCQ!HVF:'<
MZ2JZA<7%K]?T/?56OT[>NKMZ -*@DDD\C&.,8YR/?.>AK\*_^"@=II/@KXZZ
M''X?T33M+M=<\$VVLZQ%IUK%9I>:HVKZC;2:A+'"J1&ZF@ABCDE"#>R!I SD
MNW[K5^&7_!2S_DN?A+W^&EKSZ?\ $_U3_P#77\1_3_P6#Q'T?,?B*V%PU7$X
M;BOA187$U</1J8C#+$8W&TZZPU>=*5;#JO3BJ=94:M)58*,:L:BC'E_IOZ([
ME/QFRW"RG4^K8G(.)%B*$:M2%*M[++Z-2DZM.$XPJ.C4_>4G4A/V<_>ARR;;
M^.K'5+2_!:)U1^IB<[7&."=K8)'&<CC!!K1;HW(/!Z>N*\I4LC*R,R,O*LI*
MD<YXQCKWKH+'Q!-'F*]!E0\+,@"NHZ_,!PV1P2,'/)SBO\)Z^!:4W1=UROW9
M/7X9[-OMK9[;;G^I&+R>=.\\,W4AH_9NWM(ZKX7]M?<_)G]"_P"QMG_AG'X;
M?]>6K9_\'^K?UKZ@KY;_ &+Y4F_9L^&<L;!TDT_5'1L_>4Z]JN&Z=><&OJ2O
M^F7P7BUX1>%Z::MX>\')IZ/3A[*UL?XE>("<>/>-HM6:XMXC379K.<P37R::
M.7\8>"O"/Q!\-:OX-\=^&="\8^$]?M);'6_#?B72[+6M%U2TE&'AOM-U"&>U
MG3/SJ7C+QR!9(RLBJR_Y5'QH\>:9X(_:#_: \#?V3#IWA;PI\;OB]X:\+II:
MO'%HN@Z%X\\0Z7HNEF)W=WM-/L+6WLX)4D,Z00H7$K*6/^K_ %_D7_M9E1^U
M#^U&3C:/VA_CLQ.P2;0OQ*\4EL1MD.<9PO&_[O\ %FOZM\(H>WQ.?49RDX1H
M8*<8<[Y8S=>NG-0;Y5/E27,DFXI)R:T7XYQDHJC@)<JYG6K0<K6ER^S@U[R7
M-9-72;:U=K-G[F?M1>(UU;]B']GO2M#\,^%M2\!:%IWPVO\ PS\2P/#.B^,3
MJ7B'PQ->>*-!/@IOACHOC3P[HK:[]MMY)7\>ZIHFO/81>)FL[ZYU47$7P;^S
MES^T5^SV2>OQS^$IY[9\>Z#C/X?6O8OVJ_&7C33?V!_@'X%TE&\.Q_!*+X(Z
MIXST>RU_X[W7A;6=1^.O@G5?$_A3Q5::CX_N[WX:?&+Q/J>@V$5AXF/A4V-O
M\)8(;?0?"-BVBQ:E=#Y&_9%^*NFZY^TA^SKINJPG2]4G^.WPB@B=-TNGW<S>
M/= 5%CDSOMY)7 412!E+L%20D@5]QEN&E')\PLDHJMG#2C:_*UBI1<W&<XNI
M.+]I-PY8^]'W(23B_F,4U+'85)MM+!<SE;XKT4XJR6D+<JYKRNG[SW/]4L'&
M>#P3VZY)Z4ZD'?W/\N/Z4M?S.ME_7<_7!&945G=E1%4LS,0JJJC+,S' "@ D
MDD  9/%>;>$_C/\ ![Q]K-UX=\"_%?X:^-?$%C;2WM[H7A+QUX7\2:S:6<$T
M=O/=W6EZ-JE[?6]M#<31033RP)%'-+'$[J[JI[O5(I)],U&")=\LUA>11H"
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M'TQOASX8\!Z#\4O O@Y] _87_99_9CU2Z\._!BQM]%\=?%W]E_XTZ!\;=/\
MBS\0?# \3QZ?XQ\&_$#6_#T6B^,O &M2W&L7VCZGJ@?QK+<S)(B_%[_@CW\2
M/C-<^#O&/B;XO_ '3O&TG@CXI_"CXK^"_!7[/_C'X;? 3Q+\.OBAXPTWQ7>-
MX;\$_#SXW>&?%-CXX@_LQ-/\1^)?$'C/78/'T+V$FMZ9:2^'M&>+]2?'_P"V
MU^R+\+/&\OPU^(?[1OPA\(^/H/"\_C2?PCJ_C;1H==A\,P:/?>(O[4FL$N9)
MHDN/#VF:EK]A:N%OM2T33[[5K"VN;"TN+B/UKPU\8?A;XR\4-X+\)>/O"WB7
MQ2G@3PM\3Y-$T+6+/5+R/X>>-Y]1MO!WC%Q9R31KH/BB72-2_L&^,@CU2.RN
M)[/S8(VD !^0TG_!(OQ3I/[0_AOX@>#_ (Q?#6U^$/A_]M#X>_MHQ:/XK^"]
M[XJ_:$_X2'P?X*TSP)?_  N7]H"Y^(4%[=?#R?2=(M;K0_[6\,:AKEC,6L]4
MO]8M5R_T9\6_V"_&7BO]L2Y_:C\!^/O@VNG>/?#_ ,%?"GQ4\'_'+]G^P^-F
MJZ/I'P/\7ZSXIT*^^!/B:]\8>'5^&NKZ^FOW]OK OM*\1:=9Z_:Z3XVTZT&M
MV(CD_3:B@#\'I_\ @B7H6I?#;X9?#RY^*^A>&[S0?!/[?_@CXG_$'P'\-8O#
M_COXC6/[:>OW^O\ A^YNM;_X2.:ZN?\ A5\]U;QW]AXGN/$5GXOMK>6Q@7PY
M97'DQ7_AI_P1Q?1+CX-:U\3?'7PM\:>(/ '[4'P[^.7Q!BL_A[\0KWPI\5?"
M/PJ^ 7Q%^"W@SPOJ?A;XD_%_XB:7I'BNROO'4'B5?$^GP)I=GIVAZ?X9@\.R
MPV6FZC9?NE10!^"-K_P0\\,CX6?#GX8)\3_"WA#^P?AC_P %"/AG\0O&7PW^
M%%GX4\4^.=/_ &TO'\?C'P5+-<P^(I!<:=\&=/MK+P[/X=\12:[I?BW2H)-.
MM!X7TR=K-7O_ ,$=_B%J6E^)?'&M_&#X 1_'F]^,W[*/Q4\.6OA;]F./PU^S
M=IMC^R;IWBG1-!T/4_A#!\0KG6;O5/B7I?C/68_B)XCT_P ::9+=0Z;X0T>R
ML%T?PU;03?O710!^,[?\$F+2[\0?\)?>?$'P78^-=3_;K^,?[6OB/QSX<^&(
MTCQM<>!_B]\*_%?PQN_A%HWBO_A))]:TU]"M?%+W.G:Y-=WNCM!8VUHWA564
M7"^ ^ _^"&D_A[X2ZI\+O%OQ;^'OC&6V;]E;P1X?\4W7P[^(4\OB#X'_ +-7
MQMTKXOOX*^)?A+Q%\9O$?@?5]8\8_P!D6^F?;_"_A_PQI6B7UWK5\NEZCIFL
MW&AQ_P!"U% 'X*?&?_@E/\7]7^,OQ-_:!TKXO^&_&6G:3X:_:_F^$_P@TWP#
M/X1UQM)^/7[,?B;X,>$/@S:ZK9>-++X;Z-HO@;5;S2Y=(\3Q>!8-<\1VB0Q^
M+M0EFL;.^M_EN7_@EI^TCX _9<TCQ:_AK0?'/[3R?LT?LL? ;X#^ _V=_ 'P
MZ^"47P(^)7P8UJR^+G@?XX?&_P 4>*_B5=Z+\2?$_P /OBSI>F:!XL\3^'6@
MBE\'W/B4:)X-U.'Q-JZ1?U'T4 ?-7[(7P B_9C_9W^&_P@GU"+7O%&CZ;>Z_
M\2O%L:XE\=?%SQOJM]XS^*_CJZD:&"6>?Q;\0-=\0ZVKSQ+-';W<%NP58$1?
MI6BB@ HHHH *:QPK9[<?H/7CO^5.J.7[I_SV-3+_ #_#4.WJOS1^ '[8.MVE
MY^TO\2[7!@ELIM!L292NV9HM!L&9XFS@*3*H*D;\@]<BK6H37-S\']%MK6S1
M9K+P)!?WMB?B!K=IJ<NB0>(+N&7Q2O@" OH-WHWVB2* W%S(M_/'_ICV@BC2
M0^:?MED_\-0?%G!(_P")UIOOPOAS1R!ZX]A7<:=-JUK^RS)KTFA>+TBM[I=
MCU6[N=+DT[4M%FU;[7,VBW5EH5SKMOX:TZ\ &HZ1KVJZ=ILEX4?2[F\??9C^
M_)8-4>!?"+$4W%RJ2X6P\859QA'VF,RZ,(ZNM1E*-U434%.I!NG./)%3D_\
M*'-LNGB/$+QQE3G)^VEQE7JPC!\W+ALUJ3DJ=2-&JH2E>ERJHZ=.256,Y2E*
MG%?/]TVZ&4Y!S;G..@)5@>.W_P"KZ5_2;\*O^2:?#_\ [$KPM_Z9+.OYHX[Z
MVO+:4Q2*6\IS)&Q E0A3G(R<C^Z1D D="3C^EWX5@CX:?#_N/^$+\+@'UQHM
MF,U^;?25A*G@>$83BX2CCLX34DT_]SP=GKNGTW[GZ?\ 0?A*GG7B%"<7&2R;
MA^Z:DO\ F9X_I))KT.^KY8_;1U*+2_V;OB1<3([(]CI=L0A4,IN=;TZ(,<\8
M3.2,Y(Z<U]3U\?\ [=X_XQ@^)'M#H7_J0Z8/\_RK_/[QMDX>#WBE*.DEX>\7
MV>^CR',(O?2]IR^_R/\ 47PUHPQ'B-P%1J)NG5XQX:IS2=FU+.<#LUJG=+4_
M#6UO+:ZB66&0,F!GD$IQR&'7/X?IS5KT/KS7D]O+-;E9()'C?AB5. W&<,.C
M#..H_(8%=9I_B%&*1WRF.0+@S*?W9&>"RY&PD<'&5S@\#)K_ )FZF#E!7I7E
M%17N[R248Z+N_2]]$EH?[48K**M"\J%ZU.[M%+]Y%7;U6G,EWBK^6I^F'_!.
MK_DI?Q"_[$NQ_P#3S#7Z^5^0'_!.>1'^)7C]D8,K^";!E(.00=:BZ$9'09Z]
MZ_7[/X=N>_T]:_WH^@/=?1KX83NFN(>,DT]T_P"W(O5=/F?Y0?2<T\8^($TT
M_P"S^'[III_\BF'1ZBUS'B+Q-9Z$;2Q&^YU[68[U= TBWA>YN]2GL84DN)!#
M&5V65CYUN]_>32P6]M'-&'F626)7Z>O,O&5GJ-EXK\(>-X+*34=*\+Z1XQL=
M9M;-T.J)!K__  CLL5]96TICCO(K,:).;RW29+HI+&]K%<.C1'^S#\ /)/V;
M_$7Q)T3P58>%?CQX+L/ASXTF\4:U9:'::3JO_"1^'M>@O(TU^2\L]?MVFBAN
M]1U:Z\036FD:D+._M[&V@MB+J>-YYOJBOE;X4_&+3?VDO#?A;Q-X)FT?7-(T
M3QQ)<ZYXDT.YOAX;MSID=[<V.BV7]L66GZW=>(UTC4]$DU_3YM*M+?1-4N+N
MQ>\F:T4R?5/IQU_3@_\ ZJ;O=W5GU78 K\,O^"EG_)=/"/\ V32U_P#3_JE?
MN;G\/K7X9?\ !2S_ )+GX1/8?#6U&?4_V_JG\L<U_%OT^-?H[9M;_HK.#_\
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MY)AZM/,.)<^G&,I0HY+D6%K3QV+]H^2/UJ=/#9?24U.MCHP33]G^"GQV\<_
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M!=26,\6J:?:74UU82V][%)9W$5U%$]O=*8)ECEPIZJ@ HHHH **** "BBB@
MK)U_6].\,Z%K7B35Y98-)\/Z3J6MZI-!;7-[-#IVE6<U_>RPV=G%/>7<L=M;
MRO';6L,US.X$4$4DKHAUJ/K0!\N?#;]JSP5\>?V5-,_:Q_9ZT/Q7\4O!_BWP
M3K7C#X?>'#X?UCPGXN\6G2+S4],.DIH&OV%OK%A>SZGI5W;Q12:=-/=1(L^F
MP7Z7%F+CS6#]LT6]JEC?^%[36=2@^'GC_P <:WXT\%WMU?\ P[\,7W@+Q;X6
M\*WO@[Q%IGB6#PM\5-+\5^=XMTV:_P!)F\![],WPK-.Z7!D@^T-9\-:#K_A[
M4/"NJZ=!/X?U2PFTN]TR)I+*)[*>,H\,$EC);3V;*IW0SV<UO<6T@2:WEBE1
M'7QT?LR? 6WL]-@F\!V,L6DQ>)X4N]2USQ)?:AJ$'C1M*;Q/'XEUC4=:N-3\
M5QZK)H>AO*GBF]U=8)-&T=[3[.^FV1@ ."O?VR?!%GJ6JV(^''QGNK+2I?B-
M,_B"V\'Z0V@W>@?"#QC)X'^)_BRUNIO%-O=)H'A#6DC>47ME9ZUXCTV87_@O
M1O$L-MJ'V.[\0?VKO"7AGP=/X@\,6%WK^IS7'C*WT6TOXY-,TO4?^%?>,/"W
MA3Q5<OJ$8NIX+56\46MYHTBV<C:C$C"2.T((KV.;X5?"\PW&GS^%M%$.H:1X
MYT2XM9&D7[3HWQ/UQM;\>6+(;@,UOXJU^Z:\U+'S27DX6%HMR)7*3?LV? :[
M\1ZUXBN?AWH5SKVMV-S9ZHT]SJ<\'V+5)] N-3^S:/)J+Z7I3:Y=^$O#USK=
MUIEC9SZ]=Z'97&K37L]OO !YXW[8?@R?QI;>!M%\#^/M>U=/B':^!M<DT\^!
MVLM$TF^\,?$;Q19_$3[:?&IL]5\'-;?##Q1#<PZ9<3^+;$V;O=>&(Y'M+>[S
M]'_;C^$&OV6E7VDZ1X^N(-=UC0;'1I[K1=%TC2[[0?%.F7.L^'?'#^)=;\2Z
M;X3TSPWK&F6DUS::?K.O:;XV#>3:3^$(;ZYMK67U"S_9F^!&DO?W-EX!T^PE
MOM>\.^)Y[N'5O$$%Q:ZGX0OM:U+PZ-,NQJXGT/1](E\1^(HK?P[H\MAX=.F:
M]K>D3Z7)I.JW]E/&/V9_@3<Z!+X;7P7%+X5NM:.OR^'X_$OBL^'9YQ%]G73/
M[)CU_P#LQO"4, ^SP^"%M_\ A"[>%1!#H,<:A  ,\<_M(>!OA_K'C.PUO2_%
M\^B?#?0X]8^(7C;3-&M;OPGX.N+S27UO1_#^J3/JL&MW>O:WIQM9M/MM#T+5
M[&%]3TF#5M1TR;4K1)/*K;]L73]?\1^#](\+^#=3CMM=U_2O#&OV_BQQHVN^
M&M;O/&GAGPW=VA@TPZWH.L11:3XHT_7;34=#\0:GI5SYR:>;Z.]AOX++Z \0
M_!+X4^*_$TWB_P 0^#=,U37+S0;CPQJ,D\]^NFZUHMQ9W5A]DU_0(;R+0/$,
MMM87MY::;>ZUIE_?Z3:W,\&EW5I%*ZF'2_@3\*=(A\.Q6WA*&Y?PI)%-H-YK
M&K:]X@U6PE@UV#Q-!)_;&O:IJ6JW;0:Y;6^H0&]O;DPR6\,4>VWB2%0#G+_]
MHOPA8>(_$6C-X?\ &]QH?A/Q=H?@'Q)\0K;1K!_ VB^,M=N?#]M'HE_>RZS%
MKD2Z8?%.@RZSK8\/MX:L8M093K4D]AJ<-EY]KW[7>@2^#_B#XI^'O@KQ?XNL
M? FE:Q<7/B>ZL;+2? ;:UIQ$]AH-SJYU*XUP3Z_HTMAX@TN^L/#E_I2:3K&C
MC5+_ $W4KY=.3NOB3^S1\.OB*GC>417WA35?B7HEUX7\>ZOH#6TQ\2>&M5L8
M]&\1:?=:#KMMK'A.'5/$7AV-?#NH>,+?0(O&4>CQ6MG9Z];QVEJ(=FZ_9Y^"
MEU?">Y\#Z8TT_A*W\$SV0U'6(-.U/PWIUA#I=I!J6B0ZG'I.L7^GZ6D.FVNO
MZA87>OV>G!+"#5(;3]R0#,^%'[2GPY^,GB?Q%X6\'KXB,^B07VH6&K:EHZV^
M@>+-%TO79_#.I:UX:U.UO+Y6L[378#8_9==BT+6+N*6#5-/TN[T>>/43] 5P
M'@_X7>!? .I^)M7\'Z"NAW?B_46U778[;4=6ETZ:^>>[NII=/T>[OKC2-"2[
MO;Z[O[ZWT&QTRWOM0NI[^\BN+R5YF[^@ HHHH **** "BBB@ I",@CU!''7F
MEHH \_\ B#\+? ?Q3T&;PWX^\-Z;XCTJ0,8TO8!]JLIBI7[5IU_&4O-/NE'*
MSVDT3@CYBRDJ?R$^/'_!/+QCX0:]\2?!NZN?'7AZ,2SR>%;UXE\8:9"IR8["
M8"*V\0PQH0!'BVU,X "74A+-^W=)ZGGC]>/3OZ5]YP5XE<6\!8A3R/,9RP$Y
MJ6*R7&NIB<JQ6J<F\,ZB>&K22M]:P<Z%9/67M4N5_FO'WA/P7XBX=QSW*Z=/
M,H4W#"Y[E\:6%S?#>ZU!/$QIVQ="+LWA<;'$46E:+HM\R_DDO;>ZL;ZYL;ZV
MN;"_LI3;7MC?V\MI>VEQ&VV2"YM9TCF@EC889)41@02 1R8@0>>N,_GT_K7]
M*/QP_9<^%/QWM))?%&C+I7B=8BECXST!([+Q!:L 3$+N01F#5[5&(W6>I1SI
MMR(7B;#C\7/CM^QS\6?@<UUJK63^-_ L;L\?B[P]:S.]C!N^4^(M'7S;O2F"
MX\RZC^U:<>3]JCY5?[8\/O'/A+C14,OQM6/#F?S4*:R[,*T5A,74>ZRW,I>R
MHU>:5^3#8EX;&:J*5>5G+^!/$KZ/?&O ,L1F.#HRXFX:IN<UFF649O%X.BKM
M/-,LC[2OAU"/QXG#_6L'=.3G0CI'Y2J,H<Y&,8XZY'<'\#GCI]*5'#C<I!!Y
M!4Y!&2.HX/3J"0?S%/K]L:C)-.*E%IQDI)2C*,DTU*,E*,HM.SC*,HR3LU).
MS_!$VFI1;3BTXRBW&491=U*,HN,HRBTFI)QDFDTXM)IGSY/((.,@\Y(&.3@9
MP .WI2@8!SCD\XZ?3Z?XTZBO(R7A_(.&\-6P?#N19+D&$Q.+Q./Q&%R/*<MR
MC#8C'8RK*MB\97H99@<#2JXK$UIRJU\14A4K5:DG*<VVSU<WS[/.(,12Q>?Y
MUF^>8O#X7#X&AB<YS/,,UQ%#!82FJ.%PE&MF.,QE6EAL/2C&G1H4YPI4X148
MP22L4TD \D#ZGC\1^1[9[=Z:SX]!R%&>2S$A0 !R2Q.%4 DG@9/78U?P_KN@
M3VUMXAT35M#N+ZTAOK*VUG3;O39;NQG7?#>6R7L,/GVT@SMEC# ="5/!^*\6
MO&+PV\#.#L?QYXJ<5Y=PEPU@(V>+QKJU<3C<3-3=# 99E^%IU\;F6/Q,H^SP
M^%PU%N<VN>M1@I3C]AX7>$OB)XT<5X+@KPSX6S'BKB'&OF6&P<:=/#X/#Q<5
M5QV98_$U*&"R_ T(RYZV)Q->*C%/DI5I6@\<G<#M(^[D\9&<X)'&<@8_#..<
M"M?P_KNM^%M7L_$'AK6-3\/Z[I\BR6>JZ3=RV-[ R@'"S0LK/$>1)#()(9!\
MDD;#-9JQ8YV\<G!)W9YQDYY.#C!&..QYJ55  X&?\_YXX]*_YUOI;?M@>//$
MFCG' OT><MK^'/!&+ABLOQG&>;T<+B>/,_P56,Z%1X'#3CBLNX4PF*I.7+[.
M.89TH37-B\'4NH?[\_18_9/<%^'M7*>-?'S,J7'G&.%GAL?@^#\HKXG#<%Y'
MBZ<H5Z:Q^+IRPN8<3XO#U5%24I8#)^>$N3#XR#3E?U?5]8\1:K=Z]K^JW^MZ
MWJ,AEU#5M6NIK[4;N0L23-<W#R2, 2=JAE1%^5%50 *(&!C_ #^7:EI"<=L\
MX_S_ "_&O\8,?F&.S7&XG,<SQN+S''XRM/$8O'8[$UL7C,36J2<ZE:OB<35K
M5:M24I-N4ZCZ)<J2B?Z_X' X++,)0P&783"X#!86E"CAL)@Z%+#8:A2IQ484
MZ-&C3ITZ<(Q2248+:[;;;:TTL ,Y'8<'N2!CZ\\#O5^QT7Q)K=IKUSX:\*^*
MO%S^&M#U+Q%J^G^#O#VJ>*-8ATO2;26^O6M])T>VN;V^NS!#(+33K2.2]OYP
MMM9PSS.J'^77]L#_ (++?%#Q7J7B/X:_LV>'-;^#.CZ9>7NA:_XV\8:4;+XO
MRW,#O;W5M9>&]0A*_#F12I0KJ$%UXGMVR'.G3 J/VGP<^CGXH^-^-A'A'(YT
M,BIUHT\PXMSB-;!</8%*2511Q4Z2J9CBH1NXX++:>)K2E:,ZE"[:_*_$_P <
M?#WPFPDY\29O"MF\J3J8/AO+94\7G6+;BW3<L/&?+@J$W:^*QT\/246Y0A6T
M3_;7]J?]NC]GS]DC3&'Q+\4C4O&\]LT^C?"OPF8-5\=:L=F^%KJS\U;;PWIT
MK; VJZ]-9Q*AWP0W38C/\R'[5_\ P5"_:-_:?FU#PYINK3?!SX370GMU^'W@
M?4;B&_UFR<G:/&?BZ,0:IKCN@Q-869T[1E)>,6<RY9OSNU/4=2UC5=0UK7-5
MU#6=:U2X>\U;5]8OKG4-6U*\E;?+=7^H7DLUW<S.Q):2:5V;=C*CBJ^<U_L+
MX'?0T\+O""&$S;,<+3XYXUI1IU)\09[A*%3 X#$)*4O[!R6I"OA<"J<[JGC<
M2L7F,DE+VN';Y5_F+XM_2D\0/$Z>(RW 8BKPAPG*4X0R?*,34AC,;1?,E_:^
M:TI4:^*YX-<^%H?5L&G)QY*R5W&L,:#:JA%'15^4#DDG QR2S$GJ223D\T\
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M>+-1V:Z-"]@\4_M-_$/1/A7\(?&=SX2\)>$]1^(-EXJO/$&O^);KQ%KWP_\
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MV@:+9P:;HVAZ'IUGI&C:1IUK&(K73],TO3X;>RL+*VB58H+6U@BABC541%4
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3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b5_002.jpg
<TEXT>
begin 644 form424b5_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (] D # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BH_-7L&/T'7\>E5WE(+9+9X)0<J/J?<<]1^= %RHO-&.C9YX ST]ZI
M><,X&/3.X_H,G\/Y5&+D 8R.I&/Q^AH TO-7T;_ODT>:OHW_ 'R:S?M"_P#/
M1OT_PH^T)_ST;]/\* -+S5]&_P"^32^8G]X5F_:0/XAC'&< GWZ=/P_^M()T
M88."!SGIW/7'7KUH T0<C(Z'D453#Y V/RV2J@X4=21STQSG]14JRD8!&5'&
M[J3@=3Z<\9/7&?>@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX\/7D!+6LZ2JH)6)QME<9. #GD]@<]!S0!J1W8ZJP(8$XST#8.<D8&<<'MV
MQ5J.YY8Y^0@$'/KQSGJ.V#VSUZ5QDC7EE\MU#+$#QD@E5.3C![CW'.?8<7[:
M_# #.X <'/!SP><=..?IC YH [-)6XP. /E )P5 X'4]N1TZ8YYJ<2\\C:"1
MC/ZY_IZUSMO=\J#G!'09Y S@],;1P#W_ #Q6I%*IW$Y^;D8ZD< ;>S'GU&/?
M- &D"",@Y%+4$;CG)&W'';:?3G!&1S@CZ>\] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4S,Y9P#M
M ; RH8$9()SGUXX]O44.TV]2KY7@' &,^O/0<?KTJN_RO*=NTO(00?F+'@C
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MU!]N_2O^A>G&48M2WYGMUV5^_3JWN?YDI6BERN*22L]7I?=^9\L?\,C>"_\
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M)FDA .QW!)SR3QB?P'\&?#_@Z_77[R_U#Q3XD\I[:'6M4V>;!;LPQ';VL/\
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M5DW>VMK7ZV[!1115#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH :1\P.#T//;MP?7/Z8KY3_9!A$'@+QZ@).[XX_%F0AOO
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M>X]AH11@_,?H3ZD8R >#CW [=2#RL48X; (Z[NY;(SZ?+P>,8ZU9^F /I0
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MGOS0 ]W(.&<Y//7 7'I[GH.!D$DYYKR+XJ?"OPY\4M(MK;4Y9]'\2Z3/]O\
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MXI:#!XD\$:[8:W8S10/,EK<1O=:=+*F\VVH0!M]O<1@_-'(H)(Q@9)KT=67
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MZ_Y^M $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8X@"1)*B'#$Y#-V&2<<XR>/>O3K=%CBCB7)\N-1D_3IG'<Y_*@">BB@\@]J
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M;U?XD^%K":]U^+2)-/\ %>A6R G7=%\MHS=QQD;OMU@I+*02S1J0.3S^HC9
M]>,'ICMSCOG\A43#>C JA4J5=2H(8,,88$$,"."N#G/0\5ZV1YUC>'LTPF;8
M"HX5L)5IU;*4HJI&$XS=.;C9\LE&VM[/5*^IY^:9;ALUP=7!8F,73K1DKM*\
M9.+2E'S5[VTNKG^=M\1_AOKOPRU^ZTW4].NH])-Q,-+U-H)U@> 2$I;2NZ@1
M7$ ^1ED )VYR1Q7G;.IYWH1P1N<;>"0>ASMSUQSGUZ5_=#^TC^P?\(?VA4N[
MV>QLO#^OWJCSKN&RBFTVZF5<123Z>H1#(I +21%2W).3T_#/QK_P3F\$>%?&
M.L>'Q>_#_6-0T29[:ZL[/Q-]GNTN&P\<4UA*$%M,R$.T/F,$W %LBO[NX%\?
M^'.(<-2H8^-7#9M&E>I2M*<'-0C&4HUH1<7"\=Y2CNNZ1_-_$7AIF>68JK5P
M?)6P=2H^1\RBXIN]E%R3^5GV/Q0\&>#M=^('B"Q\/^'["XN9)YD2^N0CBSM+
M1G FEEN-H1 (0[1+G._ [U^V?P"\-:5\/O$/P[\.:3(&LM+OELUN+K'[RYNX
ME225V4#,QE<B$YZX-=5X?_9OUWPM81Z=IMEX&\'Z>O'FWVLV5I#LXQ-=W4'G
M3/"W!5^>3]T=MZ*P^&GPWOK/6+SQ-<?$7Q1I=U!>VFB>%HF@\-V.IV,J2"6X
MU^3G4%$B@*BQ(&&<] :YN+^-J.?T:F PT:[YE)TX4H5*D:OO-03G:4()RC9M
MOW6U>-I)FN19%_9E>-:M;VC4>9-+W7^NO^?0\[\36SV'BCQ1!(#NM==U4LTS
M S;?M#NY?D?O"JDKUQG&17X_?&OQQ>^._B!J]U<3O_96DW4NGZ-8B0FWMUA8
MQ.S1G(+R,I8MU!) S7[??&9+/7/$8^(6A6PM/#GQ+TT:G9PH ?[,UB*'[-K-
MA.!D)<O>!YHD+#S(BK*.0*_ 3Q5I%SH?BOQ-I-VC+<V^N:BS!MP9UFG>:.3G
MGY0P)7''OBOJ/"^6&Q<98BK3Y,11A"DJ<X)RIUDG&<-M)0:MI;:_4\SB^K7I
M<L5)^RJ.:DEM.[TZ=MGIUU,$G)VAPISR<-U[<#]#D_X.94(<*SHZ,DJ,N?-1
MP20Z' )/?.1UR>U-&00HS@G)(! &.V3V/KG_ .N\<G(!) R2,'';)YSP.A[5
M^S<U*2:J*<J;YXU5*#<5&[>[32=FET/SOEITI1=-R52_-3::NI-/>W;;?73S
MM^G/[-/CJZ\:?#[[)JUPUSJOAF5=,EF)W/-9G!M7D)RV](P$)Z]R:^A2 "N
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MR3_B>6&_1]=SQNO[$")YF')(G"[E/&<DX-?32?='.[W]OR%?R+B\%7R['8S
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M;% %ZBJRR-DX8/Z@Y&*D$AR-VT#GH3D$8/((]#VH <Z!@/4<@^_^![U0E7<
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MT@/)8MWRJX]L9' Z#M59Y]H(W DK@8. ...>XY_#) SCBE-=[1@, >",<*V
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M(B;>3C.,  8 '&1[\C.3S^%2444 %%%% !1110 4444 %%%% !1110 4444
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M^^B0A1U/ &:[FH)X$N$,4H5XG5XYHG4/'-%(I22*1&^5D=&*L""""00: /\
M+[^*?BW7_BW\3/'OCKXBZE/XL\5ZSXKUZ:_U#76>[EM62^F06MI%<F4Z=!8[
M?)BM8@A"H"%!K^HK_@W!^*'Q,U_P[\>/AGKFO:AK'PX\%3:'?>$;74I;F[;1
M=1U&61+_ $^QNIRRQV/E!94LT;$18$*HKZW_ &F/^"#_ .RY\>_BAJ_Q/\/:
MYXA^$5[XC9KK7M \(1VZ:!>ZI(VZXU."R:2)+2YNF)>X$0VO(Q; SBOT?_9"
M_9"^$/[&/PKL_A;\)=-FCM!,;[7?$&HLL^N>)=6D4";4-2NMN^3)XBBW%(5
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M@_CDY_/C\JG50H"CH/?/ZFEH 8$ .<Y(&!Z#/7'?]?7UI]%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2'H<=<'%+3)#M4G\/SX]10!6D8^4S#J &_$,,]<]_Y5A7LGR3-
MG!YQD8 /&#@^^<9Z_I6O.P",,$;",'(R<$9P/\1V![US-_(H61<Y/S$GC(/8
M$D8/;Z<]* ,@J;R\MK7#$R2H6(!Y4#+?+VR3Z=\8/6O28XEC"+'\J1@IL X(
M' S].O>N-\-Q"2[N;MQQ&%C7=CY6.5)!ZGCJ1T]AS7;)G:,]^<^OO_GTH 4
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M "[K 6UE90V]TIMIH(IX+^VOP8;J"Z0,MVUXESMGCFD97$J2@3,V=QK^U?\
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MX3?%GQ/;Q:5<12S^%-=U*ZU?PQKUFCH9=)U&PO))3Y$\:%%D1T*-AMWRX/\
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M/J ..YY]??H.P!D^'9%MM0FMBQ'VJ(%<L,%TXR..>,G!'!X]J[J,G!!!&TD
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MX:GHUTE]IGA:XLEL?":W<#B2WEU.WX?5$A8!OLUPODN0,Y P0#Y+_P""$?\
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M2,[LL"0?51V&/YG'2LZ;3EQC:W.>?[P]^V?09[]Z["6-?E..^PCU!![]>/\
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J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b5_003.jpg
<TEXT>
begin 644 form424b5_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &R D # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_3RHSR44
MGOQ1Y,7_ #S7\A4E% $?DQ?W%_*CRHO[B_E4E% $?DQ?\\U_(4>3%_<7\JDH
MH C\F+^XOY4>3%_SS7\A4E% $?DQ?\\U_(4>3%_<7\JDHH C\F+^XOY4>3%_
M<7\JDHH C\F+_GFOY"CRHO[B_E3P0<X(..#2;UR1D9 R1[4 -\J+^XOY4>5%
M_<7\J=O7U'X<_G_G^5&]<$YZ'!QSS^% #?)B_P">:_D/K_/FCR8O^>:_D*JV
M^IZ==W%W:6M]:W-U8-&E];03QRSV;S*7B2ZB1F>W>1 7190C,H+ $<U>H C\
MJ+^XOY4>3%_SS7\A4E&<_P J (_*B_N+^5'DQ?W%_*I** (_)B_N+^5'E1?W
M%_*I** (_)B_N+^5'E1?W%_*I** (_*B_N+^5'DQ?W%_*I** (_)B_N+^5'D
MQ?W%_*I** (_*B_N+^5'E1?W%_*I** (_*B_N+^5'DQ?W%_*I** (_)B_P">
M:_D*/)B_YYK^0J2B@"/R8O\ GFOY"CR8O[B_E4E% $?DQ?\ /-?R%'DQ?W%_
M*I** (_)B_N+^5'E1?W%_*I** (_*B_N+^5'DQ?W%_*I** (_)B_N+^5'DQ?
MW%_*I** (_)B_N+^5'DQ?\\U_(5)10!'Y47]Q?RH\F+_ )YK^0J2B@"/R8O[
MB_E1Y,7_ #S7\A4E% $?DQ?\\U_(4>3%_<7\JDHH C\F+_GFOKT'7UH\F+_G
MFOY"I** (_)B_N+^5'DQ?W%_*I** (_)B_N+^5'DQ?\ /-?R%244 1^3%_SS
M7\A1Y,7_ #S7\A4E% $?DQ?W%_*CR8O^>:_D*DHH C\F+_GFOY"CR8O^>:_D
M*DHH C\F+_GFOY"CR8O^>:_D*DHH C\F+^XOY4>3%_<7\JDHH C\F+_GFOY"
MHGA3:,*%RZ$J!P<'CICGH:LTQ^B_[Z?S% #Z*** "BBB@ HHHH **** "BBB
M@ KS+XN_%/PO\&/A[XJ^)?C-]2'ASPEILVIZA%HNEWNLZM<K$,16>G:9I\4]
MW>7EW,4A@BBC8EW4MA 6'IM9][;B:"=7B27,;E$>-) 7 ++A7W*23@#*YR1C
MGKC7E.,&X:-7UT>MG;1[W=M!Q2<HJ7PN4>;I[MU?7II?7IN?'G[!W[7MG^VY
M\!(_CIIW@'7OAM97WCOQOX1M/"GBD%/$%O!X3U>33(KS5[8JIL;R_2,7$ED1
MNMMX1\MG'RM\;/\ @I3X[\!?$7XQM\-OV?Y?B5\!OV7=>T7PS^T=\3/^$E&E
MZ[H>M:O):&\L? OAH6\B>)'\.VM[;7FLF:>W$4+_ +HNP:G?L+ZWXI_9I_90
M^)7B+XD_"[XHOJ+_ +5?QBO(O"6A>%;O5?%]]HWBWXAO#H_B&UT6+;//H<MO
M.NH&]3;&M@DD^-H-?$GQ<@^,'PCN/V_OV<=,_9^^+GC[Q#^VO\3-.^)/P'\8
M>%O"%YJO@"2Q\7V&A6&KV'C[Q)&IM/"%[X76PN+F^CU/AU"I%DX%)SJ)TY1@
MI1]C*;BW;GJ*%-J-M&M7/1=O(T<::G*,I-)5^3GBKVIJ4^::W5^2,;7T;\VC
M[,^+G_!3GQ;H'B_XD7_P-^ Z?&'X%_L^:#X-\5_M!_$S_A*(]'U#1M'\9:7!
MKZCP#HOD3?\ "37OA_1)9+[78)I;<0""6)&9@!7ZJ^"?&FB>/O"'A;QUX9N!
M=^'?&7A_1O$^B7LN(GN-)UNQAU"SDDC9L1R?9IX]Z [E;(P<&OYN=:\#_%_]
MDKPW^U_^R6OP-^+'Q3US]J+X>>!O#OP2\>>!O"%UKW@2\UW4_!4?A;Q/:^.O
M$,&;;PC;>&-5NI+EYM1REQI\#M",D8_9O0_V0/"7BW]G'X%?!GXMOXDGO/AC
MX \(Z%?R>#/&&O>%,ZUI>@V=AJ>;[0KRTENK5;F*5(5D<H5YP"16LOA34KQ;
MIN,D]7*:?MJ33V5*5E%M7>WIAS/1J-DG4B[N[<8\BIU++7FG[S:VCIU.>_96
M\P?M,_MQAY9)(QX_\ &,&X,\,8?PI,Q6$&1TB!R&98PH)Y(+<#[IO=8L-/=?
MMU]8V$;8V/>WEO:B7@,PC\V1=Q4=0,G!R<#K^7__  3]^#/@CX,?%C]M+X;>
M!O\ A(U\,:9\2?!5U:IXD\2ZMXGUD37?AJ:>X,NN:O<7%_/$)<^7%)*ZQKA5
M. "?H']J/]AOX-?M</X07XI7OQ LD\$S7<NCGP3XXUOPF93?(J3+J!TNXB^V
M  $Q><K^7U'(J9R<(^ZG.;TBF[*_2\K-[OL=6$AA:N(A#&UZF%PSYO:5Z5+V
M]2"C%M.%+F@IMM)6YENW?1'UY;ZUI^H/ML+[3[U0N]OLE[!<L #R6$,C$(.[
M$ 9('/6D?Q!I$4CPR:KI44R-M:&34+5)5)(&&0R@AB3C! .>V>*_!C_@C9\$
M_#?A'XC?MKZI:>(/'NO7WPZ^.WB;X0^$AXJ\9:UKMII_@K3V2:UMOL=[<O;&
M]60'?>;!.0,9Y-?5'Q?_ ."5W[)GB74O'GQ.\7>*OB_X3O=<GN_$6O>(+3XQ
M>+-)TK0K@_OY=0MK3^T4LM/MK9E\Q8P@@3'(QFML=AL;@*KP]6G3E7I\CJ*-
M6*AR5*5.M!QDUORU4FNC7J=F!7#>.K5)0S;,E@)P7U+$+*.;$5JRDX3A6PWU
MK]TE).*E&51S>J@M$_U06XW \+C;N#!@1@@%21G'(8$8)SVZBIA(, G&#@9R
M.O?CD^N*\>^$7AWPQIGPQ\#:;X<\87WCSP[IWAZPLM&\876JG4[KQ'IUM&([
M?4+C4HF:.^FE5</<*6,FW).1FO3/[%LNNR?&/^?F3_'-0G?EDK).*NK\UI=;
M26C7:VYYDXNG5JT[N483G&,G%TY249-1<Z;]ZG-I>]!MV?:S-C(]1^8HR/4?
MF*Q_[%L_[D__ ($R?_%4?V+9_P!R?_P)D_\ BJ9%Y_RK[S8R/4?F*,CU'YBL
M?^Q;/^Y/_P"!,G_Q5']BV?\ <G_\"9/_ (J@+S_E7WFQD>H_,49'J/S%8_\
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MB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *8_1?]]/YBGTQ^B_[Z?S% #Z*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "LO5Y=2@L+V?2+:*]U.*TG?3[*XG^S6MW>+&Y@MY[C:YACED"HTP1C&I
MW;3C%:E% 'YA_L%:K\0=;^-?[:^H?%+PEHG@?QH_Q)\&17_ASP]KC^(]*M[6
M+PU<+8W,6KR06S3RWD 6>>+R5$$C&,$XK]-';)8#(VXP0?Q_G^E? _[*F?\
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M+NS#>9+;JPR(R6!&0"3DGFOHU<X&?SSG(['.!UZU\(_L:_%W34_8A^ GQ/\
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MX-UW0_$_A?\ 9[\#Z/K_ (;O[?4]%U.UBO%N-/O[1Q+;W$):[9=\4@#+E<9
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M+&815/8N@X3GAYTY2C)J>':HR?-#1IN#:?\ 3IC3[(?\NT)^L:G^E+]@LO\
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MK!_W[7_"C[!9?\^L'_?M?\*MT4!9=E]R*GV"R_Y]8/\ OVO^%'V"R_Y]8/\
MOVO^%6Z* LNR^Y%3[!9?\^L'_?M?\*/L%E_SZP?]^U_PJW10%EV7W(J?8++_
M )]8/^_:_P"%'V"R_P"?6#_OVO\ A5NB@++LON14^P67_/K!_P!^U_PH^P67
M_/K!_P!^U_PJW10%EV7W(J?8++_GU@_[]K_A1]@LO^?6#_OVO^%6Z* LNR^Y
M%3[!9?\ /K!_W[7_  H^P67_ #ZP?]^U_P *MT4!9=E]R*GV"R_Y]8/^_:_X
M4?8++_GU@_[]K_A5NB@++LON14^P67_/K!_W[7_"C[!9?\^L'_?M?\*MT4!9
M=E]R*GV"R_Y]8/\ OVO^%'V"R_Y]8/\ OVO^%6Z* LNR^Y%3[!9?\^L'_?M?
M\*/L%E_SZP?]^U_PJW10%EV7W(J?8++_ )]8/^_:_P"%'V"R_P"?6#_OVO\
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M%\1?!9O?$&D:<NDV,]H_AJ=K"W2Q0!$EM8"(I).6D(W9.:_3Z@ J*7.UCGC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$BY^*/B#0M2TVY\LR7GB:Z=WE@U"%DNK&),(+=@5 Y _3]/NCWS_ #K\OO\
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M3GR*>'JIMJE&4E%Z)W3A_-;1K^@I-8L]JY+Y.?\ EG)C&3SD<8P. /8>]/\
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M_F!6N(ASSW_NI_53_0>U'EK_ )6/_P"(HLO/[W_D%G_,_P #(_M2R_V^N/\
M5-TXYZ=#^?'(%']J67JYY XA?OT_A[UK^6O^5C_^(H\H>O?^ZGM_L_\ UO8\
MY-.S_P# G_D'*_YG^!D?VI99QE\>ODMC^6?TH.J6([OT)SY+]!_P'/7CZ^W-
M:_E#U_\ '8__ (B@Q#U_\=3^BC_/YT:>?_@3^_8.5_S/\#).IV0'5_IY+Y].
MX XYZGM],I_:EEQR_/\ TQ;C@GG ] 36OY0SG/;^ZG_Q./TS[T>4/7_QV/\
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MP<^(_BGX<ZP?A')+=?#;Q1K6CW9.H>(_#U]<-)<7<EU.S)JC3SSLEZCQF0C
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M0 4444 %%%% &?J=[:Z=97%_?3I;65G%)<W=S*2L4%O C22RR,/NHB LS'@
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M>HKSST@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC\=_VH/AS\+?B5/I-Y-IM[>>!M66_O=6TA-0MVCFM8]2>P@@E=)(R8V= P)
M.]=3==QC+WI^R@G)*R?);6SLGLEYM7N]#EB[*3:;4.>323;ERJ4[12UDFD]5
MY'ZB:1K&EZS9)?Z5JNG:O92,RQWNFWMM?6CE>&5+BVDDA9E(.Y0Q*]P#Q4U[
M?V5DJ27E];64;ND,;W-Q%;I)-(2(XHWF94>60\)&I+N>%4U^//[&FB6'P&_;
M[_:M_9<^&?VO3_@A8> ?A[\1]"\'2ZAJ&IZ=X*\3:C;I8:E;Z5)?W%U-9P:P
MJC4)[5YR'E8RHHSD?F=_P5)_;)\.?&3XV_#[PUI/QM?X<?#/]EK]K3X3>%M=
M\-VVIWFAZQ\5/B#?7H;56O51X9;CP9X6MIH@DF6MKZYG9"#LS1&$G5PU&[_?
M)2E*WPTU+DE-WW:M>VE[]2VFHU9.UJ<'+3WN:T%)))=7=;O2SO9G]4UUXCT3
M3[^TT_4-=T>QO]1)33M/O=2L[2]OW&05L[6>>.>Z;H,0H_S?7-;@8G&&&02&
M!]0<8[_IU[>W\S/Q;\'>'?VB+W_@J7\?/'&L:P_C?]G;2O#LW[/&NV>OZOIJ
M_"N#PYX'7Q%IFK^'+:UO+>T#:_J4$=W>2W,$XO(V>+E6K]?/!/[0'Q*TG]EW
M]G;XC1?"CQI\9_%?C?X:>!=3\26OA'['_:,6H7OAO3[J\U6[%]+;(5O9Y7DX
M.0[Y(QDU*;LVU:W*]OYI5(K7H_<3:W5^P2LIQC=/F3LTU:ZC"6CZ_$_PZF9^
MRH<_M+_MQ<Y/_"?^ B5[KGPK.<8/3/8$_E7Z  Y'3'L>U?E;^P-X^\2?$#XP
M?MJ>+_$7PT\4?#+6K[XB^"$F\$^*Q:1Z_8PP^&I8H[FX%K-/!Y=RH:6+9(?D
MP2!7Z=C4+T_\PR<=1@R1#.TX)/?G(QTJA7TOJ_1:FQ167]MO/^@;-C_?3GK_
M /6H^VWG_0.F_P"^TH%S+M+[C4HK+^VWG_0-F_[[3_&C[;>?] V;_OM/\: Y
MUVE]QI;%W;N<YSUXSC&<5!,@!5@,9&#S@<<CCIW/X "J?VZ\_P"@=-_WVGJ/
M_P!7X^N*:]W=N,'3IASG[Z>^0>>F.M3).SY='OV3]?(3DFK-2U\NS3_0_&'_
M (*4Z;\9O!_[5?[$/[1OPT^!WC3XX^'O@_=>.HO%V@^!4BDUB!==M8K>RD F
M'EHH<%BS\$ \9K??_@I[\?02#_P34_:<R02,G1QP>.<+P3Z<8&.W7]>5N;Y6
MP-.G ;KAXP0 . #GIUQGOG&.:>;R^!P-/N",]3+'D#\3_3^E>M3S+#O#87#X
MK*J6)EA*;HPJRQ5>DY4W4G52E&DN5\LIRUT<KI:<IY<L!76(Q5?#XZKAUBJD
M*E2"P]&I%3C3C3NG4]Y)QC%.*TOKO<_(0?\ !4#]H' Q_P $UOVFQC _Y@Y_
M#[O^?QK7^&W_  53UCQ'\>OA-\!OBO\ LD?&KX$:K\9KO5].\&^(O&YTXZ3<
MW^CV1OKJV(MAO:3R5.%'(R">*_63[7?\'[!<'/;S(^/H>^>O?%?CI^WI/=R?
MM]?\$OT,$R ?$3XDNR.00)#X4D#%=OREE3))QT &3T'H9>\LS'$3PKRJG0;P
MN+JQJPQ>*E*$Z-"=2'+&;Y9>\E=/HGZG'CGF& I0Q*S*I6BL1AZ<J53"4(1E
M&I5C"7O13:T>GG;4_9Z)W.X,,[3UYR<D@8^F/3'6IZQ?MMXDD@&G3L@8@,"@
MRH8X8# .",'.,<D9!&:>M_>D\Z;,1USN0?AU[<CN:^:V:3<7*UVDT^MOZ]>V
MI]$FFK]/1ZZ*^CUT;:^1KT5E_;KO_H'2]_\ EI'D8]1GC\:/MMY_T#IO^^T_
MS_\ JIBYUVE]QJ45E_;;S_H&S?\ ?:?XT?;;S'_(.F^N]/S]* YUVE]QJ45E
M_;;S_H'3?]]I1]MO/^@=-_WVGY?Y]: YEVE]QJ45E"]O.?\ B73?3>G'_P"L
M<\TOVV\_Z!TW_?:?YXH#G7:7W&I164+V\(_Y!TWUWQG^7''TI?MMX.NG3?4N
ME <Z[2^XU**RC?7G_0.F'7^-.?\ ]5+]MO/^@=-]-Z?_ *Z YUVE]QJ45E_;
M;S_H'3?]]I1]MO/^@=-_WVG^>: YUVE]QJ45E?;KS_H'3=_XT['_ #].] O;
MS@_V=-T_OI_3_P#50'-Y2^XU:*RQ>WG/_$NF//\ ?3CVX_\ UT?;;S_H'3?]
M]I0+G7:7W&I167]MO/\ H&S?]]I_C2?;KSOITW_?:<'CC_/K0/G7:7W&K167
M]MO/^@=-_P!]I_C0;V\_Z!TP_P"!I_7\_P * YUVE]QJ45E?;KS_ *!TV>>-
MZ=,]?\^M'VV\_P"@=,..F]/\_P!* YO*7W&K167]MO/^@=-_WVG^?_U4?;;S
MG_B6S#CKO3W_ )4!SKM+[C4HK*-]>?\ 0.F[?QIW/^?K]:/MUY_T#ICSC[Z<
M=OY_J: YEVE]QJT5E_;;S_H'3?\ ?:<T?;;SG_B6S=?[Z>@_SS0'.NTON-2B
MLO[;>?\ 0.F_[[2C[=>?] V;_OM/;/?MG- <R[2^XU**RC?7F"1ITW3^^G_Z
MJ7[;>?\ 0.F'_ T]1_\ J_'Z4!S>4ON-2BLH7UYQ_P 2Z;H#_K(^>N?_ -8X
M].]!O;S_ *!TV<?WX^?\_ES]* YO*7W&K167]MO/^@;-_P!]I_C1]MO/^@;-
MU_OIZ?X_YQ0'.NTON-2BLEKZ]'(TV8]?^6D8Z?4_7\J:M_>^:%?3ID0X^;<C
M8R><XY  _'ZT#3OT:]4;%,?HO^^G\Q2J6.<K@<8Y!ZCG/I@_SI'Z+_OI_,4#
M'T444 %%%% !1110 4444 5[A@J#)P,@D_[.&S@C)SC_ #C-?SS?\%6M"^'-
MY\5]*UCQKXJ^ /QFU;2/#^G7'AO]E'XG_#Z[\2>/)K@/,Z7W@O6/"L#^(H&U
MUAY BU%QIT<@!& S"OWQ\?>*;'P/X-\3^,]2BFGT_P +:%JFO7D-NI>>:#2[
M.:[>*)0,[Y/+" ]MV>U?A;\*/V8/VMOVQ=-MOVS]1_:6T#X)>._B-#/J/PT\
M-^!OAWH6MV/ACPAI^H7<7A32O%VMZFL]_K]TJ0I/J7V*:Q56G>!,.A(P?OUH
MR:DJ=%*<JJ3M!R7NPM?>;V=K*SNUH:P2C3J5):J5J4(NUJDM)S3ZI1@KWNM6
MM^GZ(_\ !/3X@Z]\1?V9_!NJZ]^RYJ/[(']F276CZ9\'+^&RMDL-.LG9(-7L
M;*RCC-I9:F%^T10W2F\ .9V>3)KV3]I+]G+P1^U%\+]0^&?CS^T[&UFOK#7/
M#WB70[EK'Q%X2\3Z5.+K2/$F@W:'=;ZAI\ZJT63LEC:2.0;'85Y#^P;\<_B/
M\:_A?XGTWXT+HTOQ@^#WQ \0_"SQ[K'AB%K?PUXFU#PY<M!:>)M)@8N+1=8M
M%2ZN=.#L;*=GB;-?=*9V@'/ X)[C_/\ C6U>G&=2<97:_=3:NTKJ*E"2DFI:
M[[KS.>E%P2U::<UOLG*2:TZ6=O3>Y^>7P\_X)_Z1\._ WQ$TVU^,GQ,U;XM?
M%KQ!X8UOX@_'F\N+2/QYK</A-X$TC1(UB066GZ.EC;BQFMK1426.225P96R=
M[]H/_@GA^S;^TAI'A>Q\<_#WPQ!J_AGQOX4\>/XJT_PYHZ^(-;UGPHP>$:O>
M&!9+N'46PU]YCLSD9R",U]XT4>\VI.3O%QL^J4'=*_9VC?O;76]Z2LK+;56Z
M--6?WK3R6UC\T/C9_P $S?AC\9?B3KWCBW\>>/\ X=>'?B/8>%](^-_PU\'7
M<%GX0^+^D>#HH;?0K'78"!+IJPVD"6-R^FF)KNT+13%U)-?HGX?T#3/#&BZ/
MX>T*RBTW1-"TRPT;2=/@^6"RTS3+>*TLK2('GRX+>)(USR0HSGK6Y10EHUT<
MG)^;?7Y=.W03BFXO^7;R_I*Q\ ?LJLS?M,?MQ;R6/_"P/ (#,<L5'A6? R>>
M,X_"OOIHE8D\\Y/XGO\ YZ]Z^!?V5?\ DY?]N'_L?_ ?_J+W%??],HB\E/?\
MZ/)3W_.I:* (O)3W_.CR4]_SJ6B@"'R4]_\ )_PX_6E,*=LC\?\ /UJ6B@"+
MR4]_SH,*=LCGUZCTJ6B@"(0H.>?SK\\?VX?V%=1_:YU_X*^-_"OQH\4? _X@
M? S7M7USPIXI\,Z;9ZG.9-8L38744T%Z1$%:$G:VW.6P?6OT3]./_K4A&01Z
M]^/PZ8Z5OA<7B,%B(8G"S5.M2YHQE*$)KEJ1<9KEFG&2E%M.Z_$Y\5A:.,H2
MP^(BYTIN+DE*4'>$E*+4HM---)W6M['\^<6B?M;?LD?MU_LC?#GQA^V%XS^.
MO@?X[7'BW3_$GASQ1X<TC38;:/1[$7,,MM/9 OEY#QR&7!' XK^@5=CL4Y.,
M]!@<<Y/XXY]<\U^&_P#P4D^)'@CX/?MY?\$ZOB)\2M?M/"?@?1-7^(,>J^(]
M3\Q-,T]Y],"0"YN$C=8S*Y"@$$L2#C!Y_5OX'?M&_!']HO2]8USX)_$?PY\1
MM)T*_P#[-U>\\/77VE-.OY%\U;6[#(DD3NGS('4;@,C/4^QG,,1BL-E.8N@K
M3PE1XBM0P\:-)S6+JTES^SA"FI.,8))=%U=SQLJE0PN-S'+UB'*4*].5&C6Q
M%2O64)8>G4E;VK<K)N3T;2T;:V/<#$A&.>,XYZ9H\E/?\ZESU]NM%> ?0D7D
MI[_G1Y*>_P"=29'/(XZTM%U>W7L!%Y*>_P"='DI[_G4F021GD=:"0.I ^II-
MI:MV C\E/?\ .CR4]_SJ3<O]X?F*,CU'YBG=?<%UM?7L1B%.^3[YQ084[9'O
MG-2;E]1^8HR/4?F* (C"G;(Z^_T_*E\E/?OW]^/RZ>]29'J/SI: (O)3W_.C
MR4]_SJ6B@"+R4]^_.?R_*CR4]_SJ6B@"(0ISG)Y]>@]*/)3W_.I:* (O)3W_
M #H\E/?KZ]N./QY_.I:* (O)3W_.@PIVR/Q_S]:EHH B\E,]\8Z9[^N:/)3W
M_.I:* (O)3W_ #H\E/?\ZEHH B\E/?MW]^?SZ>U'DI[]?7MGI^7'ZU+10!%Y
M*>_YT>2GO^=2T4 1>2GO^='DIGO],_3_ .O^?M4M% $7DICOG'7/?UQ1Y*>_
MY^X_^N/QJ6B@"'R%R.3TY'J?7VI?)3W_ #J6B@"+R4]_SH\E/?\ .I:* (O)
M3WZGOVYX_#C\J>%50  ./IG\Z=10 4Q^B_[Z?S%/IC]%_P!]/YB@!]%%% !1
M110 4444 %%%% %#4["UU.QNM/OX(;JQOK>>SO+6X0207-K=1-#/#,C##))&
MS(P.1AB:_'*3_@G;^UC\+KVY\%?LI_MX>*?A)^S[J>LZMJ,7P]U_P1X?\8:S
M\/[77+F:[U+3/ GB/487NQ9)<7$T^FQ7S$6#L!$,*IK]FRH8889'H:;Y:?W1
MUS^/K]?Z<5/+:7,K6<'&46M'JFK^B5N]M+VNF:]W:Z=NEU=7^YV/G;]F/]G#
MPC^RW\*M*^%WA'4M:\0E+[4?$'B?QAXFN%N_$OC3Q;K<[WFN^)]<N%&UKS4K
MMWF,$9\FW0K#" BBOHM>@P<^_2DVKP,?=Z<GCMZ\\>M.I)2YY2;O=);[)*R2
M6]DM-6 44458!4;RI'RY"J%+L[$*J*O+,[,0%51R6)P!4E9FK:9::Q87FEW\
M)GL=1L[BQO80[QB:UND,4\1>,K(FZ-F 9&5ER2"#B@#X+_9,N[6\_:4_;BEL
M[JVO8?\ A8/@,)<6<\=S;MCPM/N59H6>-F4G# ,2IR#@@BOT'K\QOV$/ASX+
M^%/QP_;7\$_#[1/^$>\+V'Q'\%W5KIGVR]OS'=7WAF:>\E^U:A/<W3>=,2Y1
MYV1.D:JHQ7Z<T %%%% !1110 4444 %%%% !1110!YC\0_A'\+OBG'IUK\3/
M 'A'Q]:Z=,TVG0>+- L-<CL)I<+)+:K?0S+ [C"LR ;@,'BOR0_X)F:-X.^'
M7[37_!2W3/#ND:%X-\'Z'\8?#4L>GZ7:P:1H6DVD7AZ5Y7C@C5+>UB0*TDK#
M:."3T K]M9@2RX.#QGCMNY_7''/;IUK^=WQ1\%?^"B7P5^-/[;G_  I7X">!
M/BAX!_:CUJ#5-)\2ZKXXBT.[T<?V-+I+I-9O!(7V><TC L!GIT)KWLIJRKX+
M-\#/%4J?/AL/]7IXK$.G2<XXE59>R4YN$9<JD[J*3?6[/ S6,:&-RO&+#U)>
MRQ%;VU7#45*IR3H^SBJG)'GE%MJZ;M9;JVG]#.DZMIFNZ?:ZOHU]:ZEIE]$)
MK._LIDGM;J$Y"RPS(2LB$@@$$C(/-:-?DE_P2D_:&^)WQ(\ ?$+X!_&3X<6'
MPY^)/[+&OV?PY\2P:3K*ZSIFJS2P-?175O<+''@>5( W!R3Z Y_6W(]17DXO
M"UL%B)X:NHJK34)-0G&I%QJ0C4A*,HW33C)6LSU\+BJ.,H0Q%!RE2FYJ+E&4
M)7A.4))QDE)6E%K5=#YS_:*_:E^"7[*_AO1?%GQP\6KX1T3Q-XCLO".@3"RO
M-0N-5\1ZCO-AI5G:6<4LTUW=F)UAC5"7<;1R15WX!?M+?"']I7PS?>*?A'XE
M;7+/2=2ETC7-.O[&YT?7] U*$M_H>NZ'?QQ:AI<TJ+YD"W,">;#B1,J01^;_
M /P5]UN^\,1?L6>(-*^&I^+NHZ5^UQX"N[?P!!#:W-]K)CBU%G.EV]XK03:E
M" 9;6.3 :15&5X(]8_87^&7Q+E^-O[5G[3OCCX8ZI\%M&^/FM^#X?"GPOUZ.
MUM?$UI:>#=*?3+CQ!XGTZRW6MGJ>JS$-&J,[R0?-*YR*XZ:E.,JDTHKGJQA>
MUVJ<8<MU>Z]Z3NVM5HSKKQ5.-!QYG*K&,G?;6I4A.S6ME&":1[3XN_X*)?LA
M^!O&NI_#_P 3_%C3],\6Z+J2:1J.E/I^I/)!J,S)&EN98[9HF8NX&]691DG=
M@$UT7[6O[4%C^SC^S]??&C2]('BZ_P!1N?#6A^!M",IMH==\1>-+^VTOPY'<
MR95X+%KJ\@DNY!AT@W$8(%?.7Q _X)[^/?''Q-U[Q_:?M->(O#MEK.O1:S#X
M9@\ ^"+Z"PACDC<V*7U[I,EY*CB-D,LLKR@'*MD#'??M]_L^^/\ XP_LJ+X*
M^',,?B+Q_P" /$/@#QQH-A=-%9'Q1<^ =:T_69]-3:GDV]YJL-C)#;( L:SR
MJJA5 Q+:="-_CE4C&2?2/,DVNVEVNR$E!5;7;@HR:?\ ,^1M7_[>LN_4R/V8
MOVI/CAXB^.?C']F/]J/P/X#\)?%O1/ 7A_XH^'=3^&NHZE?^$?$'A37KB:UE
MT_=JKM>1:SHEQ&T5[T@EQYD.4*FO)_CS^V_^T1I7Q=^.OA']G/X9?#[Q;X*_
M9.\*:1XO^.FK^.-5U&QUC5TU+3Y]<E\._#^&P<0-JEMHMI=3M-J.+<SHD08L
MX!Y#X3R_'[QE^T)\5?V[/%W[-OQ(\#V/@_X&^'?AEX"^#&M1V<7Q&\:^);74
M'G\1W=I:)(\,6F(TS1Z=++)BXBC$F%+<^9_%GPA^TO\ "[XJ?M:77@/]G7QQ
M\3-!_;N^&OABT\,:IH3VC0_"CQK+X9N/#FJ6/Q(\YD-AIMBNI2W<EW!YF3:F
M,+\V*TG&-X*+U=&HI1CK%U5-0I)ZV4ITTIMVMO>VIG%-*LYI:RIQA)WO"#BY
M5JBMORRLHQ=]'8]U_:,_X*?R_"_X;_LN>-_A=\&_$?Q!A_:0U3X?+=:O=0S6
MGA/X=:!XSFA@FGUW65V0S:O:3220Q:? YED>/.TJ0*S/VS/^"AGQ7^!OQEU#
MX5?#/P[\)+"V\#_!Z;XT>*=>^,>OWN@0>.--MHDFE\&_#,6LL7V_Q+(N43[2
M&@29HTD(W"H?CY^R;\4](_8*_9E_9^\%:+<^,_%_PR\;_!*[\4VNCNCHMOX<
MOH[OQ+J$32,F^RLI6FD1LEFC56"GD5\]_MN?LT^*=>_:7^)?C[XE_LH^+?VM
M_ WQ$^".B> ?@1)X4>.Z_P"%+>-[;33;ZQ_;MJ;BT;3M/U;4WM;^36LW'V86
MAQ"02!4XPA->\W;$UGHEK1CAZ<H4TD]5[1SULM%Y(J-G1HSU=2=!QG%Z)5EB
MG3C-=N:DDVK6UNK:L_;?X#?%#_A<_P '?A?\6&T'4/"S?$#P=HWBB3P]J:%;
M[2)-5LX[A[*;<<L(F<B.3+"2(JXX(Q[-7R9^Q3\./BC\)_V9/@]\//C'JZ:U
M\0?#/AJVL=;F247":?$"[V&A_:551=-HEDT&FM<;0)3 6!YKZSJJBC&M75/E
M]FJTU3<;V<-+:O7=NU]B*;;A!O>VO>Z;7Z;]0HHHJ2PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8_1?]]/
MYBGTQ^B_[Z?S% #Z*** "BBB@ HHHH **** "BBB@ HHKC?'GQ"\&_#'PIK?
MCCQ[X@TWPMX3\.6;W^M:[J]PEK86%K'PTDLCD%CN*HL<:M+(S!8T8D5,I1C;
MF:5W97ZL-].KT1V5%>/_  ?^/OPA^/OA5_&OP>\<Z-X\\-Q7KZ?<:AHLKO\
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M!_$CGK@\4C]%_P!]/YBGTQ^B_P"^G\Q0,?1110 4444 %%%% !1110 4444
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M^'6D_%36_C78>&;2V^(_B31+7PWK?B5"3=WFCV+;K6TD&%^2-NC?GSDCQ_\
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MUXWO_I)/7Q)_P3W_ .2(ZI_V4?QK_P"G.2OMO6/^07J!_P"G&]_]))Z^)/\
M@GO_ ,D1U3_LH_C7_P!.<E6,^[:8_1?]]/YBGTQ^B_[Z?S% #Z*** "BBB@
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M=6M_$T]Q!;VMKMM-\<ML;=FF9P!@X R0![M_;W_!0O\ Z$'X#?\ A6ZK^O\
MH5?26@_#KP-HOC_Q9\7M*2+_ (2+QQHFE:7KFKB[CDL;K2M&>6>Q:.0,81$A
ME=_,5]H4ENG->H6U_;W<<<UK-#=6\J[X;FVFCG@E3)&Z.6(M&XR",JQ&0<5/
M/'SZ7LGIS;7TTOYV#MY['P[_ &]_P4+_ .A ^ W_ (5NJ?\ R%1_;W_!0O\
MZ$#X#?\ A6ZI_P#(5?=B-O!.,8..N>1UI]6!\%7?B;_@H1:6=W=M\/O@1)]E
MM+BY$:>+-69Y#;PR2^4BK99+R[ B$\!F&?4<!\*?B_\ \%#/B=X(TWQB_P '
M?@_X3DU">]A_L/7/$^JPZE;"TN9+<2S)]A("S[/.CZ91P:_3&1=Z[< @D9SZ
M9Y^OT/\ /%"(L8VJ %[*H"@?@..>_ S0!\*'7O\ @H7V\ ? ;_PK=5_^0O\
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M!C"K@8PH 7''0 # '/&!3Z /@#S_ -O/&/\ A57[.O3'_(PWF/R_L[]*//\
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MD,DCVTLBHXYRC$'@]*&TFEKJKZ)O3N[)V7FPVU>BV^9\._:/V\_^B5?LZ_\
MA0WG_P KJ/M'[>?_ $2K]G7_ ,*&\_\ E;7WX&SMQT89!S[9_P __6IU,#X
M\_\ ;RX/_"J?V="1W_X2&\_'_F&\9YS@UU/A35_VY?[>T>#Q/X"^"6G^%C<Q
MKJ\VB^)=0FO[>R)_>M8VS6<<;S#/RQDJ"1R17VM10!#"6*Y< .0I8@ #<0,@
M'O@^PQZDY-/?HO\ OI_,4^F/T7_?3^8H ?1110 4444 %%%% !1110 4444
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MF/T7_?3^8I],?HO^^G\Q0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *3:IZ@'OT'7UI:*5DMDE\D F .@ _"EHHI@%%%% !1110 4=:** $VK
MQP./:EP.F./2BB@ HHK@/BE\2O"/P=^'WBWXG^/=531/!?@?1+[Q'XEU=XS(
MFG:/ID+7-[=2*IW,D42,S!020,"IG.-.,IR:2BKMO1#2;:23;>B2W;._HKY:
MTO\ ;#_9_P!:_9EB_;!T[XAZ;)^S[+X3F\<#QZ<K8+X<MV=)KUU/[Q-DB,AB
M^\& &.:]5^%WQ9\%?&7X<^$/BM\/M=M]:\#^/-&M->\+:TH6&+4],OTW6EQ$
MLI4_O5PR)C<>^,\KF^+W9>[*$79-V=2//!.RTNKVNE>S:NB;JT6M5._*U:SY
M7:35VKJ+T=MCU"BJ#70B4M++%&JD M(Z)C) !8LP'+' /0]%STKR[QG\</AM
M\/\ 6V\-^+/%VE:5X@'A;5O&BZ+/-&-1D\,Z(K-J6K16X8R26UJ$(=E'7BAS
M46HO1N_I=*3MZVB_N8U[VR;\NJU2_-I?-'L&!Z48!ZC-<'\._B+X6^*7A'1/
M'?@O58-8\,>(K%=1TB^BPOVFU=BBR%"=ZC<K9R!T[9KL_M$<GFK%-$SQ$+(B
M2([1.3PLB@DHQ'(5@O<D\8IW5[.+3MS:QM9:-/;S30KIJZUWV\FT_P 4UZHL
M8'H/RHVKZ#\AWKY?_:!_:\^"7[,JZ)%\5?%9L-7\1M,-!\,Z18SZQXDU>*U7
M==7-GI-FKW4EM;H=\TP3RT4')XJ/P?\ MA_ 7Q]X2\&>.O!WCJS\0^'/'/BK
M_A!](N-.@EFFMO%:(SSZ)J]L )M+O+<*PG2Z5&C9=I&:2FG%RCJDU%V[MV6_
M?5_)^A5MD]&X\R3T;7D?4M'6J?FDLT?VB'S""P3<F\(#@L55MV,Y!;& >XQ2
M"9@WE>9$T@ 8Q^8BR!"<!MFXN%ST) !Z9I\RLFTU>^^Z2O=]=/0F^K5GZ]"[
M1503@LR"2,R(?GC#(SQ@]"Z*VY1[L /3/%>(_'?]H_X3_LW^%[?Q9\6/%5KH
M%AJ%XNFZ-9+&]UJ^O:F_*:?HVG0![F_NRH9C%"C$*,G%#E%6NUJ^5>;[*U]=
M5]Y23;LE=VO9;V[VN>\T5\A?#[]N#]F[XE_#WQ5\3?#OQ,TFV\.>!;F.T\:Q
MZVK:/JOA.YG9!;P:YI=Z8KFR>Y#H8/-0"3<-IS7U)I^K6NIZ?9:E9W<5Q:7U
MK;W]K<1%&CGM+J)9[>=65MIBFA='1L@$$8)H?.K-P;3:3:V7,N97[>[9M/6S
M3V8EK;1Z[>>MKKNKZ7[Z&S[4F%]!^0KC_&OC;0/A_P"%=;\:>*=3@TSPYX<T
MJ[UG6+Z4KBWL;)#)<3A0VYUB3DA,DXQUJOX&\=^'_B'X1\/^.?"6IQ:IX:\3
MZ=#JNC:@J[4N[&X4M%<_,?D1P.^,<9]:5VXREROEC*$)7Z2DF^5]+V5[,7,K
MI=TVGT=K7MWM='<$*>"!]./T%+7C/QN^.GP[_9Y^'&N?%;XIZVNA>#/#J0MJ
M.J+"USL:=A'%'%#%O>9Y)&5$"@[F.!FOFSX5?\%)/V7?BYXS\.> ="\5ZQHG
MB7Q@$'A*U\8^'=0\-0^)9I83<1VVCW&H1117MP\(\R.*)BTB$$>M*$XR<HP5
MY1LG%+6[NTNFK47[MKZ.R?5OW4F]$TVF^J6[]$??-%4A.=_E^;&TN-[1;H_-
M52!SY8.['3MWZGJ4:YPY7SH@RH9&C+1^8$VD[]A;<%SWQ@X(!)XIJ=VDD]VG
MMI:U_NOKV"_X[>>ER]17FO@/XI>$_B-;:W?>&M2,]GX=UN]\.ZK+<PM9K#JE
MA(8KF$-/L#J'!VNN58?=/-6=5^)G@K1_&GA[X>:AXFTNT\9>*K.^U+P]H$L\
M0O\ 5;#35WWMQ:Q;]SQ0J1N<#OQQS3YO>4?YE>+Z.RO9=V).Z;VLVG?I9V=]
M[:L]!R.?89/TY_PHP#U&:HFZC"R,T\ 6-<R-YL86,$9'F-NVHO49<@9KAO%_
MQ/\ !?@!O#2^,/$VE:$?&.N6OAKPP+^YBC_MC7+X%K73K(EP)IYE0LBJ3_.D
MI7=N5J3M9->\[]E:^VOH-:[:ZR7_ ("KR;UV5FF^^AZ-@>@_(487T'Y"O-_
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M[4EEX-UKX46OB6.WTBQT*/7%LU\$P^$6'VN&TN+-$NA>%?G$I(;;BOZ-V_9
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M*_N;.],.[[%=#;(59N/Z /VIOA!??'G]G7XQ_!G2=3BT?4/B5X!UKPC8ZI.
M\-E<:I#Y,=TZ+RR1Y)=1G*]1Z_E%^V)_P2%U;]HCX+_LMZ/X%^)L7P\^-WP"
MM_A9X5\7>+K:WW:5\4/A=X*UW2M<UGP/XB@0!KF":\TV.[TF>4.]I,"B%$8@
M9T^5.:FE4IRGA5%:IP2DYUII?:LHJ/*^DNX:N-KV=JST2;DU&U*.NR;;<GY*
MQ^JWQV^-]O\  /X03?$R^\+^(O&]XAT/3M/\,>%[0WFKZOK>MF*WL[>( [;>
MV\]]US=2E8K>(%W(51G\@_VC_P#@K%\4-._9U_:/D^%OP;U?PO\ M.?L^^*?
M@M'XI\!ZI>V6JVL/A'XJ^)M/M=+UFSOK=GAN6OK22>QDA.'M;J920P7G])OV
MX/V>/B/^T;\!+?X8_"WXAW7P^\0V7BCPEX@O;BWN)M.B\6:)X=N%N-3\%WFJ
M6RM=Z78>((1]GN+RU7SHE"E".H_,RR_X)%_$S^R?VQ;Z'Q9X2\*ZO^TIX-^!
MEMX=T/3[B_U>S\+>)_@MKD&O6T>JZQJ"M?:G;ZW) (;FZ<LT8?<H!'-1M*6*
M4DH4U)SI237O<CA.,6GK[VL6NB04_=A1<K<S<%535VM9*33>]ERR=GKI?K?]
M._VDOVO+']E;]E2+]I+XB>"->O)+/3O!<>J^!-&V7>O+KWBU[.S32;;:-LUS
M#J%V(B$4;MIP!CGXFUK_ (*+M\,_'WQ(\?\ Q@\.^/O!FE>#/V>O"GQ'O?@Q
M)8QZA+;OXGU6TT[1;Q;Z 82^O9M1MX[N-E"VD:2-(0$8U]=?M;_LS^//VI_V
M4M'^#EYK&C>&/',NK?#/Q!K][;![C1HM0\':G8:EJD-CYJ^:T%R]J\=LS ,-
MRDUY%\8/V&?B!X\^,'Q,^*OAOQAX7LV\8?L\^%?@_8Z-XIT./7M%N+W0;RUN
MKU-;T^Y0I-I>JQV[VQD&9K9I5GC^9:N*C'V\DX)R]M&G%6]Q.A&2:_[B\R3Z
M7^1,%>*C-WERJ\MO>]M;1='[-W=]-.YX#\>/^"B?CVZ_9F3XMVN@ZA^S])X.
M_:%^!.B>+?%&OWMAJ?A74_AIXM\2VI\17FG:U:2R6SPKHLC17ZNRO;.&5N0<
M_H_^RQ^TQIO[5GA?Q)\1_!WAC5=,^%W_  DMYH_PW\9:IA+?XG:+9$PR^,-
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M4S^'/V&O#E[XRLEB_9:\ >,O!OB>Y@A)DUV7Q1X!O/!T=]IN5Q&8);A;MU;
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M** "BD) &33=XR  3D9]QZ<'GG% #Z*8KAL8#<D@Y&,=?Y]L?7H*?0 4444
M%%,WCG@G&<\>F?\ /XT\<@'UH ",^H^G6BBB@! ,9Y)SZ]OI2TTM@$X;@XZ>
M^,_3O_\ KHW9Z*Q]^ .N.I/)[X';OGB@!U%%% ";1VR,G)P<<GK2G\OI110
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M?X7V_P"SEH5G%+K7AGP/<2:D+/QG8ZI$6GNVL;.QM[S5'D5+:$72QF0L<#[
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MSJ&DZ[J'B>;Q%\.[[4+@'=<V:RK;PZE8R!HY(6:-@!D5]4?%[X,_M,_M#?\
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MB/02IT;Q1<Z4Q>TUNT5%V1/<VC*;F*,[(YPRIGG.-_P4#^"?Q"^+6E?#*_\
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MK7Y#_$3X::YXV_;-_8G^&UA<:OK-K^S3X!U7QM\0/%]S"^PWITRUTK0;*YN
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MCF[.RC=.O52DFTHP<$TG_-;DC9WW;LKMGZB8&0?3I^-(W0_0TM(WW6^A_E2
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M 6**.)0$1(T 554    5:HHH ,@=3BH=C \%=O/!&<$]#@#'IGUQ^<U% "
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*T?[T?]:** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form424b5_004.jpg
<TEXT>
begin 644 form424b5_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "? D # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^^VT^X/H?
MZ5;JI:?<'T/]*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7S]\9_&/B3PQXI^$]AH>I/86GB#5?%=OK$*PP2B]AT_P .O>VB
M.9HY&00W($H,90L>&++Q7T#7RQ^T+_R.GP._[#?C?_U$Y* +O_"=^*O^@K)_
MWYMO_C-'_"=^*O\ H*R?]^;;_P",UX;\5_BU\-_@7\/_ !#\5/BYXMT[P-\/
M?"D=C+XA\4ZJMR]CIB:EJ5IH^G^;'9PW-U(]YJE_96-O%!;RR27%S$BKEA7/
M_"K]H?X%_&_PMIWC3X5?%?P/XP\.ZKJ6JZ-8W5IKMG87KZUH=VUCK6C3:+J\
MFGZU:ZOI%ZK6VHZ;<Z?%=V<HV3Q(3BK4)N/.H2<$^5S46XJ5KV<DFD[:V;1+
ME%/E<HJ5KV;2=MKV;6E]+GTE_P )WXJ_Z"LG_?FV_P#C-'_"=^*O^@K)_P!^
M;;_XS7G>G>(/#VL:-<^)-&\0Z!K/ARRBO9[WQ%HVM:9JV@V<.FK(^I2W6L:=
M=7.G6Z:<D,KWQEN5^RK%(TP0(:^0?#O_  46_8J\7_9#X3^/7A[Q)'J/B1O"
M>DSZ-HWBF[M=:UH>'O$WBJ,:'=C1$MM:TR[T'P;XHO;'7-,ENM'OFT:YM;6]
MENC%$[C2JSYG"G4ERM*7+";Y6[V4K1T;L]'9^74'.$;7E%73:O)*Z6K:UZ'Z
M!?\ "=^*O^@K)_WYMO\ XS1_PG?BK_H*R?\ ?FV_^,U\_1_&_P"$TW@W_A/(
MO'>@/H'_  A$WQ'-LM] ?%*^"X-&7Q#/K+>"A)_PEBB'1734)+1M'%VD,D>Z
M%6D0'5M?BK\,KG3+#5V^(/@O3K34O#6E^,8(M=\3Z'H&HP>%];MX+G2]<U+2
MM9O[+4=)T^[BN;?9/J5M:HLDJ0LPE8(9Y)K[$^J^"73?[/3OMYCYH_S+ONO\
MSVS_ (3OQ5_T%9/^_-M_\9K@?%?Q1\=Z?XM^%FGV>OS0V6O^)=?L-7@%M9L+
MRUM/!6O:I;1,S0%HQ%?6=O.&C*,3'M8E"17"Z+\8?AGXD^(^M?"7P_XOTO6O
M'_A[P-X:^)>JZ)I;27T,'@7QA?W^E^&_$<&LVJ2Z+?66JW^EWUO ME?W$R&W
M9Y8TC9&:+QO_ ,CS\%/^QQ\4?^J[\3TG&47:2<79.S33L]G9I.SZ: FGJFFM
M5=--76ZTOL>^_P#"=^*O^@K)_P!^;;_XS1_PG?BK_H*R?]^;;_XS7(,RHCR.
M0J11R2R,>B1Q(TDCGV1%9C[ U\2^'/\ @I#^PQXN$A\.?M)^ M3,/BKPUX-E
M1#JUJZ:WXQUZ\\+>&WQJ&G6H;0=1\26%[HA\4HS>';34+6:WO-3@="*J%*I4
M4G3ISJ*-N9PA*7+>]K\J=KV=K[V8I2C&W-*,;WM=I7MO:[5[7/T)_P"$[\5?
M]!63_OS;?_&:/^$[\5?]!63_ +\VW_QFO+X/&/@RZU.UT6T\9^#KS6;^P75=
M/T>S\5:!=:KJ.DNK.FKZ=IUOJ,EY?Z5(BM)'J5G#-9/&K2).44L*L/C_ .']
MQ!;75O\ $'P#<6M[J[>'[*Z@\:^%YK6]\0)CS- L[F/56AN]<CW#S-(MWDU%
M,J6MAN7*Y9?RRU_NR\_[OD_N?9V=UW7]6_S7WGK7_"=^*O\ H*R?]^;;_P",
MT?\ "=^*O^@K)_WYMO\ XS7@7C'XU_"7X?>._AG\+_&OC_PYX<^(OQFU/4='
M^%G@O4;PQ^(/&]_I%C<ZEJD>B6*([S1:?96=S-=7$IB@B\LQF3S&12WX4?&S
MX3_'/P]-XH^$WCO0?&VCVNK:YH=ZVF7:)J.G:IX;US4/#>L6VIZ)<F'6=,6V
MUK2M0L89[^QMH+UK9Y;*2X@*R,_9U%'GY)\C2?/R2Y;2;47S<O+9N,DG>S<6
MKW32.:-^7F7-VNK]]KWVUVV/4?B!\3/&^C^ _&>K:;KDMKJ&F>&=8OK&Y6VM
M':"ZMK222&4+) R,4=0P5U9<YR"#BM[1_B#XNN=&T6YGUB1Y[K1=(N9Y/(M0
M9)[C3;6::0@0@ O+([D   G  &!7DWQ2_P"29?$+_L3M?_\ 2"6NFT#_ )%_
MP[_V+V@_^FBSJ!GH?_"=^*O^@K)_WYMO_C-'_"=^*O\ H*R?]^;;_P",U\V_
M&_\ :%^#'[-OA?2O&?QQ\>Z9\/O#.N^(K3PCHNI:E:ZI?-JWB?4+>XNK+1-.
ML='L=0U"[O[BVM+F=(8;5SY4$KG"H2,+X7?M6?LW_&O6;[P_\*OC-X%\:ZK8
M>&_"?B]K?2M9MT2_\->.-/U/5?#6KZ+->-;1Z[;WEAHVJ3W:Z0UY+I L;A-6
MCLGC*UHJ55P]HJ=1T]??4).'NVO[RBXZ75]=+J]B>:*ERN4>;3W;J^NVE[ZV
M=M#ZO_X3OQ5_T%9/^_-M_P#&:/\ A._%7_05D_[\VW_QFO(E^(?P[?2$\0I\
M1/A\_A^6^&EQ:^GC?PNVARZJS;5TJ+5UU4Z?)J;-PNGK<&\)QB'D9V['7= U
M34-2TG2_$&@:IJVC-"FM:5INMZ7J&J:,]PADMTUC3K2[FO-+:=!OA%_#;F5?
MF3<,U/+)7;C));MQDDMEJW%+=K[UW5W==U]Z_*]^C/0O^$[\5?\ 05D_[\VW
M_P 9H_X3OQ5_T%I/^_-M_6&OE7X0?M2?L^_'SQ'X[\'_  @^*&A>-/%GPRN(
M+?QUX;M8-4TW6_#Z7=Y?:?9:A-IVLV&GW-UHM]?Z9J-G8:Y8I<Z5>W%C<Q6]
MW(T3"O?*)PG3ERSC*$K)\LHN+M)7B[-)V:U3V:U3:!-25XM-=T[K31[=FFC-
M\ ?%+QYJ[^/1J.ORW(TGXC>(M%TX-:V:?9M,LH=/>VM5*0+N6)IY"'?=(=Q#
M,1C'H'_"=^*O^@K)_P!^;;_XS7S_ /"[[_Q-_P"RM>+/_2?2:\V\=_MG?LM?
M##XMVGP)^(?QK\)>$/BS?6^@W-MX.UDZC!=,OBL7_P#PBL,NHBQ?1[6]\3/I
M>H0Z!8W=_!=ZO<VLEM8Q33X0N$)U&U"$IM)R:A%R:BMVTDW9=78'*,5>344W
M9-M)7>RUZZ,^R?\ A._%7_05D_[\VW_QFC_A._%7_05D_P"_-M_\9KYQ\"?M
M!? _XE_#W0OBMX,^*_@/4OA]XDM[.XTOQ-=^)](T6S/]H^=]@M=1BUJ[L+G1
MM2O!!,]MI>KPV6HSQH9([5H_FKT"3Q=X0AOWTF;Q?X2AU:+2VUV32I?$^A1Z
MG'H2Q^<VNR:>^H+=IHBPD3'5WA&G"%EF^T^40])PG%N,H33BVFG&2::=FFG'
M1IM)IZJZONKB::NFFM[IIJWJFST[_A._%7_05D_[\VW_ ,9H_P"$[\5?]!63
M_OS;?_&:\%\=?&7X7?#?X<WOQ;\6^,])@^&]A]@$OBS0VG\7:=</JE_%I>G0
MZ6OA.'6KC6+B]U*>*RMX-+ANY6N'"%1AL6OA3\6?AM\<O 'A_P"*?PC\8:1X
M\^'WBF.[DT+Q/HCRM8WK:?>3Z=J-N4N(H+JUO=.U"VN;#4;*[@ANK*]MYK:X
MBCEC90<D^3GY)<G-R<_*^7GM?EYK6YK:\M^:VMK!=7Y;J]KVNKV[VO>WGMYG
M8>$OBGX\U'Q;\5M.O=?EGL_#_BO0M/T>$VMF@LK.Z\">&-6N(59( T@DU"_N
MK@F4NP:8J"$"JOH'_"=^*O\ H*R?]^;;_P",U\_^!?\ D>OC?_V/'AK_ -5G
MX-KU*I&==_PG?BK_ *"LG_?FV_\ C-'_  G?BK_H*R?]^;;_ .,UR-% '7?\
M)WXJ_P"@K)_WYMO_ (S1_P )WXJ_Z"LG_?FV_P#C-<C10!UW_"=^*O\ H*R?
M]^;;_P",T?\ "=^*O^@K)_WYMO\ XS7(TC,J*SNP1(T>21V(5(XXU+R.[$A5
M1$!9F) 506/ -'ZZ+S?EW Z__A._%7_05D_[\VW_ ,9H_P"$[\5?]!63_OS;
M?_&:^%?"/[?/[&?CJ:SB\-?M$_#VY35/%FC^!]"O-3O+SP]IGB;Q1X@?4X]$
MT[PIJWB"STW3/%$>J2Z-JL5I?Z'=7NGO)931M<HYC#^R>+?CU\#O =A::IXQ
M^,/PS\/Z=>^-=$^&\%[?>-_#IMU\?>([N2QT+PA=20:A,MAKVIW<4UO;V%]]
MGE\R&82!!%(5T=&M%J+I55)[)TYIOT3C_P 'RT=IYX-74X677FC;_P!*/H;_
M (3OQ5_T%9/^_-M_\9H_X3OQ5_T%9/\ OS;?_&:\QD\7^#XK>>\E\8>$8K*V
MM;F_N;Z3Q1H265M865PMI?7UQ=MJ MX;*QO&6SO;N21;>UO&6UGDCN&6,ZFG
MZCIVKV-KJFD:A8:MIE]"ES8ZGI5[:ZEIM];R#,=Q97]E+/:7=NXY2:WFDB<<
MJYJ&FM6FE>UVFE?M=I*^CTO?R*.Z_P"$[\5?]!63_OS;?_&:/^$[\5?]!63_
M +\VW_QFN1HI ==_PG?BK_H*R?\ ?FV_^,T?\)WXJ_Z"LG_?FV_^,UR-% '7
M?\)WXJ_Z"LG_ 'YMO_C-'_"=^*O^@K)_WYMO_C-<C10!Z3X;\8^([[7])L[K
M4GEMKF\6*:,Q0 .ACD8KE8E8<J.00:]_KY:\(?\ (T:%_P!?Z?\ HJ6OJ6@"
MI:?<'T/]*MU4M?\ 5CZ'^E</KGQ;^&'AG4[C1?$7C_PCHFKV@C:ZTW5->TZR
MO;<3()(C+;SSI*@D0AT+* RG(R* /0Z*\F_X7S\%?^BJ> O_  J-)_\ DJC_
M (7S\%?^BJ> O_"HTG_Y*H ]9HKR;_A?/P5_Z*IX"_\ "HTG_P"2J/\ A?/P
M5_Z*IX"_\*C2?_DJ@#UFBO)O^%\_!7_HJG@+_P *C2?_ )*H_P"%\_!7_HJG
M@+_PJ-)_^2J /6:*\F_X7S\%?^BJ> O_  J-)_\ DJC_ (7S\%?^BJ> O_"H
MTG_Y*H ]9HKR;_A?/P5_Z*IX"_\ "HTG_P"2J/\ A?/P5_Z*IX"_\*C2?_DJ
M@#UFBO)O^%\_!7_HJG@+_P *C2?_ )*H_P"%\_!7_HJG@+_PJ-)_^2J /6:*
M\F_X7S\%?^BJ> O_  J-)_\ DJC_ (7S\%?^BJ> O_"HTG_Y*H ]9HKR;_A?
M/P5_Z*IX"_\ "HTG_P"2J/\ A?/P5_Z*IX"_\*C2?_DJ@#UFBO)O^%\_!7_H
MJG@+_P *C2?_ )*H_P"%\_!7_HJG@+_PJ-)_^2J /6:*\F_X7S\%?^BJ> O_
M  J-)_\ DJC_ (7S\%?^BJ> O_"HTG_Y*H ]9KY8_:%_Y'3X'=,_VWXWZ_\
M8IR9_2O3O^%\_!7_ **IX"_\*C2?_DJOF?X\_&7X2ZAXS^"1LOB5X)N1%K7C
M8R&'Q'IDNP'PHR@OLN&*@LZJ"< EAC.#@ \._;$_9MM?VNOV=?'W[/E]XRU#
MP!:>/)_"$D_BW2;$ZCJ>DIX5\:>'_&&;"W6_TN1+J\.A"PAO(K^";3GN1?P^
M9+;)&_QMXM_X(^_LT:YKM[>>'9=5\)Z+<? 'XQ_":R9WU'Q3\0=(^)WQH\5#
MQ5XB_:/M_B5XAUFZUF\^)\-PT]H+G4+6XDN()WQ?VR?N:_23_A:_PQ_Z*#X0
M_P#![8__ !VC_A:_PQ_Z*#X0_P#![8__ !VNBEBL11@J=*K*$%*4^6-DN:7(
MFWI=NT(VO>VMDG*3><J5.;YI0C*5DKN][+FT6NB?,[VM?2][*WYJ_LX?\$D_
MA7\&_A+K?PQ\<>/_ !?XREU74O$-ZFH_#KQ!\0/A'X=E'B7P)I7@+5;KQ#X%
M@\>^)M!\3:IJ%EI4.K7BWZKH*ZG+,;71(8II_.H1_P#!,GXFZU\*O@3\&?B'
M^UC9^+/!'[,K'2/@R-)^ ^@>$M;L?!T/PB^(WPCLM-\6:IIOBQVU_7H]-\>V
MNIW&K6T6EZ8\_AQ5M-#L[C6KZ[C_ $Y_X6O\,?\ HH/A#_P>V/\ \=H_X6O\
M,?\ HH/A#_P>V/\ \=K1X_%.3DZO-*4N>\H0;4N5QO&\?=;C)IV>J[-)I>PI
M62Y%:,>56<E[MT[/WM;22>O7O=H_'J/_ ((G^#X;I=;A^.%S#XR_L2'PO)XT
MB^'%LGB";PHO[(W_  RO=>&);X>+/M+Z%?3K!\3;G3VF,$FKVT.D.DFQ-667
M4/\ @CC?)H7Q2\,^'?VA_#L%C\4K+P =4\6>*O@'HWBWXL6DW@SPOX#\)ZCX
M-M?B+=^,+?4;;X-^)M/\#1SOX#L+:RU#1;C5KHZ?XES$LC_L!_PM?X8_]%!\
M(?\ @]L?_CM'_"U_AC_T4'PA_P"#VQ_^.U7]I8W1^V=TTU>%-V<6I1WCM%I.
M*;<5TCJR?JU'3]VM$TG>2>JY6[J6[26OEI8^%OV%/^"=EE^Q)JL.J6GQ;O\
MXC"V^ WA?X%6UG=^%CH$5MIOA;XF^//B-9ZM;S2>(M?N5A5?&_\ PCMMI$DD
M@L[/2(+E;V5KAH(OMGQO_P CS\%/^QQ\4?\ JN_$]:'_  M?X8_]%!\(?^#V
MQ_\ CM>8>-OBK\,SXY^"Q7Q]X29(_%_B=I677+$K&K?#[Q+&K.?-^52[!021
MEBH&<US5JU2O4=6K+GG*UY62O:]M(I+[3V74UA"-.*C!6BKNUV]]7JVW^)]%
M3Q^=;W,&=OVFUNK;=C.P7-O) 7QQG9YF[;D;L8R,Y'XU^$O^"*W[/WACX1>
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M5AA\(Z[X?TG5GOSKWA3P=XMF\/\ B.?2?%.L^$;SQ#HV@>))WENR3-I=K8N
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MSF$], @CD$ @@@$?05>'?$/_ )*[\ _^PG\0_P#U#9: /7O[%T;_ *!.F?\
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M2NKWQEK_ ,&[,:EH^N7TLOA]K#2])^,>BO+:WS6]Y=:O%):QM%;Q23-0TO\
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MW<VGZWXBM]2T2R9K[3KR*$ ^LO[%T;_H$Z9_X 6O_P :H_L71O\ H$Z9_P"
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M28M7T>XN[.XTZ]2,RRVUU9ZA872)<66HZ;?6]UIVHVDJEK>]M9X@SJ@=O0:
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M_C&SO-9U&V\=:EX/ENO[(O?&<>I:[?ZB=>\B*YDO#;32A_LEN(P#G?V:K_\
M8(_:?^&FN?M#> ?@K)X?^!_PY^%4O@C4O'EQKFLV/@_7_#^A>'_%L_Q$^'M_
MX8\/^(YD\<:?\);/7_$N@ZMJGB/2;^U76-7UK2?#4MX;&XEASO@Y\=O^"=GP
MR^+.@_&GP=X@\8:/J?Q7^"/PN^$WA#6O$7@'QZ?#W@7X*^%/'>M:+X,EU_QO
MJVB7-QH'AKQK\1?%EOIFG:YX_P#$,D&H:P=%TW39K9"\+_2?PO\ AG^SW\%M
M(\7Z!\*O@[\=_ NB>.O!VB>#?$>DZ!X0^(=IIMU%X?T.Y\-V/B>WL,M9V'CN
M;1)X;'5?&=E#!KNLIINDRZK=WEQI]O*OS#X>_80_90\.>/+#Q';^ ?VG[[P/
M;:!#9:O\)M2T#XFW7@WQOXHA\?VWQ%A\7_$.V%TD'C)[/7M.T>[TOP[JMFWA
M_3-1TNWU>VLQ>[G !>C^/_\ P2PTVSU/7(O"-S%)XR\6-XRUZP/PE^+,NKWR
M>'6O_B;;?%W6M#DT9[NU^&WV'XB:IX\T_P"(%U:P>$=1T37+W4H;R>TB9(*D
MOC3_ ()6:%\/OB-\-],\(ZM?^"]'^(?A?P+KMGX3\*_&;Q!JM[XQ^"FCZG-H
MT_@G6M%-[XJEM?@KX8\.:G+>Z_X8OH+#P?X8TJ1KJZ726C\[T?PU^R?^R+X8
ML=;L;?X,?M)ZLVO^"O%OPUU#4?$EG\7O$&K?\*Y\7>#M'^'\W@6UU+4[Z>ZM
M/"_A_P &Z'I^@>$-,@=$\-6:3'36CFN9Y7R]8_8]_9'UO7O%GBZZ^%G[55MX
MS\8ZDE[J?C/2)/C#HOBBVL#I'B+P[>^&M+U?2KNSGL?#.K^'?%FO^']9TI X
MU/1KX:?=3/!:62VP!4^'W[7W_!/']EN/QM/X6^)?B+3/"7B+QOX<\#:3!'X:
M\>:E\/-*'@+P5HVC+X>^%+IHTFC7/A/P;X?2P\1^.=8T"?4(H-2\4C7O$FHS
M7^N1,_UK\)/VT?A5\<OCCXB^#/PSM?$GB"T\.> M2\;M\37T/5=,^'_B+^R?
M&EOX(U'3/ ^N:E86UEXVAL-5EFCO]>\-W>H:-:W-M)8M<-.RFOGOQ!^S)^R7
MKWAWP=X9A^!OQY\.6/P]\;^)O'O@BY\+^%/B%I&I>&-5\8V]A9^)M.TB]"SR
M6OAO5[32M+MKC0%4V"1:;8FWCADMT<7OA_\ L^_LX_"[Q=J_C+P/\/\ ]J_0
M]1U.YMGM-.@D^,3^'?#&EQ>-U^(MYX6\'Z!+?-IOAGPCK?B\/JNO^'-+@ATS
M5_/GM+R%[*0VX /TSHKR;2OB[IVK:G8Z7'X)^*EC)?W*VR7FJ_#KQ%IVFVS.
M&(EO;^XMD@M( 5PTTS!%)4$C<#7K- %2T^X/H?Z4W4=1L-(L;K4]4O+;3]/L
MH7N+R]O)DM[6U@C&7FGFE98XHT'+.Q '<TZT^X/H?Z5Q/Q7\'WGQ ^&_C/P5
MI]W;6-[XFT&^TFUO+V.26TMIKI J2W$</[UXE(RZQ_,1P.:\O/,5F&!R7.,;
ME& 6:9M@\JS+%97ECG[-9EF6&P.+KX#+W4YH>S6-QE+#83GYX<GUCFYX\O-'
MKR^CA<1C\#0QN)>#P5?&82CC,6H\[PF%JXFA3Q.)4&I<[P]"=:OR\LN;V7+9
MWL]?5/'/@W0[K3K+6?%.@Z5=ZQ'%-I5OJ.JV=G+J$,[B*&6T6>9#/'+(RQQN
MF59R%!R<5K:KK>CZ%;)>:UJ=CI5I)/!:QW.H74-I#)=73B*VMHY)W0///(RI
M%$FYW<A54FOB#XE?LZ?$/XB2^&M>\1>*?AYH[>%O"D?ARZO+0:Z-.MK/2M:M
M-9@UH_:V6"X>VCT]A=66H2)IXD_>.X2/->@^,?AA)\4?A^;+P+\1=&^(!N?%
M^B:]%XB\4:M:>)M(T.Z\.74=Y/:>&9O#-N([&2XG2.VN('FE:WLIGCW[@H;\
M=P_'WBY7I\>8A^$.+IX7)L-@J_!<\1CH8;%\15:N78"OB<'C<M>88G$PQ4<P
MJYAA*4<#BL/3I4L+2KXNK4C.:/MJG#O!E.7#=+_76C*MCZN(IY_&GAG4H95"
M&+Q%*E7H8M8>G2G1>&AAZ\I8BC4E.565*C",E$^BY/&OA"+5[W0)?$^A1ZWI
MMD^I:AI4FJV27]C81Q^=)>75J\PE@MXH2)I))%58XB)'VH<U<T'Q+H'BFP75
M?#>LZ;KNF-+)"M_I5Y!?6AFA($L7G6\CH)(R1O0D,H*G&&7/QGXG_95\5>+?
M$GBK4K[Q/X>T^P\13>*==2YT^POWUZ/7O%'ARQT.72+NZE=(Y_"MC-9FXABW
M"XEAE",BL#7NGP.^&&M?#72_$ZZ_>Z+<:IXH\0KK,UIX<M;FST'38H-+L=*@
M@L8;G$WF3QV/VJ[D*HKW$IV@X!/1PGQKXM9OQ@LJXB\,(</<*2J\1*/$4LQE
M4JJA@:B_L24\*\;74:F/@Z4:D?8VQ,L34KX3ZE2RK&4L7EG.1<&X/(_KN5\7
M2S/.53RIO*_JBA3=3$P;S&,:RH4Y-867,TW-.BJ4:=?ZQ4QN'G0]SHIN<#H3
MVX!]NG '\AZ>V)J_B?P[X?M[F[U_7M%T2TLOL/VVZU?5;'3K>T_M2\73],-S
M+>30) -1U"1+&Q,K(+N\=;:#S)F"']N5W9)-MM*R3;;;LDE%2;;>BLG?H?!-
MI;M+U=OQ=E^)NT4@)],<?_J[?_J[CU,GH!^? _KFE=#%HI,GT_SSGJ!Z<=B2
M/K2T70!7.>)O&'A/P59V6H^,/$N@^%=/U+6M'\-Z??>(M6L-&L[WQ#XAOX=+
MT'0[6YU">WAGU;6M2N(-/TK3XG:ZO[V:*VM8I9I$1NCKXV_;H_9P\/\ [4?P
M5TSX=>,/$^C^#_!FD?%'X;?$3Q=K^L77]G?8-!\!^((M=N;G1]7:2*#1/$EG
M/#;7_A[6;MQ::;JUI:W-P&C0J6!]3>'_ !AX3\5KK;^&/$V@^(D\->(-5\*>
M(GT35K'5$T+Q1H;(FM>'=7>RGF73];TAY$34]+NC%>V+.JW4,18 Z&D:UHWB
M#3;/6= U;3-<TC48!<Z?JNCWUKJ>G7]LS%1<6=[92SVUU 6!42P2R1E@0&R#
M7X#6G_!*W6=%OO!OB_X=_M)Z?J7P+T/XD>._B=<R+\2]:\-F[N?&/B#PEX@U
MSXMZSXWT#3-7TWQ7\0M<DT/Q':>,+J5]$TN]M-8:RM-2LM/N=3M7L>'/^"57
M[0V@7G[/%EX0^*/PE\&^ ?@IX1U3PLD7PWU?XB^#M7\6:1K5]\4)?$-U<ZSI
MME?:CYWQ$TOQKX5DN?L>L6FG>#M1\/7]_I5GKS76FFU /WP_MS1?[7_L#^U]
M+_MT:<=8.B?VA:?VN-(%R+(ZJ=-\[[9_9HO"+4WWD_9A<D0>;YIV5E7GCCP;
MI^J?V)>^*O#UKK0U#1=*;1YM8T]=4CU+Q)'?3>'K&;3_ +1]KAN=<BTS49=(
MBEA1M1CL+Q[,3+;3%/P-N?\ @F+\9/AQX#FUW7_BO^SAIWB)/@7XH^!]WXY\
M:_\ "2Z9#X5\*ZO\7/#OC[2[!/$NHQII&LZGK>AVFO>&/$?BW5O#MA,=9U2R
MU^U\/WTJ7L%UM?"W_@E3\<-!L=&US3OC]X$D\3:YX=^%%O??&OP]?>,M<\<:
M5I_PP_X7C9^&M)\*:Q<F#3O$N@Q>'OBIX6&EZCJ2:<8KKP4BK8K93V2VH!^[
MOBKQCX3\"Z%=^)_&OB;0?"/AO3Y;*"_\0>)=7L-$T6QFU*_MM+T^*\U34I[:
MRMI+W4KRTL+59IT,]Y<P6T>Z::-&\Y\5_M(_L^>!/[3'C/XW?"GPL=%\40^"
M-877O'WAC3'TKQA/IMMK,?A?4DN]3B>RU[^Q[VSU:32[E8[R'3+JWOY84M9H
MY6^)HOV$->\6?L37/[*'Q L/A-I4NL?$+X5Z]XQD\+WWC_Q-X6\:Z+X%^(7P
MY\7>+=7U@^-99M=C\7^/K3P=JLETB2RZ=:ZQJ5G>3SW4@OII?E[6/^"1_COP
M*/%!^!OCWPU>^)M5\8KXL\+?&CXF>*O'$'QF\,:[J'PL\)^ _%7B[Q+J6AZ1
MJ7A;XHZGXNU/PU:WGBK0?%V@2:-K6BZ-X<L4>RNK26>@#]G=(^,/PHU^V\:W
MNA_$GP-J]E\-[QM/^(-YIOBC1KRT\$WRZ?#JS6GBFY@O'AT.<:7<V^I>7J+V
M[?8+B&\Q]GE20^@6]S;WEO;W5I/#<VMW#'<VMQ!(DL-Q;S1K+#/#*C,DL,L;
MH\<B%E='5E)4@U^<FC_L?_%4_"3]N/X>^)/%GPTGUW]I[4-2O/"?B;1=&UG3
MK:"XOOA#X4^'TNI>.](6)(X+N\UWP[<ZU/8^&Y)[.QTW4$L+.1WM@S>%^,OV
M#/VG_C!X[^&_B7XE?$?X8>%['P]X*^'7P_U&Y^&7B+XL0ZSX#\->"9/&EOXW
M3X7Q7TFEZ1/=_'?0?%>E^'_'$WB:S8Z-:>#=$FL'U*10D(!^RV?\/\_E7AWQ
M")_X6[\ ^?\ F)_$/_U#9:^-/V'?V)_CS^SC\0/$OCSXW_M'7?QPEU_P#::=
M::3M\00:;H'C[Q%K%E>?$C4=*M]8OKN./PK-I?@WX=Z=X*L"IU#1C%XP>XF9
M==*U]E_$/_DKOP#_ .PG\0__ %#9: /<:\#_ &G/%WB/P)\$_&OBKPIJ+:3K
MNEPZ4UA?I%#.T#7&LZ?:S$17"2PMO@GDC^>-L;L@ @&O?*^8/VRO^3<OB'_U
MPT3_ -2'2O\ />OR_P ;L?C<K\&O%?,\LQ>)R_,<O\.>-,;@,?@J]3#8S!8S
M"\.YE6PV*PN(HRA5H8BA6IPJT:U*<:E.I&,X24DFOKO#_#8?&\=\%X/%T*.*
MPF*XKX>P^)PV(IQJT,1AZV;8.G6H5J4TX5*56G*4*E.:<9PE*,DTV?E+_P -
M@_M&?]%%N1]=)T0X)]_L %+_ ,-@_M&?]%%N>?\ J$:)V_[<*]*_9Z^$?PG^
M(/PZT\^,XTT_Q;K_ ,4T\.^&]<DN;E(+A=-TNUUR;PY>11SQQ+#K%G%?VD4R
MQ?:/M,T2Q2JX7=N:U\)_!GAO0]0U+PE\'#\6)[WXB_$70M:4:[JMNOP_T?PY
M<3II%G&MC=(+5I+2/[<VH:L9(I4C,>_=)&&_P]RGAKZ5>;<&Y#QW#Z0G$M/(
M<]R)Y]&GA>.N/<[SS 4?JL<3]2Q7#N14LPSJICE3K82O.&#P>(I4\OQ3S:5;
M^SL'CJM#_0?'9UX+X'/\SX;EX7Y3+,LLS)Y;*=7AOA?+\NQ,U5=+V]'-LSK8
M/+H8?FIUZ<98C$4IRQ-%8!4_KN)PM.KXQ_PV%^T7U_X6+<CZZ1HG_P @4?\
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MCTK3_$,KW,6EF!(Y"C2!;B?9O7R.).%OI:<,86MB<?X[<95_JN18K/\ $X7
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MJ^QG5C!4*F&J5_I?_AL+]HS_ **-<_\ @HT7_P"0*/\ AL+]HO'_ "46Y_\
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M*@ HHHH **** /GO0_%&A^"-3_:=\:>)]0BTKPUX0\0V_B?Q!JEPP6WTW0]
M^#_@W5=5OIF/"Q6EA:3SR'LD9K\I/@#_ ,%:OB#XVT?3_"WQ"^&/AK0/C1XQ
M^*>K3>%])\>:AJOP!\$Z!\#=;\#V_P 3? FH^)M?^(EI=3W?C-M+_MOP%&FF
M6O\ 97BGQ9X8U#4M/EL=,9XX?U!GUJ/PU8_M=^(Y=,L=:B\/7%WKKZ/JBH^F
MZJND?!/PKJ#:;J".KHUC>BV^S789'4P2R J1P?R7^&W_  53T3QO\-;SQ'\<
M_P!GGP-X\\0V4]QXC6Q\+Z6OA,6/PW^&?PCT#XU?$/Q)J/ACXWV]GXFAU#X=
M:7XHB@\"VL$/V;XJW$MQ>^ YXK:"\N2 =UX%_P""L?BW0?"%A\2/C_X$\)Z?
MX2TGP=>>(/B?+\+];_X2&P^'EG-\>OB)\$]!UW4[JYEDU5KJ7Q'X=\)>'-<\
M+C3C-I=UXFCUTZC]CBN+*VNWW_!5'XM>)?B%)\+_  S^S9J7@+7=(^+GP3^&
M&MZAXU\6>%K^2#Q3XJ^(/P9T/QMX*O/#4&HV/B&Q35-)^*K:1X0\;6]A>:1;
MZQHFI:AJ40LCIR7NQXI_X*":?!9^%O&/PF_9)TSQ?\)_B#X^^,FB7MU<:W\.
M= \4>/=!^$.F>,-4\=>)V\-3$S^&[K2_%G@K4KR+2_&D3WOB:VBM;ZV^PWFH
M120>]?L\?MJ? []IW]I'Q]X*\#_ CQ-'<>&M'N9H/CQK?@*UM=,\1ZAX+/@G
M4;[0)];N-*CN+&YT^3Q?H-[X5WZS?MJ9TW5+J*WTLZ5 UR 9^F_M_P"K_%#]
MDO\ :A_:%^&GP[O_  K=_ GPYXBT2P3QK#)?17?QD\%Z Q^)7@^31H&TFZOK
M?X;>.!/X+N+I+VTMO$^HV%Q-IUS;64D<]?)GPY_X*U_%'26\"_#[X@_!;5?B
M-\3=9^('C33?$R6=CH?P-\5>%_ 'ACQ)\.O#5O/XJ^&/C/QGKT6C?$G4G^(<
M/BG0_"6G^,M5L_$GP]TRW\3:5?-+K=E9UU/@[_@I-\$_AKX%U[P3X(_9=\4:
M=H7AKQ=\8-2\<> =6\7^%['Q1H'AS0/$.AZ]XZ\=>.-(\<7$&I76O^*KKQ\G
MB+0/#?VO7+CQ78S1R:1K4]J85@ZV_P#^"D/P=\::QIL?A_\ 90U'XA^+/%7B
M+3-0^!L-]<?#*VU+Q_I^FZWX@\$OXRU.[U9Y[SX7:CX>U3PE<65II'BN*+Q&
MVE-97%C"BPW=I9 %[3O^"I'C#7_#UAXI\*_ /PQXGTO5OAI\8_C<MCI/QQ\-
MW/B7PM\,OA!HR:K>6/CGP];Z+<7VA_$W69)8;"'P6!*;"Y>X2[OBVFWRQ\C\
M3O\ @JQKLOB_4M+^ NA?#7Q1I'AWQ'X+\.ZAK?BGQKI@\ :C;^(?%/P%T[7-
M:?Q]H=_-;Z$^@VOQE.BO;7-I=V<&LZ9-<:A=1"-;"3?TO_@IM\!H?$5UIG@O
M]G"\M/$/Q"TOX;7OP[@U%?!7@+4OC-XJ^-=EH%Q%%:WNHV<.E?\ ")6<NLG2
M?&7Q!O=:O[:PUC2[NQU;28O/T^:\YRX_X*8_L^:9\.[G6/"7[(&NZGX&U#7/
MAM\,K#3]-\.>"(M-U[XI_%;1=3\6Q> /["\/Z?KMU)INE6/@[5KC6_%:Z1=Z
M%=7NG:*;!;Y=0MKFV +.A_\ !6G7=+L];UCQ7\$+_P 0^"?!VI>(O#?B/QAX
M:\0Z;#XBU'QD/#?QX\>^&=#\.^ (XM1:YTV7PY\$-2TJ]UR;7U:34=3TZ^@L
M#";R"V^]OV,_VHI_VJO ?C3Q3>Z#X/T/4? _Q%U3X?W[?#_XB:5\4_!FISV.
MB:!K\=]H?C/1K6SL=0$=MXA@L-0ACAS::G9W<0=T",?EWX7_ +:/@GX\_'?1
M/A+X<^#.E^"/@MKWA/XR-X@\=>+K[0?"OC4^-/AMH/PT_MC2X/!VERP>(/ L
M?A^T^+FHZ7/XHUVZL[N\NWO(]&2R6*>:ZXCQK\6(?V ?C!H/[/'P%^$/AGP_
M^S]IW@KPI\;?BMXJU;Q+X@\4>,=<\5?&CXXVGP=LK6!M=UB]UR[U R64VJ7O
MB#4]1U%/+BL+!((K>WVD _9BBOQU\:_\%7[WPYX:TC48_P!FKQ;H&L>.O@/X
MD^.7PKC^('C7PYHFB>-K*PTWQ)JOASPQ9ZQI$.LZ<?%.L:=X:N]8U?P\=0BU
M?0=#N]/U)+74XY+I;/Z%^-_[=DOP&^$?P2^(?B3X-:QX@\0_%OP=XL\;ZEX.
M\-^.O"+6W@_1/AY\+=1^+GCN<^+-3ELM)\12Z;X7TC4$T.TTN,7'B+4UMK&V
M$!N/.C /T%HK\9=7_P""O&CZU\1+;X;?"#X,WOC?5;SXD_"SP[I.KZOXQM/"
M_AKQ#X)\=>,5\"^)-:M]<U/1X;'2/%O@KQ%<V6G:EX9FFU2S2\:\L[K6+:\M
M&MVJ6/\ P60\#6LD^EWOP7^*/BV\\._#Z[\7>./$/@O19E\,Z%KDUEXRUCP[
MX;%WJ:'3H[35=+\(7-M=>)+[7+6SL=;O--L1:7*7CRVH!^TM%?G'\"_VZO%W
MQL_:)L?@C_PHN7P79Z;X'\>ZE\2-2UKXA>'KS6O GC_P)XUL_#5QX5M--T^%
M[;QII6I:9J^AZM'K.B7,;V,FH/#>6HCM7D/Z.4 %%%% !1110!4M/N#Z'^E<
M_P".M$U_Q+X.\2Z!X6\7W_@#Q'K&CWNGZ)XVTS3-*UK4/"VI7,+1VNMV>DZY
M!=:/J-QI\I6>.SU.VGLIRFR>)XR0?RO_ &J?^"M7A_\ 90^-?B#X)7_['W[8
M'Q<NO#VE:!JC^.OA'\-(/$O@;4EU^R-ZEIIVK/J=JTUWIX'D:A$81Y$Y"!F!
MS7SO_P /^?"F<?\ #O/_ (*%Y]/^%+6N?_3Y7N4>&\[Q%&E7HX'GHUH1J4I_
M6L!'GA-7C+EGF%.<;KI.$)+K%;'GU,UP%*<J<\1RSA)QDO8XF5I)V:O'#3B[
M/M)KS/L_]@7]D_\ :+_9?_9I\=?#+X_?&N3]IOQ5KNO?%/5M!T#Q38Z!I_AF
MPL/%'B[QKK5CHDVO6.A)J%[9>+K36]/N?$46KZ?J-IX<N)KS2M$M9M)M(%N/
MSG\"_P#!,7]N7PU^S]\&/A=X9\=^'/@5JWPG^'?Q LGT[X-?&KQAX>\.>(?B
MIXB_:!\*>.M&\9ZV=&\&:.FMI;_"Y?%OA>=-6TVX:&^_LV#;<6<I>U](/_!?
MCPICG_@GG_P4+Q_V1:V'_N<H_P"'_'A,?\X\_P#@H4/^Z*VHZ?36_P#.:];
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M$6F:W'9VU^)8M7TR?4-#UO2$\0:+I']KZ5>:>;B.ORT_X?\ /A7I_P .\_\
M@H7GT_X4M:__ "\H_P"'_'A7_I'E_P %"_\ PRMK_P#+RO)_U5S_ /Z%[_\
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MM,:AXMFTRV\*6/B6TO/$]QK9MQHUOX>MOA%X,FUJ?5S=@VHTN+34N9-0-R#
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M'WP\\966G:'X2T%->UZ"7Q9KGCJ^M9/$8:X\*>'I["67Q5?6,-[#<)F>%/\
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M@'\2[KX9:MI'A 7_ (0:UE^-_C'4K*/4_!?@73+P;=+C62]U$220HOC6G_\
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MP\>WT_@R^U+2Y!%J6GVGBGX*^$]#N;[3Y3Q%?6<%\]Q:2'A)XXV[5^;WCO\
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M3QCXPL8IVM_AQIGAC59+;7 ;V^TL67BFSN/$&D:?#')IHCN#B""9(U7]$_\
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M3A6;QSX?\+Z'JGPZT:>R\9:I>26^CZ=I.J1Z'JFE:^TVE>)Q97%E.5][U?\
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M?#\%O8?$&S\$>$M''@[QMJVHSLWA*#Q/=:MKDJ76GPQZ#+/,=$L-7LHY#+J
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M[&XFM+J$MK^F(_E7%N\4T>]&96V.-REE.5)%?2]?,'[97_)N7Q#_ .N&B?\
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MQP#Q[RF.79CXD9#A,75AAJE#'3KO,,''^SZ.9N%%YC@%EN(_TAS+CW#8#/\
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M7Q/XL\4Z;X,TJP\-6VCW5Y/J\<7B#5K*SU6[LHYK31@[S:I-:Q12,OY.6?\
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M[&-K<_%.WO+/XE3P?#:^CE\>VFHW1OM0M?%S#3,^(+:^OF-]>P:F;F*[OO\
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M+7ZMQT/VO1\@#L,W_ Z]/4U^S&/VD/[WP1_[Y\>?_%T8_:0_O?!'_OGQY_\
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M7[9I&<>F?[0SBOV7Q^TA_>^"/_?/CS_XNC'[2'][X(_]\^//_BZ/^*7/@?\
M]%KXG?\ A;PU_P#.0/\ B<+Q$_Z$'!__ (39O^/_  IZ_.Y^,_\ PR3^T/G/
M_"L-6SZB[T<$_4B_R>I'/;CI2_\ #)7[1/\ T3'5_P#P,TC_ .6%?LOC]I#^
M]\$?^^?'G_Q=&/VD/[WP1_[Y\>?_ !=)_LN/ ][\:^)S]<;PS_\ .0?_ !.%
MXB?]"#@__P )LW_^>9^-'_#)7[1/_1,=7_\  S2/_EA2C]DK]HCO\,=7_P#
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M'G_Q=&/VD/[WP1_[Y\>?_%T >W45XCC]I#^]\$?^^?'G_P 71C]I#^]\$?\
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M@/Q=\+=;UKQWJ?A[PUIWQ$\.>(-6\!Z%)?WFB7,FLZB+JT_0S'[2'][X(_\
M?/CS_P"+HQ^TA_>^"/\ WSX\_P#BZ /;J*\1Q^TA_>^"/_?/CS_XNC'[2'][
MX(_]\^//_BZ /;J*\1Q^TA_>^"/_ 'SX\_\ BZ,?M(?WO@C_ -\^//\ XN@#
MVZBO&K(?M"?;;/\ M%O@U_9WVJ#[?]B3QO\ ;?L7F+]I^Q^>_D?:O)W^1YW[
,H2;3)E<@^RT ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
